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Abstract
The hypothalamo-pituitary-adrenal (HPA) axis is hyporesponsive during late
pregnancy to emotional, physical and metabolic signals. This is due to reduced
responsiveness of the parvocellular paraventricular nucleus (pPVN) corticotrophin
releasing hormone (CR11) and arginine vasopressin (AVP) neurones. Major
adjustments in metabolic regulation during late pregnancy will help ensure a
successful outcome. These include increased appetite and reduced energy
expenditure during exposure to a stress, to which reduced neuroendocrine stress
responses may contribute. Glucocorticoids have a key role in mobilising energy in
response to acute stress, and have longer-term actions in the regulation of fat storage.
I investigated the relationship between the HPA axis and endocrine factors relating to
adipose tissue storage and appetite regulation during late pregnancy in rats. The
responsiveness of the hypothalamic neurones regulating ACTH and hence
corticosterone responses to insulin induced hypoglycaemia (IIH) and the orexigenic
peptides NPY, orexin and ghrelin was investigated with particular focus on the
mechanisms involved in restraining these responses during late pregnancy.
IIH increased ACTH secretion similarly in both virgin and pregnant rats. Unlike
most stressors IIH did not stimulate parvocellular CRH mRNA expression in pPVN
neurones but it did increase AVP mRNA expression.
The responsiveness of the HPA axis to the orexigenic peptides ghrelin, orexin and
NPY given by i.e.v. injection was markedly reduced during late pregnancy. This was
at least partly a result of reduced activation of the pPVN neurones, as revealed by
reduced stimulation of Fos expression in the pPVN compared with virgin rats given
these peptides. ACTH secretory responses were also strongly attenuated in late
pregnant rats. In contrast all three orexigenic peptides increased food intake to a
similar level in both virgin and pregnant rats. Thus neuroendocrine stress responses
to central administration of orexin, NPY and ghrelin are absent during late pregnancy
whilst ingestive behavioural responses remain intact. Changes in brain circuitry
regulating appetite during late pregnancy were shown by increased Fos activation in
the lateral hypothalamic area (LPIA), ventromedial hypothalamus (VMH) and
dorsomedial hypothalamus (DMH). Supraoptic and magnocellular PVN oxytocin
responses to centrally administered NPY were reduced during late pregnancy.
Endogenous opioids are involved in the attenuation ofHPA axis responses to orexin
and NPY during late pregnancy since pre-treatment with the opioid receptor
antagonist naloxone reinstated the ACTH response and restored CRH and AVP
mRNA responses. Naloxone administration revealed that endogenous opioids
facilitate NPY-induced feeding in both virgin and late pregnant rats, but more
importantly in late pregnant rats. Naloxone restored a Fos response in the PVN and
SON in response to NPY in late pregnant rats indicating that oxytocin neurone
responses to NPY are suppressed by endogenous opioids.
Basal blood glucose levels were lower in late pregnant rats than in virgins. Ghrelin
increased blood glucose levels similarly in both virgin and pregnant rats, whilst NPY
and orexin increased blood glucose in only the virgin rats.
In conclusion, neuroendocrine stress responses to orexin, ghrelin and NPY are
reduced in pregnant rats, and this was shown for orexin and NPY to be due to
endogenous opioid restraint. Endogenous opioid mechanisms have opposite effects
on neuroendocrine stress responses and feeding, which will enhance energy
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General Introduction Chapter 1
1.1 General Introduction - Stress
When faced with excessive demands or threats, a subject's adaptive responses attain
a non-specific nature, known as "stress" (Habib et al, 2000). Hans Selye defined
stress as the non-specific response of the body to a demand (Selye, 1949). Stress is
defined as the state in which the brain interprets the quantity of stimulation as
excessive or its quality as threatening (Chrousos et al, 1992). During a stress
response, cardiac output and respiration are enhanced and blood flow is redirected to
provide the highest perfusion to the brain and muscular system. The brain focuses on
the perceived threat and acts accordingly (Habib et al, 2000). Endocrine mechanisms
of pleasure, growth and reproduction are shut down to save energy, catabolism is
increased and fuel is used to supply the brain, heart and muscles (Chrousos et al,
1992). Metabolic changes that occur during stress involve secretion of
glucocorticoids from the adrenal cortex and secretion of adrenaline and
noradrenaline by the adrenal medulla and sympathetic nerves respectively. Both
adrenaline and noradrenaline have been associated with the "fight or flight response"
described by Cannon in 1914 (Cannon 1930).
1.2 The "fight or flight response"
The fight or flight response was first described in 1914. The theory states that
animals react to threats with a general discharge of the sympathetic nervous system
(Cannon 1930). In other words, an animal has two options when faced with danger.
They can either face the threat ("fight"), or they can avoid the threat ("flight"). The
onset of a stress response is associated with specific physiological actions in the
sympathetic nervous system, both directly and indirectly through the release of
1
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adrenaline and to a lesser extent noradrenaline from the medulla of the adrenal
glands (Wurtman et al, 2002). The release is triggered by acetylcholine released from
preganglionic sympathetic nerves (Wurtman et al, 2002). These catecholamine
hormones facilitate immediate physical reactions by triggering increases in heart rate
and breathing, constricting blood vessels in many parts of the body—but not in
muscles (vasodilation), brain, lungs and heart—and tightening muscles (Habib et al,
2000). An abundance of catecholamines at neuroreceptor sites facilitates reliance on
spontaneous or intuitive behaviors often related to combat or escape. Normally, when
a person is in a serene, unstimulated state, the "firing" of neurons in the locus
coeruleus is minimal. A novel stimulus, once perceived, is relayed from the sensory
cortex of the brain through the thalamus to the brain stem (for an overview of the
relevant brain anatomy see Fig 1.1). This route of signalling increases the rate of
noradrenergic activity in the locus coeruleus, and the person becomes alert and
attentive to the environment (Wurtman et al, 2002). If a stimulus is perceived as a
threat, a more intense and prolonged discharge of the locus coeruleus activates the
sympathetic division of the autonomic nervous system (Thase et al, 1995). The
activation of the sympathetic nervous system leads to the release of noradrenaline
from nerve endings acting on the heart, blood vessels, respiratory centers, and other
sites (Habib et al, 2000). The ensuing physiological changes constitute a major part





Figure 1.1: A sagittal section of the rat brain. PVN = paraventricular nucleus, DMH
= dorsomedial hypothalamus, SON = supraoptic nucleus, VMH = ventromedial
hypothalamus, ARC = arcuate nucleus, LHA = lateral hypothalamic area, NTS =
nucleus of the solitary tract; 3V = 3rd ventricle, 4V = 4th ventricle
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1.3. The components of the HPA-axis
1.3.1 The hypothalamus
The hypothalamus is a region of the mammalian brain located below the thalamus,
forming the major portion of the ventral region of the diencephalon and functioning
to regulate certain metabolic processes and other autonomic activities (Jiang et al,
2003). The hypothalamus links the nervous system to the endocrine system by
synthesising and secreting neurohormones, often called releasing hormones, as
needed that control the secretion of hormones from the anterior pituitary gland
(Guillemin, 1972). The hypothalamus is a very complex region, and even small
nuclei within the hypothalamus are involved in many different functions. The
paraventricular nucleus (PVN) for instance contains oxytocin and vasopressin
neurons which project to the posterior pituitary, but also contains neurones,
producing CRH, that regulate adrenocorticotropin (ACTH) secretion (Koutcherov et
al, 2000).
The PVN (see Appendix B) is an aggregation of neurones in the hypothalamus,
adjacent to the third ventricle. The PVN is highly vascularised, but is inside the
blood-brain barrier, although the neuroendocrine neurons in this nucleus project to
sites (the median eminence and the posterior pituitary) that lack a blood-brain barrier
(Armstrong & Hatton, 1980). The PVN contains magnocellular neurosecretory cells
whose axons extend into the posterior pituitary, parvocellular neurosecretory cells
that project to the median eminence, and several populations of peptide-containing
cells that project to many different brain regions (Armstrong & Hatton, 1980).
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The parvocellular PVN (pPVN)
The parvocellular neurosecretory neurons of the PVN project axons to the median
eminence, at the base of the brain (Swanson & Sawchenko, 1980). At the median
eminence, the neurosecretory nerve terminals release peptides into the blood vessels
of the hypothalamo-pituitary portal system. These vessels carry the peptides to the
anterior pituitary gland, where they regulate hormone secretion into the systemic
circulation (Swanson & Sawchenko, 1980). The parvocellular neurosecretory cells
include: cells that synthesise corticotropin releasing hormone (CRH), which
regulates ACTH secretion from the anterior pituitary gland, cells that make arginine
vasopressin (AVP): AVP released from these neurons also regulates ACTH
secretion; CRH and AVP act synergistically to stimulate ACTH secretion (Gillies &
Lowry, 1979). AVP has little ACTH secretagogue activity alone. In non-stressful
situations, CRH and AVP are secreted in the portal system in a circadian and
pulsatile fashion (Chrousos & Gold, 1992). The amplitude of these CRH and AVP
pulses increase in the early light phase in humans; this results in an increase of
ACTH and Cortisol in the general circulation. The circadian release of CRH, AVP,
ACTH and corticosterone is controlled by the suprachiasmatic nucleus (SCN)
(Takahashi et al, 2001). These circadian variations are disrupted by stress.
The magnocellular PVN (mPVN)
The magnocellular cells in the PVN produce oxytocin and vasopressin (Sokol et al,
1976). These peptide hormones are packaged in large dense-core vesicles, which are
transported down the axons and released from neurosecretory nerve terminals in the
posterior pituitary gland. Similar magnocellular neurons are found in the supraoptic
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nucleus (SON) (Reaves & Hayward, 1979). In the rat, oxytocin secretion is increased
by several types of stressors (Lang et al, 1983; Gibbs 1984).
1.3.2. The pituitary gland
The pituitary gland is located at the base of the brain. It consists of two parts; the
anterior pituitary and the posterior pituitary.
The anteriorpituitary
The anterior pituitary (also called the adenohypophysis) is the anterior lobe of the
pituitary gland. Under the influence of the hypothalamus via releasing factors
secreted into the hypothalamo-hypophyseal portal system the anterior pituitary
produces and secretes several peptide hormones that can regulate many physiological
processes including stress, growth and reproduction (Thorner et al, 1995). Blood to
the anterior pituitary is supplied by the superior hypophyseal artery, via the primary
and secondary portal capillary vessels in the median eminence and anterior pituitary
respectively and it secretes hormones into capillaries that drain into the hypophyseal
vein (Bergland et al, 1977).
The posterior pituitary
The posterior pituitary (also called the neurohypophysis) is the posterior lobe of the
pituitary gland. The posterior pituitary consists mainly of neuronal projections
extending from the SON and the magnocellular PVN (mPVN) in the hypothalamus
(Zimmerman et al, 1984). The posterior pituitary receives its blood supply from the
inferior hypophyseal artery and secretes hormones into capillaries that drain into the
hypophyseal vein. These hormones are all made in the hypothalamus and transported
in axons to the posterior pituitary where they are stored (Choy & Watkins, 1977).
5
General Introduction Chapter 1
1.3.3. The adrenal gland
The adrenal glands are located in the abdomen above and adjacent to the kidneys.
The adrenal gland is separated into two distinct structures, the adrenal medulla and
the adrenal cortex. The adrenal medulla is at the centre of the adrenal gland
surrounded by the adrenal cortex. The adrenal medulla is the body's main source of
the catecholamine hormone adrenaline and also produces noradrenaline, which is
also released by sympathetic nerve terminals. Some cells of the adrenal cortex belong
to the HPA axis and are the source of glucocorticoid hormones.
The adrenal medulla
The adrenal medulla is the principal site of the conversion of the amino acid tyrosine
into adrenaline and also produces noradrenaline (Seidi & Unsicker, 1989).
Physiological effects of adrenaline and noradrenaline include increased heart rate,
blood vessel constriction, bronchiole dilation and increased metabolism, all of these
are characteristic of the "fight or flight" response (Cannon et al, 1914).
The adrenal cortex
The adrenal cortex produces mineralocorticoids and glucocorticoids including
aldosterone and corticosterone respectively. The adrenal cortex is divided into three
distinct layers; the zona glomerulosa which produces mineralocorticoids (e.g.
aldosterone) and the zona fasiculata which chiefly produces glucocorticoids. The
final layer of the adrenal cortex is the zona reticularis, which is the principal source
of glucocorticoids with the fasiculata becoming activated after prolonged stimulation
(Ricciardi et al, 1984). Glucocorticoid, but not mineralocorticoid secretion is
controlled by and dependent upon ACTH. Corticosterone increases metabolism in
6
General Introduction Chapter 1
several ways; stimulating the release of amino acids, breaking down fat to stimulate
gluconeogenesis, producing glucose from newly released amino acids and
conserving glucose by inhibiting uptake into muscle and fat cells (van de Kar et al,
1981).
1.4. Neurocircuitry of stress: Pathways regulating HPA axis
Because excess glucocorticoid can cause detrimental effects it is crucial that the size
and duration of the stress response is limited. This control is accomplished by a
"glucocorticoid negative feedback" loop where glucocorticoids themselves can
control their own release (Keller-Wood & Dallman, 1984). The parvocellular
CRH/AVP neurones in the PVN play a key role in the stress response (Antoni,
1986); these neurones integrate excitatory and inhibitory impulses from a wide
variety of neuronal inputs into a signal to increase ACTH secretion. CRH is the main
regulator of ACTH secretion (Orth, 1982), but AVP is also released into the
hypothalamo-portal system where it stimulates release of ACTH (Da Costa et al,
1996).
1.4.1. Excitatory stress pathways
Three different groups of afferents- an ascending brainstem pathway, the
circumventricular organs and hypothalamic and basal forebrain pathways- can
activate the CRH and AVP neurones in the pPVN. The combined properties of these
three groups, dictates the strength of individual stressors (Zeigler & Herman, 2002).
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Brainstem pathways
Activation of the brainstem is needed for autonomic activation, somatosensory pain
processing and controlling arousal. It also plays a key role in activating the HPA
axis. The medial part of the pPVN receives information directly from
catecholaminergic and non-catecholaminergic regions of the nucleus of the solitary
tract (NTS) (Cunningham & Sawchenko, 1988). Information sent to the pPVN from
catecholaminergic regions of the NTS is critical for HPA axis activation following
stress (Plotsky et al, 1989) and damage to the ascending noradrenergic pathways also
reduces HPA activation following stress (Szarferczyk et al, 1987). The ascending
noradrenergic pathways affect HPA responsiveness differently depending on the
nature of the stressful stimuli (Herman et al, 2002). The A2 region of the NTS is
known to relay information directly to the PVN (de Horst et al, 1989) and can
quickly initiate gluocorticoid responses to and in defense of cardiovascular collapse.
The locus coeruleus is the source of another ascending noradrenergic pathway which
plays a key role in activation of the HPA axis, it does not however project to the
PVN indicating that its role in activating the HPA axis may be via interneurons
(Cunningham & Sawchenko, 1988). Both serotonin and acetylcholine have
excitatory effects on the HPA axis and both increase CRH and corticosterone release
(Jones & Gillham, 1988). Ascending pain pathways are also thought to provide a
stimulatory input to the HPA axis, these pathways are thought to act via the
ventrolateral medullary Al noradrenergic neurones or through the A6 region of the
locus coeruleus (Palkovits et al, 1999).
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The circumventricular organs
The circumventricular organs are midline structures bordering the 3rd and 4th
ventricles. They are unique areas of the brain outside the blood brain barrier and are
recognised as important sites for communicating with the cerebrospinal fluid (CSF)
and between the brain and peripheral organs via blood-borne products. CVO's
include the pineal gland, median eminence (ME), subfornical organ (SFO), the area
postrema (AP), the subcommissural organ and the organum vasculosum of the
lamina terminalis (OVLT).
The medial part of the pPVN receives direct projections from the CVO's including
from the SFO and the OVLT. Projections from the SFO to the pPVN increase CRH
secretion (Lind et al, 1984). The SFO is an important component of a system of
neurones that surrounds the OVLT and the medial preoptic nucleus. This collection
of neurones has direct projections to the magnocellular secretory system as well as to
the parvocellular system and serves as a link between the HPA axis and the
neurohypophyseal system (Lind et al, 1984). Damage to the area postrema impairs
ACTH secretion following stress (Lee et al, 1998) though it does not have substantial
direct projections to the PVN (Oldfield & McKinley, 1994).
Hypothalamic and basal forebrain pathways
Local projections comprise the majority of inputs into the pPVN. This includes
inputs from the dorsomedial hypothalamus (DMH), medial preoptic area (MPo),
anteroventral third ventricular region, ventromedial hypothalamus (VMH) and the
posterior division of the bed nucleus of the stria terminalis (BnST) (Zeigler et al,
2002). The PVN also receives projections from cells immediately surrounding it in
the subparaventricular zone and the perifornical area (Sawchenko & Swanson, 1983).
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Projections from these areas communicate with the PVN mediating both excitation
and inhibition of the HPA axis. Inhibitory GABAergic projections are positioned to
supply inhibition of basal and stress-induced HPA activity (Cullinan et al, 1993).
Local circuit excitation may be initiated by glutamatergic afferents (Herman et al,
2000).
1.4.2. Inhibitory stress pathways
Inhibition of the HPA axis is mediated by humoral (glucocorticoid mediated) and
neuronal (glucocorticoid independent) pathways (Keller-Wood & Dallman, 1984).
The humoral part comprises a "glucocorticoid negative feedback" loop.
Glucocorticoids were originally assumed to exert delayed effects via a steroid
receptor-mediated action, however glucocorticoids can also inhibit ACTH secretion
within minutes (fast feedback) (Keller-Wood & Dallman, 1984). However neural
inhibitory pathways to the PVN can function in the absence of glucocorticoids
(Keller-Wood & Dallman, 1984).
1.4.2.1. Glucocorticoid negative feedback
Glucocorticoids play a key role in regulating basal activity of the HPA axis and in
termination of the stress response. They act on hypothalamic regulatory centres such
as the hippocampus, frontal cortex, hypothalamus and pituitary gland (Chrousos,
2000). The inhibitory glucocorticoid feedback on the ACTH secretory response
limits the duration of total tissue exposure to glucocorticoids minimising the
detrimental effects of these hormones.
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1.4.2.2. Different types of feedback
There are three major types of glucocorticoid feedback with respect to timeframe of
action: fast, intermediate and slow. These involve three separate mechanisms of
corticosteroid action. Fast feedback does not require protein synthesis to occur
(Keller-Wood & Dallman, 1984). The action ofCRH in stimulating ACTH release is
thought to be inhibited by a rapid effect of corticosteroids acting directly on the
corticotroph cell membrane (Keller-Wood & Dallman, 1984). Only stimulated but
not basal CRH and ACTH release are inhibited in vitro so it is possible that
corticosterone may inhibit an event early on in stimulus-secretion coupling (e.g.
cAMP production) (Hyde et al, 2003). In contrast, evidence to suggest that inhibition
of ACTH secretion by glucocorticoid is controlled by either cAMP or cAMP-
dependent phosphorylation has been found (Shipston et al, 1992). CRH acts via
cAMP to exert short (Shipston et al, 1992) and long term control (Shepperd et al,
1991) over glucocorticoid action at the pituitary.
Intermediate feedback also decreases ACTH release in response to stimulation of the
corticotroph and does not affect synthesis ofACTH (Keller-Wood, 1989); it does
however appear to affect CRH synthesis and release (Keller-Wood, 1989). It requires
the presence of a protein whose synthesis is corticosterone-dependent although the
role of this protein is unknown (Keller-Wood & Dallman, 1984). Intermediate
feedback just like fast feedback does not inhibit basal ACTH secretion in vitro
(Boscaret et al, 1990).
Slow feedback involves a steroidal mechanism of action reducing pituitary ACTH
content by decreasing levels ofPOMC mRNA (coding for the ACTH precursor
molecule) (Keller-Wood & Dallman, 1984). Consequently, slow feedback unlike
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intermediate and fast feedback inhibits both basal and stimulus-induced ACTH
secretion (Hinz & Hirschellman, 2000). Corticosteroid-induced inhibition of basal
ACTH secretion has been shown to occur within two hours in vivo; this is different
from the effects on stimulus-induced secretion, suggesting that basal secretion is
activated by different pathways in the brain to CRH and hence ACTH secretion
(Dayanithi & Antoni, 1989).
1.4.2.3. Glucocorticoid receptors
Glucocorticoids predominantly exert their effects through ubiquitously distributed
intracellular receptors. The non-activated glucocorticoid receptor resides in the
cytosol in the form of a hetero-oligomer. On ligand binding the glucocorticoid
receptors dissociate from the rest of the hetero-oligomer and translocate into the
nucleus where they then interact with specific glucocorticoid responsive genes. The
activated receptors also inhibit several transcription factors such as c-jun, c-fos and
NF-kB (van der Saag et al, 1996).
A dual receptor system exists for glucocorticoids in the CNS consisting of the
glucocorticoid receptor type I also known as the mineralocorticoid receptor which
responds to low levels of glucocorticoids, and the classic glucocorticoid receptor
type II which predominantly responds after stress (Reul et al, 1985). The type II
receptor participates in the negative feedback control of the HPA axis. Type I
receptors bind aldosterone, corticosterone, Cortisol and deoxycorticosterone (Luttge
et al, 1989). They have restricted distribution in the brain and are expressed in high
levels in the hippocampus, lateral septum, dentate gyrus and brainstem (Reul & De
Kloet, 1985). Type II receptors demonstrate high affinity for synthetic
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glucocorticoids (e.g. dexamethasone) and lower affinity for physiological
glucocorticoids (e.g. Cortisol and corticosterone) (Reul & De Kloet, 1985). Type II
receptors provide a mechanism by which negative feedback can terminate stress-
activated neural and endocrine (HPA) activation and regulate behavioural responses
to stress (McEwen et al, 1988). Type II receptors are concentrated in the
hippocampus, septum, amygdala, PVN, cortex, brainstem and in the pituitary (Evans
& Ariza, 1989).
1.4.2.4. Neuronal feedback
The HPA axis can also be inhibited independently of glucocorticoids. Lesions of
selective hypothalamic nuclei can enhance the HPA axis response to various
stressors (Herman & Cullinan, 1997).
GABA
The neurotransmitter GABA inhibits ACTH release (Makara & Stark, 1974).
GABAergic neurones project from the BnSt, MPo and from within the hypothalamus
itself directly to the PVN. A potential role for GABA is also thought to maybe exist
in controlling HPA axis activity by working through neurones in the hippocampus
(Herman & Cullinan, 1997).
Opioids
The HPA axis is also tonically inhibited by endogenous opioids, as shown by
injection of an opioid receptor antagonist (Grossman & Besser, 1992). Opioid
inhibition can be reversed with the al-adrenoreceptor thymoxamine (Grossman &
Besser, 1982) so it is thought that opioids may control the HPA axis through central
noradrenergic pathways (Holsboer et al, 1988).
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Otherfactors
Atrial natriuretic peptide (ANP) has been reported to inhibit the release of CRH and
AVP stimulated ACTPI release from pituitary cells (Antoni & Dayanithi, 1990).
Somatostatin also inhibits ACTH and CRH release in vitro (Tizabi & Calogero,
1992). Oxytocin has also been shown to inhibit the HPA axis in women during
lactation (Lightman & Young, 1989), however it stimulates ACTH secretion in the
rat, provided CRH is present (Antoni et al, 1988). Other compounds such as
adrenomedullin, thymosin-a-1, pre-pro-thyrotrophin-releasing hormone, endothelin-
1, lipocortin, substance P, leptin, nitric oxide and carbon monoxide (Jessop, 1999)
have all been reported to inhibit the HPA axis in rats. Exogenous cannabinoids can
also exert robust effects on hormone secretion from the pituitary inhibiting
neuroendocrine function suppressing pituitary hormone release, and in particular
inhibit CRH neurons (Tasker, 2004).
1.5. Stressors
Individuals can experience either internal or external stressors. Internal stressors can
be physical or psychological. An example of a psychological stressor is intense
worry about a harmful event. The neural circuits mediating neuroendocrine stress
responses to psychological stressors involve cortical activation of the basolateral
amygdala, which in turn activates the central nucleus of the amygdala. The central
nucleus then activates hypothalamic neurones directly and indirectly through the
BnST (Le Doux, 1995); it may also activate circuits involving brainstem serotonergic
and catecholaminergic neurones (Van de Kar et al, 1999).
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A physical stressor has a direct effect on the body; this may be an external
environmental condition (e.g. heat, cold and noise) or internal physiological demands
on the body (e.g. cardiovascular, osmotic and immune challenge or hypoxia). These
stressors are all relayed directly to the PVN by visceral afferent pathways and
represent a direct threat to survival (Dayas & Day, 2002). In these situations it is
advantageous to rapidly relay information directly to the PVN.
Stressors can also be defined as those that arise suddenly over a short period of time,
i.e. acute stressors, or those that develop over a longer period of time and constantly
recur, i.e. chronic stressors (Kennedy et al, 1988).
1.5.1. Acute stress
Acute stress is the state of reaction to an immediate threat, preparing for what is
commonly known as the "fight or flight" response. Common experimentally used
acute stressors include cold, ether, intra-peritoneal hypertonic saline, restraint, forced
swimming, emotional stressors and infection. All of these lead to an increase in
ACTH and corticosterone secretion. Normally, once the threat has passed, the
response becomes inactivated and levels of stress hormones return to normal. At a
hypothalamic level acute stress causes a rapid increase in CRH in the median
eminence (Murakami et al, 1989), which increase reflects increased transport of
CRH. The median eminence content ofCRH begins to decline around 15 minutes
following the onset of acute stress (Moldow et al, 1987). A second increase in CRH
release occurs around 60 minutes after the onset of stress (Moldow et al, 1987); this
is likely from increased CRH synthesis. Acute stress also increases AVP production.
AVP is co-produced with CRH and is secreted into the hypophyseal portal blood
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from where it stimulates corticotroph activity (Antoni, 1993). Increased CRH and
AVP mRNA expression in the pPVN begins to increase two hours after exposure to
an acute stress and peak expression is observed 4 hours after the stressor (Ma &
Lightman, 1998).
A range of intracellular transcription factors can also be seen activated in the pPVN
after exposure to acute stressors. The normally quiescent immediate early gene c-fos
is seen to be expressed in CRH and AVP containing cells in the pPVN in response to
a variety of acute stressors (Hoffman et al, 1993). The functional relationship
between c-fos and CRH gene regulation may not be straightforward and CRH may
not be under regulation of c-fos (Chalmers et al, 1995). Other transcription factors in
the PVN could also modulate CRH expression (Ehlers, 1986).
Increased POMC mRNA expression (providing the precursor for ACTH) in
corticotrophs has also been shown following administration of an acute stressor
(Harbuz & Lightman, 1989).
In summary, acute stress results in increased release of CRH and AVP from the
median eminence with rapid stimulation of gene transcription for these peptides in
the pPVN. CRH and AVP cause increased release of ACTH from the anterior
pituitary, with stimulation ofPOMC gene expression in the corticotrophs, and ACTH
secretion results in increased corticosterone secretion from the adrenal gland.
1.5.2. Chronic stress
In chronically stressed animals activation of the HPA axis in response to a stressor
may be reduced with each exposure until eventually there is no longer a response
(Gomez et al, 1996). This desensitisation ofHPA responsiveness to a repeated stress
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may be due to desensitisation of the pituitary and down regulation ofpituitary CRH
receptors.
It has been shown in repeatedly restrained rats that pPVN neurones fail to respond to
a single episode of restraint stress, but there are increased AVP stores in the median
eminence (Ma et al, 1997). Basal AVP mRNA expression in the pPVN is increased
during chronic stress whilst basal CRH mRNA expression is reduced (Herman,
1995). Similarly AVP mRNA expression in response to repeated stress is maintained
or even sometimes increased whilst CRH mRNA remains reduced (Aguilera &
Rabadhan-Diehl, 2002). Co-expression ofAVP with CRH in pPVN neurones
increases (Lightman & Young, 1987). The difference between CRH and AVP gene
expression under chronic stress is mediated by the action of glucocorticoids, which
selectively enhance vasopressin responses (Kovacs et al, 2000)
1.6. Corticotropin releasing hormone
After years of research the hypothalamic factor that stimulates ACTH secretion was
identified as a 41-amino acid peptide which was named corticotropin releasing
hormone (CRH) (Vale et al, 1981). CRH acts as the main regulator of ACTH
secretion (Orth, 1982). I.e.v. administration ofCRH produces a stress response and
administration of a CRH antagonist suppresses this response (Habib et al, 2000).
CRH type I receptor (CRH-R1) knock-out mice have a markedly deficient ability to
mount a stress response (Smith et al, 1998). CRH has also been implicated in other
components associated with the stress response such as arousal (Shibasaki et al,
1993) and autonomic activation (Brown et al, 1985).
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1.6.1. Distribution of CRH neurones
Several hypothalamic nuclei contain CRH neuron cell bodies, including the MPo,
DMH, ARC, posterior hypothalamus and the mammillary nuclei (Habib et al, 2000).
The PVN of the hypothalamus contains the majority of CRH cell bodies that
stimulate ACTH secretion (Habib et al, 2000). These CRH neurones originate in the
pPVN and send axon terminals to the capillaries of the median eminence (Habib et
al, 2000). CRH is also present in a small group of neurones in the PVN that project
to the brainstem and the spinal cord. These neurones regulate the autonomic nervous
system (Turnbull et al, 1997).
CRH cell bodies are also found in the central nucleus of the amygdala, the substantia
innominata and the BnST (Cummings et al, 1983). CRH neurones in the central
nucleus of the amygdala project to the PVN and to the brainstem (Weidenfeld et al,
2002), these projections may account for neuroendocrine, autonomic and behavioural
effects ofCRH (Weidenfeld et al, 2002). The CRH neurones in the BnST project to
the parabrachial nuclei and dorsal vagal complex in the brainstem to coordinate
autonomic activity (Grigoriadis et al, 1993).
CRH interneurones have been seen in the second and third layers of the cerebral
cortex and project to layers I and IV (Palkovits et al, 1985), these may be very
important for the behavioural actions of the peptide. Scattered CRH cells have also
been seen in the deeper layers of the neocortex. The highest density ofCRH-
containing neurones is found in the prefrontal, insular and cingulate areas. The
distribution of CRH in these areas may explain its effects on cognitive processing
(Palkovits & Brownstein, 1985).
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Several groups of CRH neurones are also located in the brainstem and in the spinal
cord (Palkovits & Brownstein, 1985). In the midbrain, CRH cells are found in the
Edinger-Westphal nucleus, the periaqueductal grey and the dorsal raphe nucleus
(Palkovits & Brownstein, 1985). In the pons, CRH cell bodies in the parabrachial
nucleus project to the medial preoptic nucleus (Mpo) of the hypothalamus (Owens &
Nemeroff, 1991). The locus coeruleus noradrenaline system also contains CRH
neurones that may mediate the cross-talk between the two systems (Berridge &
Waterhouse, 2003). In the medulla CRH neurones are known to exist in the NTS in
the dorsal vagal complex, in addition to some scattered groups in the reticular
formation and the spinal trigeminal nucleus (Palkovits & Brownstein, 1985). CRH
cell bodies are found in laminae V, VI, VII and X of the spinal cord, as well as in the
intermediolateral column of the thoracic and lumbar regions (Yao et al, 2004). Spinal
CRH neurones have an important role in modulating sensory input via ascending
projections to the thalamus and brainstem reticular formation (Chrousos, 1998).
An additional CRH-like neuropeptide urocortin has also been identified in the brain
(Vaughan et al, 1995). Urocortin is a potent anorexigenic peptide of 40 amino acids
that induces fed-like motor activity when administered centrally or peripherally in
fasted animals (Kihara et al, 2001). Urocortin activates CRH receptor 1 and CRH
receptor 2 (Torpy et al, 1999). I.c.v. administration of urocortin can also activate the
HPA axis under basal conditions (Jamieson et al, 2006). Urocortin II and III also
belong to the CRH family. Urocortin II is a 38 amino acid peptide which is highly
selective for the CRH receptor two; it has been shown to have anorexigenic effects
and hypotensive effects but it does not stimulate secretion ofACTH (Arai &
Shibasaki, 2006). Urocotin III is also a 38 amino acid and similar to urocortin II it is
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also highly selective for the CRH receptor two with anorexigenic effects but it does
not stimulate ACTH secretion (Arai & Shibasaki, 2006).
1.6.2 Stress activates CRH release
Stress activates release of CRH from the hypothalamus and other areas within the
brain (Habib et al, 2000). CRH initiates all aspects of the stress response including
behavioural, autonomic and neuroendocrine responses (Behan et al, 1996). Stressors
activate CRH neurones in the pPVN to stimulate CRH release into the hypothalamo-
portal system; CRH neurones respond to acute and chronic stress in different ways.
Acute stress increases CRH mRNA expression in the PVN after 2 hours (Harbuz et
al, 1991; Imaki et al, 1991) with peak expression occurring 4 hours after stress (Ma
et al, 1997). Intraperitoneal injection of hypertonic saline has been shown to increase
CRH mRNA expression in the PVN (Harbuz et al, 1989). Parvocellular CRH
heteronuclear (hn) RNA was also increased by administration of i.p. hypertonic
saline (Ma & Aguilera, 1999). As discussed above, CRH is the dominant agent in the
HPA axis response to acute stress, while AVP is more important in mediating
responses to chronic or repeated stress (Harbuz & Lightman, 1992). Chronic osmotic
stimulation decreases CRH mRNA expression in the PVN (Aguilera et al, 1994).
1.6.3. The CRH receptors
Receptor binding sites for CRH are found in the pituitary, brain and in various
peripheral sites including the adrenal medulla, prostate, gut, spleen, liver, kidney and
testes (Slominski et al, 2004). The CRH receptor is part of the seven-transmembrane
G-protein-coupled family of receptors. CRH binding to its receptor increases
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intracellular cAMP (De Souza & Battlaglia, 1988). The CRH receptors belong to the
same family as the growth hormone releasing factor, parathyroid hormone (PTH),
glucagon, vasoactive intestinal peptide (VIP), calcitonin and 5HT receptors (Parham
et al, 2004).
Two distinct CRH receptor subtypes have been characterised; CRH-receptor 1
(CRH-R1) and CRH-receptor 2 (CRH-R2) (Beglinger & Degen, 2002). After
cloning, expression of the CRH-R1 receptor was found in various parts of the brain
with CRH binding sites found within the hypothalamus (De Souza et al, 1984).
CRH-R1 expression is found in the rat forebrain, subcortical limbic structures in the
septal region, amygdala, cerebral cortex and deep nuclei (Campbell et al, 2003).
CRH-R1 expression was also found in the PVN, SON, ARC and SCN (Campbell et
al, 2003), with high expression seen in the anterior and intermediate lobes of the
pituitary (Potter et al, 1994).
The CRH receptor 2 (CRH-R2) was cloned (Lovenberg et al, 1995) and found to
have two receptor splice variants; CRH-R2a and CRH-R2p. Expression of CRH-R2
is mainly found within the brain in subcortical structures with high expression found
in the lateral septal nucleus, the VMH and in the choroid plexus. Very low
expression of CRH-R2 has been seen in the pituitary (Chalmers et al, 1995).
1.6.4 Mechanisms by which stress turns on CRH brain systems
How stress turns "on" and "off' the CRH brain system is complex. Many
neurotransmitters are involved in controlling and regulating CRH secretion. GABA
inhibits CRH neurones (Givalois et al, 1998), whereas 5HT and cholinergic neurones
stimulate CRH release (Itoi et al, 2004).
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Noradrenaline and opioid peptides have both a stimulatory and inhibitory role on
CRH release depending on the dose administered and the opioid/cholinergic receptor
subtype involved (Jessop, 1999). Glucocorticoids potently inhibit CRH release by
acting directly on the PVN; but direct corticosterone infused i.c.v. stimulates ACTH
secretion (Laugero et al, 2001) this occurs through receptors in the hippocampus
(Laugero et al, 2001). Glucocorticoids can also stimulate CRH neurones in the
amygdala and the locus coeruleus noradrenaline system; this stimulatory affect may
play a role in prolonging the effects of severe stress by creating a positive feedback
loop between CRH and noradrenaline systems (Spinedi et al, 1988).
1.6.5. Expression of CRH receptors following stress
Normally, there is a balance between the availability ofCRH peptide and the number
of available CRH receptors. Stress results in hypersecretion of CRH and a decrease
in the number of available CRH receptors in the anterior pituitary (Herman et al,
1995). Chronic administration of corticosterone causes a decrease in the number of
CRH receptors in the anterior pituitary (Hauger et al, 1988) as does i.p. hypertonic
saline (Aguilera et al, 2001). Lesion of the PVN that reduces CRH secretion
increases the number of CRH receptors in the pituitary (De Souza et al, 1987).
Expression of CRH-R1 mRNA in the PVN is substantially increased by stress (Imaki
et al, 1996). Both restraint stress and i.c.v. administration ofCRH increase CRH-R1
mRNA expression in the PVN (Imaki et al, 1996), as does immune challenge and i.p.
hypertonic saline (Mansi et al, 1996; Rivest et al, 1995). Increases in CRH-R1
mRNA expression can be seen in the PVN 1-2 hours after increases in ACTH and
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corticosterone secretion (Imaki et al, 1996). These findings indicate that there is local
feedback control of CRH neurone activity by CRH.
1.7. Arginine vasopressin (AVP)
AVP is released from the posterior pituitary when the body is dehydrated. It is
produced in the hypothalamus, and also has various functions in the brain. Most of
the AVP in the body is stored in the posterior pituitary to be released into the
bloodstream; however some of it is released directly into the brain (Ring, 2005).
AVP is secreted from the posterior pituitary gland in response to changes in plasma
volume and osmotic pressure. The neurones that make AVP in the SON and PVN are
also osmoreceptors (Bourque & Oliet, 1997).
Another important source ofAVP is that released from the pPVN into the
hypothalamo-pituitary portal system whence it stimulates release ofACTH (Da
Costa et al, 1996).
1.7.1 The role of AVP in the stress response
AVP neurones in the pPVN in the hypothalamus have an important role in the stress
response. AVP works together with CRH during stress to stimulate the secretion of
ACTH (Koob et al, 1985). A subset of pPVN neurones synthesise and secrete CRH
and AVP, whereas another subset secretes CRH or AVP only (Charmandri et al,
2005). The subset that secretes both neuropeptides enlarges significantly during
stress (Hauger et al, 1993). pPVN neurones expressing AVP project to noradrenergic
neurones of the brainstem and the hypophyseal portal system in the median eminence
(Buckingham, 2006).
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AVP neurones also project to POMC-containing neurones in the ARC which in turn
project to the PVN CRH and AVP neurones (Herman et al, 1997). During chronic or
prolonged stress, there may be a shift in the control ofACTH from CRH to AVP
(Hauger & Aguilera, 1993).
1.7.2. Stress activates AVP release
AVP controls ACTH secretion mainly by regulating the effect of CRH in the
pituitary corticotroph (Gillies & Lowry, 1979). In control non-stressed rats,
approximately 50% of CRH-containing neurones in the pPVN co-express AVP.
Acute stress increases AVP hnRNA expression in the pPVN 1 -2 hours after the onset
of stress (Ma et al, 1997) and AVP mRNA expression 4 hours after the onset of
stress (Ma et al, 1997). Chronic stress enhances activity of the pPVN AVP system
(Harbuz & Lightman, 1992). Levels of CRH hnRNA and mRNA, which increase
following acute stress, become progressively less if rats have been repeatedly
restrained for 14 days (Ma et al, 1997). The levels ofAVP mRNA in the pPVN
progressively increase however in response to repeated restraint stress (Bartanusz et
al, 1993). These data suggest that AVP synthesised in the pPVN plays a more
important role in maintaining HPA axis activity under conditions of chronic stress
(Ma & Lightman, 1998).
1.7.3. Glucocorticoid feedback
Glucocorticoids restore basal AVP mRNA expression following a stress response
(Herman, 1995; Kiss et al, 1984). Glucocorticoids inhibit transcription of AVP by
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binding to the glucocorticoid regulatory element in the vasopressin promoter region
(Pearce et al, 1988; Uht et al, 1988).
1.7.4. Control of AVP synthesis
AVP hnRNA expression does not peak until 1 hour after acute stress, unlike CRH
hnRNA which peaks 5 minutes after (Imaki et al, 1995). The promoter region of the
CRH gene does not contain the AP-1 sequence to which many transcription factors
bind (Seasholtz et al, 1988) unlike the AVP gene which does possess an AP-1
binding site (Pardy et al, 1992). Transcription factors such as Fos and NGFI-B
binding to the AP-1 site have been implicated in inducing AVP gene responses to
stress (Che et al, 1993).
1.7.5. AVP receptors
AVP stimulates ACTH secretion by binding to the V1 b receptor in the pituitary
(Lolait et al, 1995). AVP receptors, ofwhich there are three types, belong to the G-
protein linked super family. The Via receptor has been found in the liver, vascular
smooth muscle, platelets (Laszlo et al, 1991), brain (Tribollet et al, 1988), and
mesangial cells (Jard et al, 1987). AVP binding to the Vja receptor activates
phospholipase C, which stimulates phosphatidylinositol production to increase
intracellular calcium and stimulate protein kinase C (Laszlo et al, 1991). AVP
binding to the Vib receptor also stimulates phosphatidylinositol production,
increasing intracellular calcium like Via activation (Tanoue et al, 2004). The Vib
receptor is found mainly in the anterior pituitary where it mediates AVP stimulation
ofACTH release. The V2 receptor is the final member of the family and works by
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activating the heterotrimeric G protein Gs, promoting stimulation of adenylate
cyclase (Birnbaumer et al, 1990). The V2 receptor is expressed mainly in the cells of
the renal collecting ducts where it plays a key role in water homeostasis (Carmosino
et al, 2006).
1.7.6. Regulation of Vib receptor
Vib receptor expression in the anterior pituitary is increased during chronic stress
(Aguilera & Diehl, 2000). Removal of increased glucocorticoids by adrenalectomy
(ADX) decreases VIb receptor mRNA expression (Aguilera & Rabadhan-Diehl,
2000). Administration of gluocorticoids decreases pituitary AVP binding but
increases Vib receptor mRNA (Antoni et al, 1995). This change where pituitary
binding is decreased and Vib receptor mRNA increased suggests that V^ receptor
levels depend on post-transcriptional mechanisms (Aguilera et al, 2003). It is thought
the interaction between glucocorticoids and vasopressin play an important role in
regulating anterior pituitary V]b receptor mRNA expression during alterations of the
HPA axis.
1.8. Oxytocin
Oxytocin is structurally very similar to vasopressin; it is made in the SON and the
magnocellular PVN and released from the posterior pituitary into the blood.
Oxytocin is also made by neurones within the PVN that project to other parts of the
brain and spinal cord (Ranson et al, 1998). Stress also increases oxytocin release into
the blood, increasing oxytocin levels 2-3 fold (Lang et al, 1983; Gibbs, 1984).
Oxytocin secretion increases alongside ACTH secretion although some stressors do
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not increase peripheral oxytocin secretion (Engelmann et al, 1999). Oxytocin can
also act centrally, but once secreted from the pituitary it cannot re-enter the brain
(Rinaman et al, 2000). Oxytocin that controls the responses of the HPA axis is
thought to more likely come from the magnocellular neurones within the PVN, but
may be secreted in the median eminence into the capillaries of the portal system from
axons of both PVN and SON neurons (Wotjak et al, 2001). Also, oxytocin is released
either by dendrites or cell bodies within the magnoceullular PVN or SON where it
can act locally on nearby neurones and synaptic contacts (Ludwig & Leng, 2006).
Oxytocin has also been described as an anti-stress factor within the brain, as central
administration of an oxytocin antagonist increases basal and stress-induced ACTH
secretion (Neumann et al, 2000). Also daily peripheral injections of oxytocin over a
five day period also decrease blood pressure (Moberg et al, 1988). Oxytocin
receptors have been found to be expressed in the brain and spinal cord including the
amygdala, VMH and brainstem (Tribollet et al, 1991). Oxytocin may also act in
other brain regions that express the oxytocin receptor to play a role in feeding
(Sabatier, 2006) and in reproductive behaviours (Pedersen & Boccia, 2006).
1.9. Circadian regulation of HPA activity
Connections between the PVN and suprachiasmatic nucleus (SCN) control the
circadian rhythm of glucocorticoid secretion through regulation of pPVN CRH
neurons. Connections can be both direct and indirect. Lesions of the SCN stop the
rhythmical control of Cortisol secretion (Moore & Eichler, 1972). In humans the
lowest peak in Cortisol secretion occurs about midnight. Cortisol levels rise about 2-3
hours after sleep onset (Van Cauter et al, 1994) and continue to rise until morning.
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The peak in Cortisol occurs at about 9am.Cortisol levels decline throughout the day.
Rats are nocturnal animals and their plasma levels of ACTH and corticosterone peak
in the evening and are lowest in the morning (Dallman et al, 1978). CRH is also
released in a circadian-dependent pulsatile fashion from the parvocellular cells of the
PVN (Hauger & Datzenberg, 2000), although CRH and Cortisol levels in the aCSF
are not under circadian rhythm (Kling et al, 1991). CRH gene transcription is
however under circadian control; CRH gene transcription in the PVN increases
during the night and decreases in the early morning in humans (Watts et al, 2004).
1.10. The relationship between glucocorticoids and energy balance
After acute stress the increased adrenaline and sympathetic neural activation
characteristic of a stress response interact to increase blood glucose to ensure the
brain has adequate amounts. As discussed above glucocorticoids inhibit activity of
the HPA axis through feedback mechanisms (Di et al, 2003). Increased
corticosterone concentration also leads to increases in food ingestion, especially
sweet and fatty food (Ipel et al, 2001). It is known that there are very close
relationships between feeding, metabolism and energy storage and glucocorticoid
secretion. In the presence of low insulin level, glucocorticoid concentrations are
elevated. Glucocorticoids are a key requirement when energy stores are low, and
they do not serve to inhibit the HPA axis in this state (Dallman et al, 2004).
Adrenalectomised (ADX) rats, with low glucocorticoid level, increase their caloric
intake with high energy diets; the increased caloric intake alters CRH expression in
the PVN and the amygdala and none of the normal effects characteristic ofADX are
seen (Dallman et al, 2004).
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An extensive neural system that regulates energy balance and controls activity of the
HPA axis has begun to emerge (Dallman et al, 1995). It is known that
glucocorticoids stimulate feeding and insulin secretion (Dallman et al, 1995), but
also mobilise energy stores peripherally, yet insulin inhibits food intake (Dallman et
al, 1995). Centrally, insulin inhibits NPY mRNA expression but corticosteroids
stimulate it (Dallman et al, 2005). It seems that there may be reciprocal actions of
insulin and corticosterone at the level of the NPY neurones controlling food intake.
1.10.1. Appetite control - hypothalamic neuropeptides
The hypothalamus has been known to play a major role in energy regulation for a
long time. The VMH has often been referred to as the "satiety" centre and the LHA
the "hunger centre" (Stellar, 1997). Rather than these nuclei specifically controlling
hunger and satiety it is thought that neuropeptides signalling via interconnected
neuronal circuits are in fact regulating energy balance (Schwartz et al, 2003). The
ARC is known to play a key role in regulating appetite. There are two major groups
of neurones in the ARC which control energy homeostasis (Cone et al, 2001), the
first inhibits food intake via expression ofPOMC and cocaine-amphetamine-
regulated-transcript (CART) (Elias et al, 1998), the second stimulates food intake via
expression ofNPY and agouti-related-peptide (AgRP) (Broberger et al, 1998).
NPY
High levels ofNPY are seen in the CNS (Allen et al, 1983). NPY mRNA expression
increases with fasting and when administered centrally NPY stimulates release of
insulin and reduces energy expenditure independently of increased food intake
(Moltz & McDonald, 1985). NPY belongs to the pancreatic polypeptide family; it
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binds to G-protein coupled receptors called Y1-Y6 (Larhammar, 1996). The
orexigenic effects ofNPY are thought to be mediated through the Yl, 2, 4 and 5
receptors (Fekete et al, 2002).
POMC and CART
POMC mRNA expression in the ARC decreases with fasting (Schwartz et al, 1997).
The melanocortins are produced from POMC and bind to the melanocortin receptor,
both melanocortin 3 and melanocortin 4 receptors are expressed in the ARC, VMH
and PVN and have been implicated in reducing food intake (Mountjoy et al, 1997).
CART mRNA also decreases with fasting (Kristenson et al, 1998); it is coexpressed
with a-MSH in the ARC and when administered centrally both CART and a-MSH
decrease food intake (Aja et al, 2001).
1.10.2. Downstream pathways
Hypothalamic nuclei such as the PVN, DMH, LHA and perifornical area receive
NPY/AgRP and POMC/CART neuronal projections from the ARC (Elias et al,
1998). These areas contain secondary neurones which process information regarding
energy homeostasis. A number of signalling molecules that are expressed in these
regions have been shown to be physiologically involved in energy homeostasis.
PVN
The PVN receives projections from the ARC and is sensitive to many neuropeptides
implicated in energy homeostasis including NPY (Lambert et al, 1995), ghrelin
(Lawrence et al, 2002), orexin (Edwards et al, 1999) and leptin (Van Dijk et al,
1996). Neurones projecting to the PVN which express NPY have been shown to
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reduce GABAergic signalling unlike neurones projecting to the PVN that express
POMC which increase GABAergic signalling (Cowley et al, 1994).
DMH and VMH
As well as indirect projections with other hypothalamic nuclei involved in energy
homeostasis the DMH receives direct projections from the NPY neurones in the
ARC (Kalra et al, 1999). The VMH has long since been thought to be the "satiety"
centre in energy homeostasis (Stellar, 1997) and receives projections from both the
NPY and POMC expressing neurones in the ARC (Stellar, 1997).
LHA
The LHA contains neurones that express melanocyte concentrating hormone (MCH).
(Marsh et al, 2002). Centrally administered MCH decreases food intake in mammals
(De Lecea et al, 1998). Orexin is also a peptide that is produced in the LHA although
it is produced in neurones separate to those that produce MCH (De Lecea et al,
1998). Orexin neurons (A and B) project widely throughout the brain, including to
the PVN and ARC (De Lecea et al, 1998). Centrally administered orexin-A
stimulates feeding (Haynes et al, 1999) and peripheral administration increases
insulin secretion (Novak et al, 2000), and the HPA axis (Taheri & Bloom, 2001).
1.10.3. Brainstem pathways
The brainstem plays a critical role in energy homeostasis, particularly via the nucleus
tractus solitarius; this is in close proximity to the area postrema, just like the ARC
which is in close proximity to the blood brain barrier-free zone in the median
eminence, which means it can react to peripherally circulating peptides (Ellacott &
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Cone, 2004). Y1 and Y5 receptor expression have been identified within the NTS
(Dumont et al, 1998).
1.10.4. Reward pathways
Reward circuitry regulating food intake is complicated (Wang et al, 2006). Levels of
insulin and leptin within the body switch "on" and "off' reward pathways, involving
the mesolimbic circuit (Levin, 2006). Other systems are also involved including
opioids where increased opioid can reduce the volume of food desired without
actually reducing hunger (Bodnar et al 2005; Yeomans et al, 1990). Dopamine has
also been implicated in this process. Centrally administered opioid and dopamine
antagonists cause an increase in the ingestion of sweet and fatty foods (Zhang &
Kelley, 2000). As discussed above the signals that activate the reward pathways are
peptides from the peripheral circulation.
1.10.5. Peripheral signals of adiposity
Leptin
Leptin is a peptide secreted from adipose tissue that plays a key role in energy
homeostasis. It is transported across the blood brain barrier into the ARC (Banks et
al, 1996) where it binds to its receptor, a member of the cytokine family (Tartague et
al, 1995). Leptin receptor expression has been seen in various hypothalamic areas
including the ARC, VMH, DMH and LHA (Fei et al, 1997). Greatest expression is
seen in the ARC, specifically in the NPY neurones (Mercer et al, 1996) and the
POMC neurones (Stephens et al, 1995).
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Insulin
Insulin is produced in the pancreas (Schwartz et al, 1992) and circulating levels
increase rapidly after a meal (Polonsky et al, 1988). Like leptin, insulin crosses the
blood brain barrier through a saturable process (Baura et al, 1993). On entering the
brain it reduces food intake (Ikeda et al, 1986), however studies investigating the
effects of insulin on food intake are complicated by the fact that hypoglycaemia
♦
caused by increasing levels of insulin increases food intake (Friedman &
Granneman, 1983). Insulin binds to its receptor which has tyrosine kinase activity
and is composed of two sub-units (Espinosa-Paez et al, 1998); the receptor is
distributed widely in the brain, particularly in the hypothalamus including the ARC,
DMH and PVN (Corp et al, 1986) and also peripherally in muscle and liver.
As well as the peripheral signals insulin and leptin, other peripheral signals from the
GI tract are also important in regulating energy homeostasis.
1.10.6. Peripheral signals from the GI tract
Ghrelin
Ghrelin is a 28 amino acid peptide released from the stomach but also from the testis,
placenta, kidney, pituitary, intestine, evidently synthesised in a group of neurones
next to the third ventricle which project to the NPY, POMC and CRH neurones
(Cowley et al, 2003). Ghrelin neurones in the brain also project to the orexin
neurones in the LHA (Toshinai et al, 2003) and i.c.v. administration of ghrelin
stimulates orexin neurones (Lawrence et al, 2002). Circulating ghrelin levels fall just
after a meal (Tschop et al, 2000). Ghrelin acts on the growth hormone secretagogue
receptor (GHS-R) and it stimulates growth hormone (GH) release either from the
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pituitary or by acting on the GHS-R in the brain, through which GH secretion is
stimulated (Kojima et al, 1999). GHS-R's are found widely including the
hypothalamus, pituitary, stomach, intestine, pancreas, liver, kidney and placenta
(Date et al, 2000). Ghrelin stimulates food intake following peripheral administration
in humans; in rats it increases Fos expression in NPY containing neurones in the
ARC (Toshinai et al, 2003).
1.11 Appetite-regulating neuropeptides and the HPA axis
The relationship between the HPA axis and factors relating to adipose tissue storage
are very important in the context of stress and obesity (Dallman et al, 1995). Many
neuropeptides that have been implicated in the control of appetite have also been
shown to activate the HPA axis. These include insulin, ghrelin, orexin and
neuropeptide Y (NPY).
1.11.1 Insulin Induced Hypoglycaemia (IIH)
Insulin
Insulin is secreted peripherally from the pancreas, and it can enter the brain. In the
ARC it inhibits the NPY/AgRP neurones and activates the POMC/CART neurones,
reducing appetite (Porte et al, 2002) (Fig. 1.2). Insulin induced hypoglycaemia (IIH)
has been shown to activate the HPA axis (Plotsky et al, 1985; Jezova et al, 1987).
Peripheral administration of insulin stimulates release ofACTH, p-endorphin, GH
and prolactin (PRL) (Jezova et al, 1987). While insulin reduces food intake,
hypoglycaemia caused by insulin injection increases food intake (Friedman &





Figure 1.2: Central processing of insulin induced hypoglycaemia and the HPA axis
PVN = paraventricular nucleus; CRH = corticotrophin releasing hormone; AVP =
arginine vasopressin; NTS = nucleus solitary tract; LHA = lateral hypothalamic area;
ARC = arcuate nucleus; NPY = neuropeptide Y; AgRP = agouti related peptide; POMC
= proopiomelanocortin; CART = cocaine and amphetamine regulated transcript
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are complicated by the contrasting effects of insulin and hypoglycaemia on neurones
within the brain.
Hypoglycaem ia
The LHA is importantly involved in controlling responses to IIH. It contains glucose
sensitive neurones that are stimulated by hypoglycaemia. It is thought that the
glucose sensitive neurones are activated mainly indirectly from projections in the
brainstem which receive information from glucoreceptors in the gut and liver (Paton
et al, 2000). Hypoglycaemia has been shown to increase Fos expression in the NTS
(Cai et al, 2001). The glucose sensitive neurone accounts for around 25% of the
LHA neurones, some of these have also been shown to express the orexin peptides
(Moriguchi et al, 1999). The orexins have been importantly implicated in the control
of food intake. Pre-pro orexin mRNA levels have been shown to be increased by IIH
but only when food was not available (Sakurai et al, 1998). When food was freely
available the increase in orexin mRNA seen by falling blood glucose was not seen
anymore (Cai et al, 1999). The orexin neurones may be very important then in the
control of short-term feeding behaviour, in particular in response to reduced blood
glucose level.
1.11.2 Orexin activates the HPA axis
The orexins have been shown to activate the HPA axis directly and indirectly
(Bornstein et al, 1997). Central administration of orexin-A has been shown to
increase Fos expression in the pPVN (Kuru et al, 2000) and also CRFI mRNA levels
in the pPVN (Brunton et al, 2003). Orexin activates neurones in the PVN indirectly
via the NPY neurones in the ARC because the stimulatory effect of orexin-A on
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CRH release in hypothalamic explants were blocked by a Y1 receptor antagonist
(Russell et al, 2001), and administration of an NPY antagonist in vivo blocked the
increase in plasma corticosterone normally seen (Jaszberenyi et al, 2001).
As well as mediating the effects of orexin on the HPA axis, NPY administration also
activates the HPA axis (Horvath et al, 1999).
1.11.3 NPY activates the HPA axis
Orexigenic NPY neurones are located in the ARC and the NTS (Heilig & Widerlov,
1993) and project directly to the PVN (Liposits et al, 1998). NPY has been shown to
stimulate CRH release and CRH mRNA expression (Suda et al, 1993). The HPA axis
can be stimulated by NPY given via various routes. The greatest CRH release was
seen however when NPY was injected directly into the PVN (Haas et al, 1989).
1.11.4 Ghrelin activates the HPA axis
Central administration of the neuropeptide ghrelin increases Fos expression in NPY
containing neurones in the ARC, and activates the HPA axis; ghrelin does not
activate the HPA axis when given systemically (Wren et al, 2000). It also stimulates
GH secretion when administered centrally suggesting a hypothalamic site of action
(Kojima et al, 1999). Ghrelin acts on the HPA axis by activating NPY neurones and
stimulating the pPVN CRH neurones (Wren et al, 2000) (Fig. 1.3). Ghrelin stimulates
release of both CRH and NPY from hypothalamic explants (Wren et al, 2000).
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Figure 1.3: Central processing of Ghrelin actions and the HPA axis
PVN = paraventricular nucleus; NTS = nucleus of the solitary tract; LHA = lateral
hypothalamic area; ARC = arcuate nucleus; NPY = neuropeptide Y; AgRP = agouti
related peptide; GHRH = growth hormone releasing hormone; CRH = corticotrophin
releasing hormone; AVP = arginine vasopressin
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1.12 Neuroendocrine adaptations to stress in pregnancy
As discussed, individuals can experience either internal or external stressors. Internal
stressors can be physical or psychological. Stressors can also be defined as those that
arise suddenly over a short period of time, acute stressors; or those that develop over
a longer period of time, chronic stressors (Kennedy et al, 1998). In chronically
stressed animals the response of the HPA axis to a stressor is reduced (Gomez et al,
1996). Pregnancy also acts in a similar way to a chronically stressed state where the
response of the HPA axis to a stressor is reduced during late pregnancy (Neumann et
al, 1998). As well as reduced responses of the HPA axis to stress, the basal activity
of the HPA axis also changes during late pregnancy (Johnstone et al, 2000; Atkinson
& Waddell, 1995).
1.12.1 Basal activity of the HPA axis during pregnancy
PVN: CRH and AVP expression
Basal CRH mRNA expression in the pPVN is reduced during late pregnancy. There
is no change in the ratio ofAVP to CRH mRNA indicating that basal AVP
expression is reduced also (Johnstone et al, 2000). Reduced basal expression could
be due to reduced forward drive or increased glucocorticoid feedback (Johnstone et
al, 2000).
ACTH and corticosterone
Morning basal levels ofACTH in rats have been reported not to change through
pregnancy (Neumann et al, 1998). However, the circadian increase in ACTH
secretion normally seen in the evenings is reduced in late pregnant rats (Atkinson &
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Waddell, 1994). Basal levels of corticosterone change little throughout pregnancy,
except for an increase seen on day 22 of pregnancy (Neumann et al, 1998; Atkinson
& Waddell, 1994), with reduced plasma corticosterone levels during early pregnancy
(Ogle & Kitay, 1977; Atkinson & Waddell, 1994).
1.12.2. Responses of the HPA axis to stressors in pregnancy
The HPA axis is hyporesponsive to both emotional and physical stressors during late
pregnancy (Neumann et al, 1998). Specifically ACTH, corticosterone and oxytocin
secretory responses to forced-swimming are reduced in rats (Neumann et al, 1998)
and in mice (Douglas et al, 2003). HPA axis responses to immune challenge with
systemic endotoxin or IL-ip are also reduced during late pregnancy (Brunton et al,
2005). I.c.v. orexin-A activates the HPA axis in virgin female rats but does not
increase plasma ACTH, corticosterone or CRH mRNA expression in the pPVN in
late pregnant rats (Brunton et al, 2003). Reduced responsiveness during late
pregnancy could be due to several reasons, including changes in limbic feedback
systems (Johnstone et al, 1997), changes at the corticotrophs of the anterior pituitary
(Neumann et al, 1998) or within the CRH/AVP neurones in the hypothalamus or
their inputs (Douglas & Russell, 2004).
1.12.3 Changes in limbic feedback systems
Changes in feed-forward activation of the HPA axis are found during late pregnancy,
including reduced responses to stress in regions of the limbic system that project to
the PVN (de Costa et al, 1996). The brain noradrenergic system is also restrained in
late pregnancy (Douglas et al, 2005) and there is reduced release of noradrenaline
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within the PVN after systemic IL-1(3 as well as reduced aiA-receptor mRNA
expression in the PVN (Brunton et al, 2005; Douglas et al, 2005). Reduced
noradrenergic release or action looks as if it is likely to contribute to reduced
activation of the HPA axis responses to stress; this has been shown to be partly due
to opioid inhibition (Brunton et al, 2005).
Enhanced glucocorticoid feedback could also be an explanation for reduced ACTH
secretion. Evidence of altered feedback was sought by looking at expression of the
mineralocorticoid (MR) and gluocorticoid (GR) receptor during late pregnancy. MR
and GR expression did not change in pregnant rats, except in the dentate gyrus where
GR mRNA expression was increased (Johnstone et al, 2000). 1 1 P-HSD 1 activity has
been shown to be increased 3-fold in the anterior pituitary by day 21 of pregnancy
(Johnstone et al, 2000). 11P-HSD1 converts corticosterone from its inert form, so
that increased 11 P-HSD 1 activity in the anterior pituitary in pregnancy is expected to
increase glucocorticoid levels at this site, thus increasing negative feedback by
corticosterone (Johnstone et al, 2000). Administration of an 1 lp-HSDl inhibitor,
glycyrrhetinic acid (GA), did not however increase the ACTH secretory response to
forced swimming (Johnstone et al, 2000). In contrast, pharmacological
adrenalectomy increased ACTH secretion similarly in late pregnant and virgin rats
(Johnstone et al, 2000). It may be that pregnant rats are less sensitive to rapid
glucocorticoid feedback but do not change sensitivity to delayed feedback (Johnstone
et al, 2000); this suggests reduced neural drive to the PVN may account for
hyporesponsiveness of the HPA axis to acute stress during late pregnancy.
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1.12.4 Anterior pituitary mechanisms in reduced HPA responsiveness during
late pregnancy
Another reason for reduced responsiveness of the HPA axis during late pregnancy
may be changes in the corticotrophs of the anterior pituitary. The number of CRH
receptors in the anterior pituitary is reduced on day 11 of pregnancy, although a
reduction in CRH-stimulated cAMP production was not seen until day 17 of
pregnancy (Neumann et al, 1998). The finding of a reduced number of CRH
receptors without changes in cAMP production indicates that during late pregnancy
reduced ACTH secretory responses are likely a result of changes at higher levels of
the HPA axis (Neumann et al, 1998). Changes in receptor numbers in the anterior
pituitary does not lead to reduced ACTH responses when CRH and AVP are both
given together (Ma et al, 2005). There is evidence that reduced release of AVP rather
than CRH accounts for reduced ACTH secretion in response to certain stressors
during late pregnancy (Ma et al, 2005).
1.12.5 Hypothalamic mechanisms of reduced responsiveness during late
pregnancy
It is possible that reduced neural drive to the PVN CRH/AVP neurones may account
for the hyporesponsiveness of the HPA axis rather than enhanced negative feedback
or changes in the anterior pituitary. C-fos mRNA expression in the pPVN is
significantly less after restraint stress than in virgin rats (da Costa et al, 1996).
Orexin-A exerts its effects on the HPA axis by acting centrally at the level of the
pPVN CRH/AVP neurones. The HPA axis has been shown to be hyporesponsive to
centrally administered orexin-A during late pregnancy (Brunton et al, 2003). This
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indicates that the CRH/AVP neurones are less responsive to excitatory stimuli which
could be a consequence of either reduced neural drive or enhanced inhibitory inputs
to the CRH neurones (Brunton et al, 2003).
1.12.6 Oxytocin secretory responses to stress during late pregnancy
During late pregnancy as well as reduced ACTH and corticosterone responses,
oxytocin secretory responses to stressors are also reduced. The content of oxytocin in
the posterior pituitary increases 3-fold at the end of pregnancy; this is due to
decreased secretion, conserving stores of oxytocin for when they are needed during
parturition (Russell et al, 2003). Possible reasons for reduced oxytocin responses
include a reduced ability of the oxytocin system to respond due to either reduced
effectiveness of excitatory input or increased effectiveness of inhibitory inputs.
Picrotoxin, a GABAa receptor antagonist (which interrupts tonic inhibition of
oxytocin neurones), stimulates oxytocin secretion in both virgin and pregnant rats
(Soafe et al, 2004).
Inhibition by endogenous opioids and neuroactive steroid metabolites of
progesterone are also thought to account for reduced oxytocin secretory responses to
stress during late pregnancy.
1.12.7 Endogenous opioids in pregnancy
Endogenous opioids restrain stimulation of oxytocin neurones during late pregnancy
(Douglas et al, 1995). Oxytocin secretion in response to IL-1 (3 was enhanced by
naloxone (the opioid receptor antagonist) indicating endogenous opioids may mask
an exaggerated response (Brunton et al, 2006).
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Secretion of prolactin (another stress hormone) has also been shown to be inhibited
during late pregnancy by endogenous opioids (Soaje & Deis, 1994). Naloxone also
restored the suppressed ACTH and corticosterone responses normally seen during
late pregnancy (Douglas et al, 1998). It is thought that naloxone may be exerting its
effects on the HPA axis via the hypothalamus (Wang et al, 1996), likely through the
CRH neurones. Hyporesponsiveness of the HPA axis to immune challenge during
late pregnancy is a result of endogenous opioid inhibition of the pPVN CRH
neurones (Brunton et al, 2005). Endogenous opioids may act by suppressing
noradrenaline release from the PVN. Naloxone triggered a pPVN CRH mRNA
response to IL-1 (3 and a noradrenaline response when microdialysed directly into the
PVN (Brunton et al, 2005). Naloxone does not distinguish between opioid receptor
subtypes; although the hypothalamus is almost devoid of 8 receptors (Mansour et al,
1987). Increased p receptor mRNA and pro-enkephalin A mRNA expression have
been seen in the NTS of pregnant rats (Brunton et al, 2005). Increased opioid
receptor and peptide production in the NTS could lead to increase transport to
terminals in the PVN; p opioids inhibit noradrenaline release in the SON (Onaka et
al, 1995) and the PVN (Brunton et al, 2005).
1.12.8 Sex Steroids during late pregnancy
Neuroactive steroid metabolites of progesterone are also involved in reduced HPA
axis and oxytocin responses to stress in late pregnancy. The neuroactive metabolite
allopregnanolone is produced in the brain, and enzymes converting progesterone to
allopregnanolone are expressed in the medulla (Khanna et al, 1995). As pregnancy
reaches term the amount of allopregnanolone produced decreases (Koncas et al,
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1998). Late pregnant rats treated with finasteride (a 5a-reductase inhibitor; where 5a-
reductase is an enzyme involved in converting progesterone to allopregnanolone) 20
and 2 hours before administration of IL-ip showed a significant oxytocin secretory
response in pregnant rats with no response seen in pregnant rats given vehicle and
IL-lp alone (Brunton et al, 2005). It is possible that allopregnanolone produced in
the medulla may act on neurones in the NTS and participate in inducing the opioid
inhibition seen at this time. As well as inducing opioid expression by acting on
noradrenaline neurones in the medulla it is possible that allopregnanolone may act
independently via the GABAa receptors on oxytocin and CRH neurones.
1.12.9. Placental CRH and POMC
CRH is synthesised and released by the human placenta (Goland et al, 1986) and
levels ofCRH mRNA increase in the last 5 weeks of pregnancy (Frim et al, 1988).
CRH mRNA has also been shown in gorilla, monkey (Robinson et al, 1989) and
sheep placenta (Jones et al, 1989) but it has not been seen in guinea pig or rat
placenta (Robinson et al, 1989). Because CRH mRNA is not seen in the rat placenta,
placental CRH is not involved in reduced responsiveness of the HPA axis in the rat.
The pregnant rat is a good model therefore to look at the adaptations of the maternal
HPA axis during late pregnancy.
1.12.10. CRH binding protein
CRH-binding protein (CRH-BP) may regulate CRH activity during pregnancy. CRH-
BP is a 37 kDa glycoprotein produced by the liver and brain (Orth et al, 1987). In the
brain CRH-BP is expressed predominantly in the cerebral cortex; it colocalises with
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CRH and CRH receptors in several brain regions (Potter et al, 1992). This co-
expression suggests that the CRH-BP may alter the interaction ofCRH with the CRH
receptor. In the brain 40-60% of CRH is bound to the CRH-BP (Behan et al, 1995).
As well as been expressed in the brain and liver (Potter et al, 1991) it has also been
shown to be expressed in the human placenta (Petraglia et al, 1993). It is possible
that the CRH-BP can regulate peripheral CRH activity in women during pregnancy
(Linton et al, 1990), and it is known that most of the CRH in the peripheral
circulation during pregnancy is bound to a 37 kDa protein (Orth et al, 1987). This
mechanism would not operate in pregnant rats, but a role for altered brain CRH-BP
in pregnant rats has not been explored, but is another possible mechanism for
reduced responses at this time.
1.13. Fetal programming
Exposure of women to exogenous agents including toxins, drugs and hormones
during pregnancy can alter the development and organisation of specific tissues
(Csaba, 1986). Males have been shown to have a burst of androgen secretion around
the time of birth; the extra androgen controls the neurochemistry of specific
hypothalamic nuclei (Arai et al, 1968). Oestrogens can also affect the developing
CNS (Simerley et al, 2002). This increase in certain steroid hormones and their
organisational actions are effective only at specific perinatal periods and determine
gender specific control of reproductive processes in the brain, but their effects persist
throughout life. Glucocorticoids during pregnancy can also have long term effects on
the foetus.
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1.13.1 Glucocorticoid programming
Glucocorticoids and birth weight
Glucocorticoid administration during pregnancy reduces birth weight in animal
models (Reinisch et al, 1978) and humans (French et al, 1998). Greatest reduction in
birth weight is seen when glucocorticoids are administered at the end of pregnancy
(Nyrienda et al, 1998) with glucocorticoids affecting placenta size also (Gunberg,
1957).
Glucocorticoids and tissue maturation
Glucocorticoid receptors (GR) are expressed in most foetal tissues and the placenta
from an early stage (Cole et al, 1995). Mineralocorticoid receptors are not expressed
until a later stage of pregnancy (Brown et al, 1996).
Birth weight andfoetalprogramming
A low birth weight has often been related to common cardiovascular and metabolic
disorders seen in adult life; e.g. hypertension and type II diabetes (Barker et al,
1993). It is thought that exposure of the foetus to glucocorticoids may account for
this (Barker et al, 1993).
Physiology: placental 11fi-hydroxysteroid dehydrogenase type II (11/I-HSD2)
Foetal glucocorticoid levels are much lower than maternal levels (Beitens et al,
1973). The mechanism for this is thought to be due to action of 11(3-HSD2 which is
expressed in the placenta. 11P-HSD2 creates a barrier to maternal glucocorticoids so
only a small proportion of maternal glucocorticoids can reach the foetus
(Benediktsson et al, 1997).
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11/3-HSD2 and birth weight
A deficiency in maternal 11 (3-HSD2 leads to overexposure of the foetus to
glucocorticoids and increases the susceptibility to several diseases in later life
(Edward et al, 1993). A strong negative correlation has been seen between placental
11P-HSD2 levels and low birth weight (Benediktsson et al, 1993).
1.13.2 Glucocorticoid programming and behaviour
Glucocorticoids are however very important in the developing CNS (Meaney et al,
1996). The HPA axis is very sensitive to prenatal glucocorticoids and perinatal
glucocorticoid exposure permanently increases basal plasma corticosterone levels in
rats (Levitt et al, 1996); this is thought to be due to a reduction in GR and MR
receptors in the hippocampus. Prenatal glucocorticoids can also affect the developing
dopaminergic system (Diaz et al, 1997). Stressful events in the second trimester of
human pregnancy are associated with increased incidence of schizophrenia (Koenig
et al, 2002). Hyporesponsiveness of the HPA axis to stressors in pregnancy is
another mechanism by which the fetus may be protected from adverse programming
actions of exposure to excess glucocorticoid.
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1.14. Aims of this thesis
It is known then that the HPA axis is hyporesponsive during late pregnancy to
emotional, physical and metabolic signals such as orexin-A. This reduced
responsiveness is known to be due to reduced responsiveness of the pPVN
CRH/AVP neurones since i.c.v. administration of orexin-A failed to activate them
during late pregnancy (Brunton et al, 2003). Part of this reduced responsiveness is
known to be due to opioid inhibition on the pPVN CRH/AVP neurones or their
inputs (Brunton et al, 2005), or due to inhibition by neurosteroid at the later stages of
pregnancy (Russell & Brunton, 2005). Oxytocin neurone responses are also
suppressed by allopregnanolone and endogenous opioids.
Several questions however remain unanswered;
• There are very close relationships between feeding, metabolism and
glucocorticoid secretion. Glucocorticoids are a key requirement for
responding to reduced energy stores. Corticosteroids stimulate feeding and
insulin secretion. Insulin-induced hypoglycaemia activates the orexin
neurones in the LHA (Cai et al, 2002) and HPA axis responses to orexin A
are known to be reduced during late pregnancy (Brunton et al, 2003). Insulin
itself has been shown to activate the HPA axis in male rats (Plotsky et al,
1985). It is not known if insulin activates the HPA axis in female or in late
pregnant rats.
• Ghrelin is another metabolic peptide that plays a key role in the control of
food intake and is also known to activate the HPA axis. Ghrelin is thought to
exert its orexigenic action via the ARC. It increases Fos expression in
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NPY/AgRP neurones. Central ghrelin neurones also terminate on orexin
neurones in the LHA and i.e.v. ghrelin stimulates orexin-expressing neurones
(Lawrence et al, 2002). Since ghrelin activates the HPA axis it is interesting
to know if it will do so in female rats and during late pregnancy.
• Ghrelin concentrations in blood increase before meals and are reduced by
food intake. Concentrations of ghrelin are inversely related to those of
insulin. Changes in the central effect of ghrelin on the HPA axis in
pregnancy, without any change in insulin action, may give an indicator of
whether insulin actions on the HPA axis are exerted via central ghrelin.
• It is known that the HPA axis is hyporesponsive to centrally administered
orexin-A in late pregnancy. Endogenous opioids inhibit CRH/AVP responses
following cytokine challenge during late pregnancy by acting pre-
synaptically on noradrenergic inputs to the CRH neurones (Brunton et al,
2005). It is not known whether endogenous opioids would interfere with
orexin signalling to the pPVN CRH/AVP neurones in late pregnancy.
• No differences between virgin and pregnant rats were found for the
stimulatory effects of orexin-A on behaviours reflecting activation of
centrally projecting CRH neurones or appetite. The loss ofHPA axis
responses to orexin in pregnancy is thus not a result of a general loss of
central responses to orexin-A. Changes in patterns of hypothalamic neurone
activation by orexin in late pregnancy may be expected, which may
illuminate the circuitries involved in HPA axis and appetite regulation.
• Orexin signals to the HPA axis in part via the NPY neurones (Jaszberenyi et
al, 2000) and ghrelin exerts its effects via the ARC NPY neurones. NPY is
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one half of the primary population of neurones in the ARC that controls
energy homeostasis. It is also known to activate the HPA axis. The effect of
NPY on the HPA axis in late pregnant rats is not known or indeed if
endogenous opioids interfere with NPY signalling to the pPVN CRH and
AVP neurones.
• Changes in patterns of activation of hypothalamic neurones during late
pregnancy could explain alterations in feeding and neuroendocrine stress
response patterns.
• Changes in NPY actions on oxytocin neurones in late pregnancy are not
known, though responses to other stimuli are reduced. If activity of the
oxytocin system after centrally administered NPY is not increased, this may
be the result of the effects of endogenous opioids on the oxytocin system.
Major adjustments in metabolic regulation during pregnancy helps ensure a
successful outcome. These include increased appetite and reduced energy
expenditure during exposure to stress as a result of reduced neuroendocrine stress
responses.
The aim of this thesis is to investigate attenutated HPA responsiveness in
pregnant rats, particularly in relation to actions of neuropeptides that regulate
appetite. This includes reduced stress responses to neuropeptides that stimulate
appetite which we know includes orexin but also to investigate the responses of
ghrelin, NPY and insulin which normally also activate the HPA axis. Suppression
of the HPA axis responses in pregnancy would help maintain a positive energy
balance, as a result of reduced glucocorticoid release with stress.
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Pregnancy changes also include suppressed activation of oxytocin neurones
which aids prevention of premature birth.
This thesis will also investigate the effect ofNPY, another orexigenic peptide and
investigate if reduced responses if any on oxytocin and HPA axis activation are
due to activation of inhibitory opioid mechanisms in the brain. The principal
techniques used in the thesis are in situ hybridisation, immunohistochemistry,
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2.1 Animals
Female Sprague Dawley rats were used (Bantin and Kingman, Hull, UK or Harlan,
Oxon, UK) with an initial body weight 260-290g. They were housed in groups of 5-
6 and maintained on a 12:12h light dark cycle (lights on at 07:00h) under standard
conditions of temperature and humidity with food and water available ad libitum.
The rats were given 1-2 weeks acclimatisation to animal facilities prior to any
experimental procedures or mating. The rats in the pregnant groups were mated
overnight with a sexually experienced male and pregnancy confirmed by the
presence of a vaginal plug of semen the following morning (day 1 of pregnancy). All
procedures were approved by the UK Home Office under the Animals (Scientific
Procedures) Act 1986. The rats were housed individually after surgery.
2.2 Anaesthetic
For recovery experiments, rats were anaesthetised by inhalation of halothane (3%
halothane in 1200ml/min of O2), and inhalation anaesthesia was maintained
throughout the surgery.
2.3 Surgery
For recovery experiments all surgery was performed under sterile conditions. All
instruments were autoclaved at 121°C, fur over surgical sites was shaved and the skin
sterilised with 70% alcohol and 1% w/v iodine.
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2.3.1. Jugular vein cannulation
The anaesthetised rat was placed on its back on an electrically heated
thermostatically controlled mat. A skin incision was made above the right clavicle
and the right external jugular vein was located and the connective tissue gently
teased away. When the vein was freed two ties (5.0 silk suture, Fine Science Tools,
Germany) were placed loosely around the vein. The cranial tie was tightened to
prevent venous return from the head. An incision was carefully made into the vein
with iridectomy scissors, and a silastic cannula (bore = 0.5mm; wall = 0.25mm :
Altec) 12 cm in length, filled with heparinised saline (0.9% saline, heparin 50
units/ml), was inserted. The cannula was inserted approximately 3cm into the vein to
reach the right atrium until blood could be freely withdrawn into a 1ml syringe. The
second tie was tightened to secure the cannula in place and prevent blood loss. A
final third tie secured the cannula tightly to the vein.
The cannula was exteriorised through a small skin incision just behind the ears at the
back of the neck. All wounds were closed off with silk sutures (size 2.0 Ethicon).
The cannula was secured to the skin with tape and sutures. A stainless steel blocker
was placed into the cannula to prevent blood loss out of the cannula.
2.3.2 Intracerebroventricular (i.c.v.) cannulation
Rats were implanted with an i.c.v. cannula 4-5 days before the experiment. In the
same procedure, the anaesthetised rat was placed in a stereotaxic frame and a midline
incision was made through the scalp. The connective tissue was retracted to expose
lamda and bregma, the skull was levelled between bregma and lambda. The i.c.v.
guide cannula (22-gauge, Bilaney Consultants Ltd, Kent, UK) was directed at the
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right lateral ventricle (stereotaxic coordinates: 1.6mm lateral and 0.6mm posterior to
bregma inserted to a depth of 4.6mm from the skull surface) through a burr-hole
made in the skull. The cannula was secured into place with dental acrylic and two
cheese head stainless steel screws (size 2mm). Finally a dummy cannula (22-gauge
Bilaney Consultants Ltd, Kent, UK) was inserted into the guide cannula.
After surgery rats were handled daily, dummy caps were rinsed in 0.9% saline and
loosened and tightened to familiarise the rats with the procedure prior to the day of
the experiment.
2.4 In situ hybridisation (ISH)
ISH was developed in 1969 (Pardue et al, 1969). It is widely used to detect the
localisation of specific nucleic acid sequences within a wide range of tissue
preparations. ISH uses a labelled probe to detect and localise specific DNA or RNA
sequences in a tissue and relies on the ability ofDNA to reanneal or hybridise with a
complementary strand when exposed to the correct temperature (Gall et al, 1969).
ISH involves a labelled (often with radioactivity) nucleic acid probe hybridising with
a DNA or RNA sequence in situ (in cells in the tissue of interest) so that the location
of the sequence of interest can be detected in the tissue (Sambrook et al, 1989).
ISH indicates the presence of a particular DNA or RNA sequence. It is the only
procedure that allows the location of the sequence to be studied (Polak et al, 1990).
The general procedure for ISH involves fixing samples of tissue onto a glass slide,
the material is then treated with chemicals to permeabilise the tissue and denature the
mRNA so that the probe can readily hybridise (Terenghi et al, 1990). A
complementary nucleic acid probe is prepared and labelled usually with
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radioactivity. A hybridisation solution is then placed onto the slide so that the probe
can hybridise with the sequence of interest. The excess probe is washed away and
then autoradiography is used to detect the location of the probe. The procedure is
summarised in figure 2.1. All equipment and consumables used in the process must
be kept sterile to avoid contamination, especially from RNAase. Once the probe is
labelled a volume containing at least 300,000 counts per minute are applied to each
slide (for quantitation see section 2.4.2.vii). Various controls are used to ensure
validation of the in situ protocol used. These are as follows. Performing the ISH
using no probe, to ensure that there is no non-specific binding. A sense probe
complementary to the anti-sense oligonucleotide probe is also used as a negative
control to ensure that the anti-sense oligonucleotide hybridises specifically with the
mRNA of interest. Radioactivity microscales also exposed to films enable
ascertaining that specific labelling is in the linear portion of the standard curve of
radioactivity against film or emulsion grain density. This enables calculation of the
concentration of bound radio-ligand. Sections can also be pre-treated with RNAase
as an additional control to check that the probe is bound to RNA. These controls
were not performed in these studies as all probes used were previously characterised
(Jingami et al, 1985; Majzoub et al, 1983) and quantification was relative between
experimental and control groups all processed in the same ISH together.
2.4.1. Materials
(T) Microscope Slides
All sections used for ISH were mounted on slides (Polysine; BDH, Merck House,
Poole, Dorset, UK). Marker sections to determine the location of areas of interest in
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the brain were mounted on slides (super premium twin-frost; BDH, Merck House,
Poole, Dorset, UK) dipped in a subbing solution composed of 2.25g gelatine and
0.23g chromic potassium sulphate dissolved in 1000ml ddH20. Slides were left to
dry overnight.
(ii) Glassware and Plasticware
Glassware and metal slide racks were wrapped in foil and sterilised by baking in an
oven overnight at 200°C. Plasticware (eppendorf tubes/pipette tips) was autoclaved
at 121°C. Items unsuitable for autoclaving were washed thoroughly and sprayed
with an RNA/DNAase inhibitor (RNAase away spray, Sigma).
(hi) General Solutions
All solutions were autoclaved and sterilised at 121°C prior to use.
DEPC-treated water
0.1 % diethyl pyrocarbonate [Sigma]
1000ml ddH20
0.1M Phosphate buffered saline (PBS); pH 7.2-7.4
11.5g di-sodium hydrogen orthophosphate (Na2HPC>4) [BDH]
2.72g sodium dihydrogen orthophosphate 2-hydrate
(Na2HP04.2H20) [BDH]
8.5g sodium chloride (NaCl) [BDH]
1000ml DEPC treated water
20x standard Sodium Citrate (SSC)
175.4g sodium chloride (NaCl) [BDH]
88.2g tri-sodium citrate [Sigma]
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1000ml ddH20
To make lx SSC solution 50ml of stock solution and 950ml ddH20 was used.
4% Paraformaldehyde in 0.1M PBS; pH 7.2-7.4
1 Og paraformaldehyde [Sigma]
250ml 0.1M PBS
Triethanolamine (TEA/acetic anhydride solution)
2.98 ml triethanolamine [Sigma]
0.5ml acetic anhydride [Sigma]
840pl concentrated hydrochloric acid [BDH ]
200ml ddH20
(iv) Hybridisation Buffer components
Hybridisation buffer was prepared from 12 different components listed below. After
preparation these components were added together to make hybridisation buffer
(Table 2.1)








Ethylenediaminetetraacetic acid (EDTA) 250mM
23.26g EDTA [Sigma]
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Hybridisation Buffer recipe
Reagents Volume of solution added
5M NaCl (292mg/ml) 12ml
Tris 7.6 (149mg/ml) 1ml
Denhardts Solution 1ml
EDTA 250mM (232.6mg/ml) 400pl
Dextran Sulphate (500mg/ml) 5ml
NaPPI (50mg/ml) 500pl
Yeast tRNA (35mg/ml) 200pl
Yeast total RNA (20mg/ml) 250pl
Salmon testes DNA (lOmg/ml) 1ml
Poly (A) (15mg/ml) 330pl
Formamide (50%) 20mls
DTT (154mg/ml) 550pl*
TABLE 2.1: Recipe for 50ml of hybridisation buffer.
All components were added to a sterile falcon tube.
* DTT was added immediately prior to use when the radioactive material was added
also.
(V) Probes
There are four main different types of probes that can be used, double and single
stranded DNA probes, synthetic oligonucleotide probes and single stranded RNA
probes; there are advantages and disadvantages to using each of these (Agarwal et al,
1981). Synthetic oligonucleotide probes have good penetration properties, are
commercially available and relatively inexpensive (Beesley, 2001). Synthetic
oligonucleotide probes (MWG-Biotech UK Ltd.) were used throughout in the studies
described in this thesis. These probes are short, single stranded pieces ofDNA which
are complementary to a designated segment of the mRNA of interest, and as such
will seek out and bind to the mRNA, similar to an antibody binding to an antigen
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(Das et al, 1983). These oligonucleotides can be produced by an automated DNA
synthesiser in a few hours and obtained within 3-4 days (Egeland et al, 2005).
2.4.2. The Protocol
(i) Tissue Collection
The rats were killed by conscious decapitation. Brains (transected at the rostral pons)
and brainstems were rapidly removed, placed on aluminium foil and frozen
immediately on dry ice before being stored in pre-labelled plastic bags at -70°C.
Coronal brain sections (15pm) containing hypothalamic PVN were cut using a
cryostat at -16°C. The location of all areas of interest was confirmed using the
marker slides (sections were stained with toludine blue and examined under a light
microscope) with reference to a stereotaxic rat brain atlas (Konig 1963).
(ii) 3'end labelling of the oligonucleotide probe
Deoxyribonucleoside triphosphate labelling of the 3'-OH double or single stranded
DNA with radioactively labelled nucleotides was catalysed by the terminal
deoxynucleotidyl transferase (TdT) enzyme (Kumar et al, 1988). A water bath was
heated to 37°C for the labelling reaction mixture below, which was put into a sterile
eppendorf:
27pl sterile ddHiO
lOpl 5 x TdT tailing buffer [Promega]
5pl (~ 2MBq) 35S dATP [Perkin-Elmer]
(calculated using documentation with 35S)
2pl Probe (working dilution lOpmol/pl) [MWG-Biotech]
1pi TdT enzyme (25 units/pl) [Promega]
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The reaction mixture was incubated in a sterile eppendorf at 37°C for 1-2 hours and
cooled on ice to stop the reaction.
(iii) Purification using Spin Columns
The QIAGEN quick nucleotide removal kit (Qiagen,West Sussex) is designed for the
'clean up' of radioactive DNA fragments and oligonucleotides >_17 nucleotides. It
also ensures removal of primers <10 bases, enzymes, salts and incorporated
nucleotides.
500pl of buffer PN (from the kit) was added to the 50pl of reaction sample and
placed into a spin column. The spin column was centrifuged for 1 min @ 6000rpm.
The centrifuged spin column was then transferred into a clean 2ml collection tube
and the radioactive flow-through discarded. 500pl of buffer PE (from the kit) was
added to the collection tube and centrifuged for 1 min @ 6000rpm. The radioactive
flow through was again discarded and the procedure repeated with another 500pl of
buffer PE using the same 2ml collection tube. The flow through was discarded and
then centrifuged again for an additional 1 minute at 13,000 rpm. The spin column
was then placed into a clean 1.5ml eppendorf and 50pl elution buffer (EB) added to
the centre of the spin column so that it covered the resin filter. It was left to stand for
1 minute and then centrifuged for a further 1 minute @ 13,000 rpm. A 1 pi sample
was removed from the eppendorf tube and together with 3.5ml of scintillation fluid
(Ultima Gold) was counted using a P-counter.
(iv) Tissue Fixation
Slides that were selected for ISH were removed from the freezer and allowed to
reach room temperature for about 1-2 hours.
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The slides were placed in racks and fixed in 4% paraformaldehyde in 0.1M PBS (pH
7.2-7.4) for 10 minutes. They were then washed twice in 0.1M PBS (5 minutes each
time) followed by acetylation in triethanolamine/acetic anhydride solution for 10
minutes. The slides were finally washed in sterile ddH20 and dehydrated in an
ascending alcohol series through 70%, 95% and 100% ethanol (3 minutes each),
washed in chloroform for 3 minutes and then dehydrated in 100% ethanol and
partially rehydrated in 95% ethanol for 3 minutes. The slides were then thoroughly
air-dried.
(V) Hybridisation
Humid incubation chambers using plastic sandwich boxes lined in the base with
moist (ddH20) filter paper were prepared. Slides were arranged on a glass platform.
The labelled probe was diluted in hybridisation buffer, so that a 90pl aliquot of
buffer diluted probe contained 300,000 cpm of activity. DTT was added (1 pl/90pl of
hybridisation buffer) to reduce background. 400(0.1 of hybridisation buffer containing
the labelled probe and DTT was pipetted onto each section on each slide and a sterile
parafilm "coverslip" was positioned over the sections. The incubation chambers were
then sealed and incubated at 37°C overnight.
(vi) Post-Hybridisation Washes
3 beakers containing 1 x SSC were set up at room temperature. Using forceps the
Nescofilm coverslip was removed and the slides moved back and forth in the SSC
slide rack. The water bath was heated to an appropriate temperature, relevant to the
length of the probe - the temperature is usually 20°C below that of the melting
temperature of the probe used; e.g. if the melting temperature of the probe is 75°C
then the temperature of the washes is 55°C (Jingami et al, 1985). The slides were
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rinsed in a rack for 4 x 15 minute washes at 55°C and then 2 x 30 minute washes in 1
x SSC at room temperature. The slides were finally rinsed in ddHfO and left to dry.
(vii) Dipping slides in autoradiographic emulsion
Slides were dipped in autoradiographic emulsion to detect the location of the
hybridised mRNA of interest. The emulsion (Ilford, K.5 emulsion in gel form,
Knutsford, Cheshire, UK) was warmed in a waterbath at 43°C until molten. Under
safelight conditions the slides were dipped in the emulsion and air dried overnight.
When the slides were dried they were transferred to slide boxes (under safelight
conditions) containing silica pouches. Slide boxes were sealed with electrical tape
and wrapped in tin foil and stored at 4°C for the required exposure time. The
optimum exposure time was determined using 14C microscales to generate a standard
curve. The standard curve enables calculation of the concentration of bound
radioligand. A sigmoidal standard curve is generated and the optimum exposure time
is chosen when radioactivity signal from the hybridised tissue is on the steepest part
of the curve. Again these controls were not performed in these studies as exposure
times were previously determined. Once exposed for the desired time the slides were
developed under safelight conditions (Kodak D-19, Sigma, Poole, UK) and fixed
(Hypam rapid fixer, Ilford, Knutsford, Cheshire, UK). The sections were then
counterstained using haematoxylin and eosin and dehydrated in a graded ethanol
series, before being cleared in xylene and coverslipped using DePex mount.
(viii) Quantifying Hybridised Cells
The amount of hybridised mRNA in a brain area was assessed using a light
microscope (Wang 6000 series microscope x20 magnification) connected to a CCD
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video camera and the NIH image analysis system (Version 1.62) on an Apple
Macintosh computer.
Emulsion-dipped slides were used for cellular analysis ofmRNA (objective
magnification x20). The first method of analysis involved counting the number of
positive expressing cells in a nucleus (of known area). A positive cell was defined as
one with more overlying silver grains than the mean over an area equivalent to 1cm2
10 cells lateral to the area of interest (background + 3 s.d.).
A second method of analysing emulsion dipped slides was to measure silver grain
density over cells in the region of interest using the NIH program. A fixed circular
counting frame was set for identification of a labelled cell and for background
readings. Silver grain density measurements were made over 5-6 cells in the nucleus
per side ofPVN and over an equivalent area in the nearby background.
When measuring AVP mRNA expression often the staining was so dense that the
area of the PVN was measured and the amount of silver grain within that area
measured. Background measures (of known area) adjacent to the PVN were also
measured and the area of the PVN normalised to 1.
2.5 Immunohistochemistry (IHC)
IHC was first used in 1941 (Coons et al, 1950). It is a technique for identifying
cellular or tissue constituents by means of an antigen-antibody interaction. An
antibody is used to link an antigen specifically to a stain that can be readily seen with
a microscope (Coons et al, 1950). Many macromolecules can be successful antigens
for raising antibodies, and these antibodies can either be polyclonal or monoclonal.
Monoclonal antibodies are much more specific (Hsu et al, 1981). Fixatives are
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needed to preserve protein in cells; either the tissue is fixed ex vivo or the deeply
anaesthetised animal is perfused with a fixative via the circulatory system. The
antigen can be localised either by direct labelling using 1 step, indirect labelling
using 2 steps or indirect labelling using two-steps and signal amplification. In the
present studies the two-step indirect method was used. In this procedure an
unlabelled primary antibody binds to the antigen and is visualised by a labelled
secondary antibody targeted against antibody from the animal in which the first
antibody was raised, in this case rabbit (Park et al, 1982).
Fos immunohistochemistry
Fos is the protein product of the immediate early gene c-fos and can be detected by
immunohistochemistry using either an indirect method as described by Shu (Shu et
al, 1988), or the avidin-biotin complex (ABC) (Srisawat et al, 2000). In the present
study Fos protein was localised using a rabbit affinity purified polyclonal antibody:
c-fos (Ab-2; Oncogene Research Products). Fos immunoreactivity was visualised
using a labelled secondary antibody: goat anti rabbit IgG peroxidase (Vector
Laboratories). Diaminobenzidine (DAB) was used as the substrate for the enzyme
reaction, which converts a colourless chromagen into coloured end products. The
reaction was enhanced by nickel-glucose oxidase (Elias et al, 1987). The procedure
is summarised in Figure.2.2.
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2.5.1 Materials
(i) Microscope slides
Super premium twin-frost slides (BDH, Merck House, Poole, Dorset, UK) were
dipped in a subbing solution composed of 5g gelatine, 0.46g chromic potassium
sulphate mixed with 1000ml ddH20. Slides were left to dry overnight.
(ii) General Solutions
1M Phosphate Buffer (PB) pH 7.2-7.4
115g disodium hydrogen orthophosphate (Na2HP04.2H20) [BDH]
27.2g sodium dihydrogen orthophosphate (Na^PCU^O) [BDH]
1000ml dH20
0.1M Phosphate Buffer-Triton-X (PB-T)
0.2% (v/v) Triton-X [Sigma]
0.1MPB
4% paraformaldehyde
40g paraformaldehyde [Sigma ]






Hydrogen peroxide/methanol solution (to inactivate the endogenous peroxidase)
20% (v/v) methanol [BDH]
1.5% (v/v) hydrogen peroxide [Sigma]
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80% (v/v) 0.1MPB
Preincubation Buffer








Biotinylated anti-rabbit IgG (lOpl/ml)




Biotinylated horseradish peroxidase (250pl/ml)
PB-T
0.2M Sodium Acetate Buffer pH 6.0
27.2g Sodium Acetate (CPBCOONa)
1000ml dH20
0.1M Sodium Acetate Buffer
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Nickel-DAB solution
5g nickel ammonium sulphate [Sigma]
400mg glucose [BDH]
80mg ammonium chloride [Sigma]
50mg diaminobenzidine (DAB) [Sigma]
3mg glucose oxidase* [Sigma]
lOOmls 0.2M sodium acetate buffer
lOOmls dH20 *glucose oxidase was added 30 seconds prior to use
2.5.2 Protocol for floating sections
(i) Tissue collection
At the end of the experiment the rats were killed by transcardial perfusion. The rats
were deeply anaesthetised with pentobarbitone (60mg/ml, 0.7ml/kg), delivered via an
intra-peritoneal injection. The chest was opened to expose the heart and the rats were
perfused with ~ 200 ml heparinised saline (50ml, 20U/ml 0.9% saline) via the left
ventricle and ascending aorta, followed by ~ 300 ml of 4% (w/v) paraformaldehyde.
The brain, brainstem and pituitary were removed and stored progressively in post-fix
solution (1:1 mix of 4% paraformaldehyde in 0.1 M PB and 15% sucrose in 0.1M
phosphate buffer) and then transferred to 30% sucrose solution in 0.1 M phosphate
buffer before being frozen and stored at -70°C.
Coronal microtome brain sections (52pm) through the hypothalamus were collected
in sterile pots and stored in cryoprotectant (200ml glycerol. Sigma; 300ml ethylene
glycol, Sigma; 500 ml 0.2M PBS) at -20°C until required for use.
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(ii) Primary Antibody Preparation
Sections stored in cryoprotectant were removed from the freezer and allowed to
reach room temperature. They were transferred to sterile petri-dishes in a small sieve
and given 3x5 min washes and 2x10 min washes in 0.1M PB with 0.2% (v/v) PB-
T. Sections were then washed in 0.1M PB for 5 minutes followed by a 15 minute
wash in the hydrogen peroxide/methanol solution to deactivate the endogenous
peroxidase in the hypothalamus. In order to wash out the methanol and aid
impregnation of the brain tissue the sections were washed in 0.2M PB with 0.2%
(v/v) PB-T. They were then washed in the pre-incubation solution for 1 hour before
being placed in small vials containing primary antibody solution for 20-48 hrs at 4°C.
(iii) Secondary Antibody and Visualisation
After incubation the sections were washed in PB-T for 3 x 5 min and 2x10 min. The
sections were then incubated in the secondary antibody solution for 1 hour and were
then further washed in PB-T for 3 x 5 min and 2x10 min. The sections were further
incubated for 1 hour in the peroxidase/antiperoxidase (PAP) complex. Sections were
washed in PB-T for 2 x 10 min and then prepared for visualisation by washing in
0.1M sodium acetate buffer. Nickel-DAB solution was added to the sections and the
reaction closely monitored. Sample sections were periodically placed on slides and
examined under the microscope to track the progress of the reaction. All sections in
the experiment were incubated for the same time. When staining was judged
sufficient the reaction was stopped by immersing in 0.1M sodium acetate buffer for 5
minutes and sections were stored in 0.1M PB until mounted onto gelatinised slides.
The slides were air dried and then further dehydrated with 50%, 70%, 80%, 90% and
95% alcohol for 5 minutes each and then washed twice in 100% alcohol and xylene
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for 10 minutes each. Coverslips were coated with DePeX and placed over each slide,
ensuring that all air bubbles were pressed out. The slides were left to dry overnight.
To validate the protocols various measures are used. Immunohistochemistry is
performed without primary antibody to ensure signal is specific; the Fos antibody
used in the present study has already been well-characterised. Rats given i.p.
hypertonic saline (2M, 0.5ml and killed 90 min later) were used as positive controls
in every Fos experiment since this treatment reliably induces Fos expression in
specific brain regions (Ludwig et al, 1997).
(iv) Quantitative Analysis
Immunohistochemically stained sections were examined under a microscope at x40
objective magnification, and the number of Fos positive nuclei counted on both sides
in the arcuate nucleus, paraventricular nucleus, supraoptic nucleus, lateral
hypothalamic area, ventromedial hypothalamus and dorsal medial hypothalamus.
The slides contained three sections and were coded to ensure that cell counts were
'unbiased' and 'blind'. Mean values were calculated from the three sections on each
slide and for all slides on each experimental group. Photomicrographs were taken of
sections using a digital camera at x20 and x40 magnification.
2.5.3. Protocol for unfixed cryostat sections
(i) Tissue Collection
This method was used where brains were also collected and sectioned for ISH. The
rats were killed by conscious decapitation and brains/brainstems were rapidly
removed and frozen on dry ice. The brains/brainstems were cut into 15pm coronal
sections through the region of interest using a cryostat. The sections were thaw
68
General Methods Chapter 2
mounted onto gelatine coated slides and stored at -70° C until immunohistochemical
processing.
(ii) Primary Antibody Preparation
Sections were removed from the freezer and allowed to reach room temperature.
They were outlined with a PAP pen (Sigma Aldrich), transferred to glass staining
dishes and fixed in 4% paraformaldehyde for 30 minutes at room temperature,
followed by 3 x 5 minute washes in 0.1M PB. Endogenous peroxidase was
deactivated with the hydrogen peroxide solution for 15 minutes. In order to wash out
the methanol and aid impregnation of the brain tissue the slides were washed in 0.2M
PB with 0.2% (v/v) PB-T, they were then washed in the pre-incubation solution for 1
hour. The slides were transferred to flat trays containing filter paper soaked in 0.1 M
PB and coated (750pl/slide) in primary antibody solution and incubated for 20-48 hrs
at 4°C. Additional primary antibody solution was applied if necessary if the sections
had begun to dry out.
(iii) Secondary Antibody and Visualisation
The following day primary antibody solution was drained from the slides, which
were washed in PB-T for 3 x 5 min and 2x10 min. The slides were returned to the
flat trays and coated in secondary antibody solution (750pl/slide) for 1 hour, these
were drained then further washed in PB-T for 3 x 5 min and 2x10 min. The slides
were further incubated for 1 hour in the peroxidase complex. Slides were washed in
PB-T for 2 x 10 min washes and then prepared for visualisation by washing in 0.1M
sodium acetate buffer. The visualisation solution was added to the sections and the
reaction closely monitored. A sample slide was periodically examined under the
microscope to track the progress of the reaction. When staining was judged sufficient
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the reaction was neutralised by immersion in 0.1M sodium acetate buffer for 5 min.
The slides were air-dried and then further dehydrated with 50%, 70%, 80%, 90% and
95% alcohols for 5 minutes each and then washed twice in 100% alcohol and xylene
for 10 minutes each. Coverslips were coated with DePeX and placed over each slide,
ensuring that all air bubbles were pressed out. The slides were left to dry overnight.
(iv) Quantitative Analysis
Immunohistochemically stained sections were examined under a microscope at x40
objective magnification and the number of Fos positive nuclei counted on both sides
in the arcuate nucleus, paraventricular nucleus, supraoptic nucleus, lateral
hypothalamic area, ventromedial hypothalamus and dorsal medial hypothalamus.
A Fos positive cell was defined as a cell with a nucleus that was stained clearly
darker (i.e. was black) than a background cell (see photomicrographs for
comparison). The slides each contained three sections and were labelled with a coded
number to ensure that cell counts were made 'blind' to treatment. Mean values were
calculated from the three sections on each slide, and for all slides for each
experimental group. Photomicrographs were taken of sections using a digital camera
at x20 and x40 objective magnification.
2.6 Blood Samples
Jugular venous blood was collected into sterile 1ml syringes and placed into 1.5ml
eppendorf tubes containing 50pl 5% EDTA. All blood samples were stored on ice
until centrifugation. Blood was centrifuged at 13,000 rpm for 2 minutes. The plasma
was separated and stored at -20°C until radioimmunoassay. In each experiment,
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blood removed from the animal was immediately replaced with sterile 0.9% saline
via the jugular cannula.
Blood glucose was measured using a Roche Accuchek Active Meter; <1 00(li1 blood
was taken and applied to the test stick. Results (mmol/1) were obtained immediately.
2.7 Adrenocorticotropic hormone (ACTH) immunoradiometric assay
ACTH is a polypeptide consisting of 39 amino acids. In this case a commercially
available two-site immunoradiometric kit (IDS Ltd. Sweden) was used to quantify
the concentration ofACTH in a plasma sample (Hodgkinson et al, 1984). A two-site
immunoradiometric assay involves two sets of antibodies one ofwhich is
radioactively labelled. The two antibodies combine with different immunoreactive
sites on an antigen molecule and therefore detect the intact antigen.
Two antibodies were used here to combine with different sites on the ACTH
1 7 S
molecule. One was a radioactively labelled " I sheep antibody which recognises the
amino terminal of the ACTH molecule. The other was a C-terminal anti-ACTH
rabbit antibody which coupled to the sheep anti-rabbit coated tubes provided in the
kit. This antibody also reacts with the C-terminal region of the ACTH molecule.
Following overnight incubation a 'sandwich type' complex forms between the sheep
anti-rabbit antibody on the wall of the coated tubes and the second antibody. The
I if
tubes were washed twice and decanted to remove any excess I sheep anti- ACTH.
The amount of radioactivity in each tube was proportional to the concentration of
ACTH in each tube. Each tube was counted in a gamma counter (Wallac) for 1
minute. The principle of the procedure is summarised in Figure 2.3. Sensitivity of
the ACTH assay was calculated. Reference standards were provided as quality
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controls. A standard curve was created from the concentration obtained from the
calibrators, which allowed the concentration ofACTH in the plasma samples to be
calculated. Reference controls I and II were provided as quality controls. The
concentration ofACTH (pg/ml) in these controls was provided and this was checked
with the readings obtained in the laboratory.
Wallac (Perkin Elmer, USA) software automatically generated a standard curve by
plotting the average radioactivity (cpm) for each tube against the known
concentration of the ACTH standards and calculated the unknown values in the
plasma sample (Figure 2.4).
2.7.1 Materials
An ACTH IRMA kit (IDS Ltd., Sweden) containing:
(i) Seven standard ACTH solutions ranging from Opg/ml - 1250pg/ml
(ii) Two reference controls containing different concentrations ofACTH
(iii) [125I]-ACTH antibody (rabbit anti-ACTH)




Tubes coated internally with C-terminal anti-ACTH, coupled to sheep anti-rabbit
antibody coated tubes were labelled for standard and plasma samples. Glass tubes
were labelled 1 and 2 for the total counts. The calibrators, controls and l25I antibody
were reconstituted with distilled water. Plasma samples were defrosted and allowed
to reach room temperature. These and the standards (calibrators, A-G) were
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vortexed gently before use. 200pl of each standard, control and plasma sample was
19 S
carefully pipetted into tubes. 200pl of the I labelled antibody solution was added
to each tube. This radioiodinated antibody binds to the amino terminal of the ACTH
molecule. The second immobilised antibody reacts non-competitively with the C-
terminal region of the ACTH molecule. All tubes were vortexed and incubated
overnight at room temperature, to allow a 'sandwich type' complex to be formed
between the sheep anti-rabbit antibody on the wall of the coated tubes and the second
antibody and between the ACTH and the two anti-ACTH antibodies. The coated
tubes were washed twice to remove any excess tracer, and then the liquid aspirated
completely. The amount of radioactivity in each tube was proportional to the
concentration of ACTH in each tube. Each tube was counted in a gamma counter
(Wallac) for one minute.
2.8 Radioimmunoassay (RIA)
RIA has been used for many years in research and clinical practice in endocrinology.
It was first used in 1960 (Yalow et al, 1960). It involves the separation of the
hormone using the specificity of antibody-antigen binding, and quantitation using
1 9 S •
radioactivity (Yalow et al, 1960). A mixture of radioactive antigen, often I, with
antibodies directed against the antigen is used. Known amounts of unlabelled antigen
are added to samples of the mixture to produce standard curves, or aliquots of the
unknown sample are added. The added labelled and unlabelled antigen competes for
the binding sites of the antibodies. At increasing concentrations of unlabelled
antigen an increasing amount of radioactive antigen is displaced from the antibody









complex with a second antibody
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Figure 2.5: Diagram ofthe principle of radioimmunoassay
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supernatant fluid and the radioactivity of each is measured (Pots et al, 1967).
Concentrations of unknown antigen are then read from the standard curve.
There are several ways to separate the bound from the free antigen. One way is to
precipitate the antigen-antibody complex by adding a second antibody directed
against the first, for example if a rabbit antibody was used to bind to the antigen then
the complex can be precipitated by adding an anti-rabbit antibody. This procedure is
summarised in Figure.2.5.
2.8.1 Corticosterone Radioimmunoassay
Corticosterone is a glucocorticoid produced by the adrenal cortex in response to
adrenocorticotropic hormone (ACTH) (Jones et al, 1987). The production of
glucocorticoids is increased by stress, therefore change in plasma corticosterone
concentration is an indicator of adrenal cortex secretion stimulated by ACTH.
Plasma corticosterone concentration shows a circadian variation controlled by the
suprachiasmatic nucleus (SCN), acting through ACTH (Takahashi et al, 2001).
Plasma corticosterone concentrations were quantified using a commercially available
• • • 19 S
radioimmunoassay kit (IDS Ltd.) which is a competitive assay. It uses I-
corticosterone and an anti-corticosterone antiserum to determine the concentrations
of hormone in a plasma sample by the double antibody technique. It permits
corticosterone measurements within the range of 0.5-62.5 ng/ml.
2.8.2. Materials
1 9 S
A gamma-B I -Corticosterone RIA kit containing:
(i) Assay Buffer: phosphate buffered saline
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(ii) Corticosterone antiserum: rabbit anti-corticosterone
(iii) [125I]-corticosterone
(iv) Second antibody: goat anti-rabbit antiserum
(v) Corticosterone standard: lOOOng/ml corticosterone
2.8.3 Protocol
Eleven glass tubes were labelled A-K for a series of standards of known
concentrations of corticosterone. Standards were serially diluted, ranging in
concentration from 0.5 - 62.5 ng/ml. The samples and standards were added to their
respective tubes (samples were diluted 1:8 in assay buffer). lOOpl 125I-
corticosterone was added to all the tubes, which were vortexed, and lOOpl of
corticosterone antiserum was added to all tubes except for the total count tubes and
non-specific binding tubes. The tubes were vortexed and incubated overnight at 4°C.
Following incubation, lOOpl of the second antibody was added to all tubes except for
the total count tubes. The tubes were vortexed and incubated for one hour at room
temperature. 1.0ml of saline was added to all tubes except the total count tubes.
Tubes were centrifuged at 1500-1600g for 20 minutes at 2-8°C. The supernatant of
each tube was then immediately carefully decanted and the rim of each tube blotted
on absorbent paper. Decanting was done smoothly and carefully to avoid dislodging
the pellet. The radioactivity in the tubes was counted for at least one minute in a
gamma counter (Wallac). A quality control report was provided with an acceptable
range of values (ng/ml). The software of the gamma counter calculated a standard
curve (Fig.2.6).
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In order to calculate the sensitivity of an assay it is necessary to calculate the amount
of radioactivity bound by each standard (B) as a % of the maximum binding in the




( mean cpm of standard - mean cpm ofNSB51)
( mean cpm ofBmax - mean cpm ofNSB)
v. _y
X 100
* NSB = non-specific binding (binding that is not specifically bound to the antibody)
From these data a standard binding curve can be obtained (Figure 2.7). The graph
can then be used to convert the sensitivity of the assay from the percentage B/Bmax
to a hormone concentration.
Sensitivity = [Bmax - (2 x s.d. Bmax)] - NSB
Bmax - NSB
2.9. Statistics
A two-way analysis of variance (ANOVA) was used with a repeated measures
ANOVA used for blood sampling experiments. Each time the ANOVA was followed
by a Student Newman Keuls multiple comparison test, to locate significant
differences. A p value of <0.05 was considered statistically significant. The statistical
package used was Sigma Stat.
76
General Methods Chapter 2



















di-sodium hydrogen orthophosphate (NaBbPC^)
dithiothreitol (DTT)

























General Methods Chapter 2
ethylenediaminetetraacetic acid (EDTA) Sigma, UK
Fixer Rapid Fixer lot # 19D0055 Ilford, Cheshire
Suture thread (2.0 gauge) Ethicon, UK
formamide Sigma, UK
Ghrelin Phoenix Pharmaceuticals, USA
Glucose BDH, Poole
Glucose oxidase Sigma, UK
Fleparin Sigma, UK
hydrochloric acid BDH, Poole
Hydrogen Peroxide Sigma, UK
Insulin (human fast acting) Novo Nordisk, UK




Nickel ammonium sulphate BDH, Poole
Normal goat serum Vector
Normal sheep serum Sigma, UK
Orexin Sigma, UK
Qiagen quick nucleotide removal kit Qiagen, Sussex
PAP pen Sigma, UK
paraformaldehyde Sigma, UK
Polysine Slides BDH Ltd, Poole
poly (A) Sigma, UK
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Primary antibody (c-fos polyclonal antibody)
RNAse/DNAase away spray
salmon testes DNA





Fine Science Tools, Germany
Sigma, UK
sodium dihydrogen orthophosphate (Na2HP04.2H20)BDH, Poole
sodium chloride (NaCl)
sodium pyrophosphate (NaPPI)
super premium twin-frost slides
synthetic oligonucleotide probes
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3.1 Insulin induced Hypoglycaemia
3.1.1. Insulin and the central nervous system
Insulin is a 51 amino acid polypeptide composed of two separate chains (A and B)
linked by two disulphide bonds (Brange et al, 1993). Insulin is secreted from the
endocrine pancreas in response to increasing blood glucose concentration, and
circulates at levels proportional to body fat and inhibits food intake by actions on the
hypothalamic NPY/AgRP neurones (Porte et al, 2002). It can cross the blood-brain
barrier into the arcuate nucleus (ARC) (Woods et al, 1977), which is a critical site for
sensing insulin. Information provided by these signals is passed to downstream areas
including the paraventricular nucleus (PVN) and the lateral hypothalamic area
(LHA), which convey information to areas such as the nucleus of the solitary tract
(NTS) (Grill et al, 2002) to regulate meal size.
Insulin inhibits the neuropeptide Y (NPY) and Agouti related peptide (AgRP)
neurones within the ARC, two peptides that potently stimulate food intake, reduce
energy expenditure and promote weight gain (Suda et al, 1993). The orexigenic
actions ofNPY are mediated via activation of Y1 and Y5 receptors (Raposinho et al,
2004) while those of AgRP come from antagonism of melanocortin-4 receptors
(Ellacott et al, 2004). The PVN and the LHA express receptors for both NPY and
AgRP. As well as NPY and AgRP the ARC also contains neurones that produce a-
melanocyte stimulating hormones (a-MSH), a peptide that reduces food intake and is
derived from the precursor proopiomelanocortin (POMC). Many POMC neurones in
the ARC also co-express the cocaine-amphetamine-regulated transcript (CART),
which has complementary actions to a-MSH, inhibiting appetite (Volkoff et al,
2005). Insulin stimulates the POMC/CART neurones which innervate the same
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hypothalamic areas as NPY and AgRP (Fekete et al, 2004). The way in which
insulin works in the central nervous system (CNS) is illustrated in Fig.3.1.
Insulin receptors have been identified in the brain and shown to be concentrated in
the hypothalamus (Havarankova et al, 1978). They have binding properties similar to
those of the peripheral insulin receptor. Studies of the pattern of uptake of insulin
from the blood into cerebrospinal fluid (CSF) have shown a receptor-mediated
transport system as a means for regulated insulin delivery into the CNS (Baura et al,
1993).
3.1.2. Insulin receptors in the brain
Insulin can affect the function of the CNS by producing hypoglycaemia, although as
discussed above insulin also acts directly on cells of the CNS to modify their
function (Woods et al, 1975). In a study of the phylogeny of the insulin receptor it
was shown that radioactively labelled insulin binds specifically to membrane
preparations of the rat brain. There are substantial concentrations of insulin receptors
in specific regions of the CNS, particularly in the rat hypothalamus (Gavin et al,
1972).
The insulin receptor consists of an extracellular alpha subunit involved in ligand
binding and an intracellular beta subunit that transduces the insulin signal as a
tyrosine kinase (Fig 3.2). Binding of insulin to the alpha subunits causes the beta
subunits to auto-phosphorylate so activating the receptor. The activated receptor then
phosphorylates a number of intracellular proteins. Several intracellular proteins have
been identified as phosphorylation substrates for the insulin receptor. Two classical
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(IRS-2). The classical insulin receptor substrates, IRS-1 and IRS-2 have both been
identified in neurones (Burks et al, 2000). Several events follow activation of IRS-1.
One potential intracellular signalling mechanism involves phosphatidylinositol 3
kinase (PI-3K). The activation ofPI-3K leads to the inhibition of food intake
(Niswender et al, 2001) (Figure 3.2).
3.1.3. Insulin entry into the CNS
Increased peripheral insulin level decreases feeding behaviour (Woods et al, 1985).
The fact that this occurs, despite the endothelial tight junctions comprising the blood
brain barrier which limits diffusion of peptides of this size, suggests that circulating
insulin acts via a circumventricular organ or may enter the brain via a facilitated
transport process (Pardridge et al, 1987). In vitro studies have shown that insulin
transport across the blood brain barrier is dependent on its binding to insulin
receptors (Bar et al, 1985). This led to the hypothesis that receptor-mediated insulin
transport may facilitate the delivery of peripheral insulin to target tissues in vivo
(Frank et al, 1983).
3.1.4 Insulin regulation of glucose production
There is interest in the role of insulin signalling in the central nervous system
because of its peripheral role in plasma glucose regulation. It was shown that hepatic
glucose production declines sharply during infusion of insulin into the third ventricle
(Obici et al, 2002) and that this effect occurs independently of any change in
circulating levels of insulin. This effect on blood glucose appears to be dependent on
neuronal signal transduction between the insulin receptor substrate (IRS)-
phosphatidylinositol 3-OH kinase (PI3K) pathway, because intracerebroventricular
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(i.c.v.) injection of a PI3K inhibitor exerted the opposite effect (Obici et al, 2002).
Hypothalamic insulin signalling is also required for the normal control of glucose
production by the liver, as indicated by effects of insulin specific antibodies or
antisense oligonucleotides directed against the insulin receptor injected into the third
ventricle (Obici et al, 2002). Because of this it is thought that insulin action in the
brain is a physiological determinant of glucose metabolism. An overview of insulin
signalling controlling glucose homeostasis is shown in Fig.3.3.
Insulin causes blood glucose to enter cells, except in the brain, as it is needed,
thereby decreasing blood glucose; conseqiienl inhibition of insulin and sliiuulalion of
glucocorticoid secretion can counteract this action by mobilising glucose stores to
make them freely available for the body undergoing a stress response. Hence, it is of
interest to consider the effects of IIH on activation of the HPA axis.
3.1.5 Insulin-induced hypoglycaemia and activation of the HPA axis
IIH has been associated with activation of the HPA axis for many years (Gershberg
et al, 1948). Insulin injection is followed by release of ACTH, P-endorphin, growth
hormone (GH) and prolactin (PRL). The ACTH response appears to be dose related
(Keller-Wood et al, 1981), but the nature of the pathways mediating this response is
controversial. It was thought that ACTH secretion induced by IIH was mediated
within the medial basal hypothalamus (MBH) (Aizawa et al, 1981). It was also
* identified that lateral hypothalamic and hepatic portal glucose sensitive cells may
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ACTH secretion in response to IIH mediated within the basal hypothalamus
The primary site of action of insulin-induced-hypoglycaemia to stimulate ACTH
secretion was investigated in rats with lesions of the MBH (Aizawa et al, 1981).
Hypoglycaemia failed to provoke ACTH secretion in rats with lesions of the MBH.
The data indicated that hypoglycaemia stimulates ACTH secretion through a direct
effect in the MBH and not in the extrahypothalamic CNS or the anterior pituitary
(Aizawa et al, 1981). Another study showed that the release ofACTH and
corticosterone during IIH (Jezova et al, 1987) was markedly reduced in rats with
lesions of the MBH. MBH lesions however resulted in normal circulating adrenaline
and noradrenaline concentrations during IIH (Jezova et al, 1987).
ACTH secretion in response to IIH mediated within the LHA
The LHA is very important in overall regulation of feeding behaviour and body
weight (Bernardis et al, 1996). It is crucial for the intense hunger that is caused by
hypoglycaemia. Eating is one component of the metabolic responses that are
mounted to restore normal blood glucose levels. Lesions of the LHA abolish the
hyperphagic response to hypoglycaemia induced by insulin (Epstein et al, 1967).
The LHA contains glucose-sensitive neurones, which are stimulated by IIH, and
these neurones account for around 25% of the LHA neurones (Oomura et al, 1974).
Hypoglycaemia activates these glucose sensitive neurones in part indirectly (Orsini
et al, 1992) and pathways ascending from the brain stem are thought to be
particularly important. These include a projection from the NTS (Ricardo et al,
1978), which relays information from vagal afferents including from glucoreceptors
in the gut and liver (Paton et al, 1999).
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It has been shown that the LHA neurones which respond to hypoglycaemia express
the orexin peptides (Moriguchi et al, 1999). In this experiment it was shown that
there was activation of orexin neurones in rats that were fasted and not allowed
access to food but in those rats that were fasted and then given food there was no
activation of orexin neurones (Cai et al, 2001).
3.1.6 Glucose sensing neurones
The brain regulates energy homeostasis by balancing energy intake, expenditure and
storage. It has specialised neurones that receives neural and metabolic signals
conveying information about the energy status of the body. The ability to sense and
regulate glucose metabolism is critical because glucose is essential for neural
function. There are two types of glucose sensing neurones, those that either increase
glucose responsive or decrease glucose sensitive their firing rate as glucose levels
rise (Oomura et al, 1974). Glucose-sensing neurones have been identified in the
hypothalamus and brainstem, in particular in the LHA, VMH and the NTS (Anand et
al, 1964). The increase in firing rate of glucose responsive neurones when glucose
levels rise (Oomura et al, 1974), is a response modulated by a K+ channel that is
sensitive to the intracellular ratio ofATP to ADP called the ATP-sensitive K+
channel (Trapp et al, 1997). Less is known of the mechanism(s) decreasing the firing
of GS neurones when glucose levels rise. It has been proposed that GS activity is
regulated by the Na+-K+-ATP pump (Oomura et al, 1974).
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3.1.7. Aims of experiments
CRH and AVP are considered to be the principal stimulators ofACTH release after
stress. Unclear, however, is the extent to which either CRH or AVP plays a role in
this response. There have been several studies investigating IIH effects on activation
of the HPA-axis in the rat (Plotsky et al, 1985). Here, in anaesthetised rats,
hypothalamo-hypophysial portal blood concentrations ofAVP were increased nearly
2-fold while CRH remained unchanged by IIH. IIH has also been associated with
elevated levels ofAVP in peripheral plasma in humans (Baylis et al, 1975). More
recently CRH mRNA expression in the pPVN has been shown to increase in
response to IIH (Suda et al, 1988). It has also been shown that there are increased
levels of CRH in hypophysial portal blood in response to IIH in the rat (Guillaume et
al, 1989). It has been suggested that the role of AVP in the rat becomes more
predominant with severe hypoglycaemia (Caraty et al, 1990). All of these studies are
complicated by whether anaesthetised animals were used and were fasted, and which
route of administration was used. The different protocols used are summarised in
table 3.1. In the present experiment the effects of IIH on the HPA axis were assessed
in freely moving, unanaesthetised, unfasted rats.
It has also previously been shown that during late pregnancy the responsiveness of
the HPA axis to physical and emotional stressors (Neumann et al, 1988) and
metabolic signals is reduced (Brunton et al, 2003; 2006). This reduced
responsiveness is evidently due primarily to reduced responsiveness of the
parvocellular PVN CRH neurones. We investigated if the responsiveness of the HPA
axis to IIH in late pregnancy provides a further example of reduced responses to a
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insulin's ability to promote glucose metabolism (Buchanan et al, 1990) and reduced
(3-cell responses to glucose (Costrini et al, 1971). This resistance is in part
compensated for by the appearance of pancreatic insulin hypersecretion.
The first aim of the experiment was to investigate if IIH activates the HPA axis in
unfasted, conscious virgin female rats; the second aim being whether this activation
was altered in pregnant rats.
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3.2 Methods
3.2.1 Animals
Female Sprague Dawley rats were used and housed individually after surgery. Rats
were maintained as described in section 2.1.
3.2.2 Surgery
Rats were implanted with a jugular vein cannula under halothane anaesthesia.
Surgery was performed under the conditions described in section 2.3.
3.2.3 Experiment 1 - The effect of IIH on the HPA axis - Insulin at 2U/kg
On the day of the experiment (day 21 of pregnancy) the cannulae were connected
between 07:30-08:30h. The jugular vein cannula was attached to PVC extension
tubing led out of the cage and connected to a 1ml syringe filled with heparinised
saline (0.9% saline, 50 units/ml). Rats were left undisturbed for 90 minutes and a
basal blood sample was taken. Thirty minutes after the first basal blood sample
another sample to measure blood glucose was taken (<100pl) and rats were given
either insulin (fast acting Actrapid; Novo Nordisk UK, 2U/kg dose, volume
0.5ml/kg) or sterile saline, (0.9%, 0.5ml/kg). Further blood samples (<100pl) were
taken for glucose measurement at 10, 20, 30, 40, 50, 60, 90, 120, 150, 180 and 210
minutes after i.v. infusion. Glucose measurements were taken throughout the
experiment using a Roche Accuchek Active Meter. Blood samples at 10, 30, 60 and
120 minutes (0.55ml) were placed into eppendorf tubes containing 50pl of chilled
5% EDTA. After each blood sample, blood was replaced with 0.9% sterile saline.
Plasma was separated by centrifugation and stored at -20°C until radioimmunoassay.
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Insulin was given intravenously as this is a rapid way of achieving hypoglycaemia,
and avoids possible interference with fetuses that may have occurred with intra¬
peritoneal administration. Rats were killed by conscious decapitation 4 hours after
insulin infusion (this time point has previously been shown as the optimum time for
showing increased CRH and AVP mRNA expression in the PVN following stress)
(Harbuz et al, 1989). Rats were examined post-mortem to check the number of
fetuses.
3.2.4. Experiment 2 - Effect of IIH on the HPA axis - Insulin at lOU/kg
On the day of the experiment (day 21 of pregnancy) the cannulae were connected
between 07:30-08:30h. The jugular vein cannula was attached to PVC extension
tubing led out of the cage and connected to a 1ml syringe filled with heparinised
saline (0.9% saline, 50 units/ml). Rats were left undisturbed for 90 minutes and a
basal blood sample was taken. 30 minutes after the first basal blood sample another
basal blood sample was taken and rats were given either insulin (fast acting Actrapid,
lOU/kg dose volume 0.5ml/kg) or sterile saline, 0.9% (0.5ml/kg). Blood samples
were taken at 15, 30, 60, and 120 minutes after i.v. infusion. Blood samples (0.55ml)
were placed into eppendorfs containing 50pl of chilled 5% EDTA. After each blood
sample, blood was replaced with 0.9% sterile saline. Glucose measurements were
taken as described above. Plasma was separated by centrifugation and stored at -
20°C until radioimmunoassay. Rats were killed by conscious decapitation 4 hours
after insulin as described above.
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3.2.5 In Situ Hybridisation
Brains were coronally sectioned at 15 pm and sections containing the pPVN were
mounted onto Polysine slides (BDH) (see section 2.4.2). To measure CRH mRNA
expression a 42-mer oligonucleotide probe (MWG-Biotech) (5'-CCT GTT GCT
GTG AGC TTG CTG AGC TAA CTG CTC TGC CCT GCC- 3') was used
complementary to bases 496-537, which encode amino acids 22-35 of the rat CRH
peptide (Jingami et al, 1985).
To measure AVP mRNA expression a 36-mer oligonucleotide probe (MWG-
Biotech) (5'-GAC CCG GGG CTT GGC AGA ATC CAC GGA CTC TTG TGT-3')
was used complementary to bases 486-521 of rat AVP mRNA (Majzoub et al, 1983).
Both probes were labeled with S as described in section 2.4.2. The melting
temperature for the CRH mRNA probe was 78°C and for the AVP mRNA probe was
76°C, therefore the heated SSC washes were performed at 58°C and 56°C
respectively. Once dry the sections were dipped in photographic emulsion under
safelight conditions and stored at 4°C. The exposure time was 10 weeks for CRH
mRNA and 7 days for AVP mRNA. The number of positive cells for CRH mRNA
and the grain density over the pPVN for AVP mRNA were measured with the image
analysis system described in 2.4.2.
3.2.6 ACTH Radioimmunoassay
Plasma ACTH concentration was determined using a commercially available kit as
described in section 2.7.3. The sensitivity of the ACTH assay was 8pg/ml. The intra-
assay variation was <9%. All samples from an experiment were measured in the
same assay.
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3.2.7 Statistics
A two-way analysis of variance (ANOVA) was used to analyse differences between
groups. For blood sampling experiments a two-way ANOVA with repeated measures
was used. IfANOVA showed significant effects Student Newman Keuls multiple
comparison tests were used to locate differences between groups. A p value of less
than 0.05 was considered statistically significant.
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3.3 Results
3.3.1 Effect of Insulin (2U/kg) on the HPA axis
Blood Glucose Concentration
Analysis of plasma glucose concentration using two-way RM ANOVA showed a
statistically significant difference in blood glucose concentration among the virgin
and pregnant groups (p<0.001). Basal blood glucose concentrations were
significantly lower in pregnant rats than virgins (p<0.05; two way RM ANOVA). I.v.
injection of insulin significantly reduced blood glucose in the virgin group (p<0.001;
two-way RM ANOVA) within 10 min (2.3 ± 0.03 vs 5.2 ± 0.47 mmol/1) with glucose
concentrations returning to basal by 90 min (Fig.3.4). I.v. injection of insulin
significantly reduced blood glucose in the pregnant group (p<0.001; two-way RM
ANOVA) within 10 min (2.1 ±0.10 vs 4.0 ± 0.23 mmol/1) with glucose
concentrations returning to basal by 90 min (Fig.3.4). There were no significant
differences in blood glucose concentration following i.v. saline in either the virgin or
the pregnant group (Fig.3.4).
Plasma ACTH concentration
Analysis of plasma ACTH concentration using a two-way RM ANOVA showed
there was not a statistically significant difference in basal plasma ACTH
concentrations among the virgin and pregnant groups (Fig 3.5). I.v. injection of
insulin or saline had no significant effect on ACTH secretion in either the virgin or
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Figure 3.4: The effect of i.v. insulin on blood glucose concenration in virgin and
pregnant rats. A basal blood sample was collected before i.v. administration of
Insulin (2U/kg). Further blood samples were withdrawn -10, 10, 20, 30, 40, 50, 60,
90, 120, 150, 180 and 210 minutes post-injection. Values are group means ±SEM.
Virgin/saline, n-=6; virgin/insulin,n=7; pregnant/saline, n=5; pregnant/insulin, n=5.
Two-way ANOVA for repeated measures followed by Student Newman Keuls multiple
comparison tests:
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Figure 3.5: The effect of i.v. insulin on plasma ACTH concentration in
virgin and pregnant rats. A basal blood samples was taken 30 minutes
before i.v. administration of insulin (2U/kg). Further blood samples were
Taken 10, 30, 60, 120 and 250 (trunk blood) minutes post-injection.
Values are group means ± SEM. Virgin/saline, n=6; virgin/insulin, n=7;
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Figure 3.6: The effect of i.v. insulin on plasma ACTH concentration in virgin and
pregnant rats. Delta values for the measurements at 30 minutes after insulin
(2U/kg) injection subtracted from the basal blood sample were calculated. Values
are the group means ± SEM. Virgin/saline, n=6; virgin/insulin, n=7; pregnant
saline, n=5; pregnant/insulin, n=5. Two-way ANOVA.
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3.3.2 Effect of Insulin (lOU/kg) on the HPA axis
Blood glucose concentration
The dose of insulin was increased to lOU/kg since 2U/kg did not increase ACTH
secretion. Analysis of blood glucose concentration using two-way RM ANOYA
showed a statistically significant difference in plasma glucose concentration among
the virgin and pregnant groups (p<0.001). Basal blood glucose concentrations were
significantly lower in pregnant rats than virgins (p<0.05; two way RM ANOVA). I.v.
injection of insulin significantly reduced blood glucose in the virgin group (p<0.001;
two-way RM ANOVA) within 15min (2.1 ±0.14 vs 6.2 ± 0.44 mmol/1) with glucose
concentrations returning to basal by 120 min (Fig.3.7). I.v. injection of insulin
significantly reduced blood glucose in the pregnant group (p<0.001; two-way RM
ANOVA) within 15 min (1.7 ± 0.18 vs 4.0 ± 0.23 mmol/1) with glucose
concentrations returning to basal by 120 min (Fig.3.8). There were no significant
differences in blood glucose concentration following i.v. saline in either the virgin or
the pregnant group (Fig.3.7).
Plasma ACTH concentration
Basal plasma concentrations ofACTH were not different among groups. I.v.
injection of insulin significantly increased ACTH secretion in the virgin group
(p=0.03; two-way RM ANOVA) (Fig.3.8 and Fig. 3.9) within 15 min (103.3 ± 21.6
vs 65.9 ± 5.1 pg/ml) with plasma ACTH concentrations returning to basal by 120
min (Fig.3.8). I.v. injection of insulin significantly increased plasma ACTH
concentration in the pregnant group (p=0.04; two-way RM ANOVA) within 15 min
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Figure 3.7:The effect of i.v. insulin on blood glucose concentration in virgin and
pregnant rats. Basal blood samples were collected 1 and 30 minutes before i.v.
administration of insulin (lOU/kg). Further blood samples were withdrawn 15,30,
60 and 120 minutes post injection. Values are group means ± SEM. Virgin/saline,
n=5; virgin/insulin, n=5; pregnant/saline, n=5; pregnant/insulin, n=6.
Two-way ANOVA for repeated measures followed by Student Newman-Keuls








Figure 3.8: The effect f i.v. insulin on plasma ACTH concentration in virgin and
pregnant rats. Two basal blood samples were taken 30 and 1 min prior to i.v.
Insulin lOU/kg/rat. Further blood samples were taken 15, 30, 60, 120 and 240
(trunk blood) min post-infusion. Values are the group means ±SEM. Virgin/
saline, n=5; virgin/insulin, n=5; pregnant/saline, n=5' pregnant/insulin, n=6.
Two-way ANOVA for repeated measures followed by Student Newman Keuls
multiple comparison tests. *p<0.05 significantly different from insulin groups.
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basal by 120 min (Fig.3.8 and Fig.3.9). There were no significant differences in
plasma ACTH concentration following i.v. saline in either the virgin or the pregnant
group (Fig.3.8).
Parvocellular PVN (pPVN) CRHmRNA expression
Analysis ofCRH mRNA expression in the pPVN using a two-way ANOVA showed
there was not a statistically significant difference in positive cell counts for CRH
mRNA expressing neurones between virgin and pregnant rats. I.v. insulin did not
significantly increase CRH mRNA expression in the pPVN in either the virgin or the
pregnant group 4 hours after insulin (lOU/kg) (Fig.3.10 and Fig.3.11).
Parvocellular PVN (pPVN) A VP mRNA expression
Analysis of AVP mRNA expression using a two-way ANOVA showed there was not
a statistically significant difference in grain density for AVP mRNA expressing
neurons between virgin and pregnant rats. I.v. insulin significantly increased AVP
mRNA expression in the pPVN in the virgin group 4 hours after insulin (lOU/kg) (p=
0.005; 2 way ANOVA) (0.1 ± 0.03 vs control 0.03 ± 0.01 mm2/mm2) (Fig 3.12 and
Fig 3.13). I.v. insulin significantly increased AVP mRNA expression in the pPVN in
the pregnant group 4 hours after insulin (lOU/kg) (p=0.028; 2 way ANOVA) (0.07 ±
0.02 vs control 0.03 ± 0.01 mm2/mm2) (Fig 3.12 and Fig 3.13). There was no


































Figure 3.9: The effect of i.v. insulin on plasma ACTH concentration in virgin and
pregnant rats. Delta values for the measurements at 30 minutes after insulin lOU/kg
Subtracted from the first basal blood sample was calculated. Values are the group
means ±SEM. Virgin/saline, n=5; virgin/insulin, n=5; pregnant/saline, n=5;
pregnant/insulin, n=6. Two-way ANOVA followed by a Student Newman Keuls
multiple comparison test. *p<0.05 vs vehicle
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Figure 3.10: The effect of i.v. insulin on CRH mRNA in virgin and
pregnant rats. The rats were killed by conscious decapitation 4 hours
after insulin injection (lOU/kg) and brains processed for CRH mRNA
ISH on sections containing the PVN. CRH mRNA expressing neurones
in the pPVN were counted.
Values are the group means ± SEM. Virgin/saline, n=5; virgin/insulin,
n=5; pregnant/saline, n=5; pregnant/insulin, n=6. Two-way ANOVA.
Figure 3.11: Representative photomicrographs of coronal sections through the
PVN in virgin and pregnant rats. Sections were hybridised with a 35S labelled
probe complementary to CRH mRNA for (A) virgin saline; (B) virgin insulin; (C)
pregnant saline; (D) pregnant insulin; (E) representation ofpositive cells at x 40
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Figure 3.12: The effect of i.v. insulin on AVP mRNA in virgin and pregnant rats.
The rats were killed by conscious decapitation 4 hours after insulin injection
lOU/kg and processed for AVP mRNA ISH on sections containing the pPVN. AVP
mRNA expression in the pPVN was measured as grain per unit area.
Values are the group means ±SEM. Virgin/saline, n=5; virgin/insulin, n=5;
Pregnant/saline, n=5; pregnant/insulin, n=6. Two-way ANOVA followed by a Student
Newman Keuls multiple comparison test: *p<0.05 vs saline.
Figure 3.13: Representative photomicrographs of coronal sections through
the PVN in virgin and pregnant rats. Sections were hybridised with a 35S
labelled probe complementary to AVP mRNA for (A) virgin saline; (B) virgin
insulin; (C) pregnant saline; (D) pregnant insulin; Scale Bar: 100|Jm. mPVN =
magnocellular PVN, pPVN = parvocellular PVN, 3V = 3rd ventricle
mPVN
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3.4 Discussion
3.4.1. IIH stimulation of ACTH secretion
We have shown that hypoglycaemia induced by i.v. insulin at lOU/kg stimulates
ACTH secretion in female rats. This corresponds with previous studies in male rats
(Plotsky et al, 1985, Jezvoa et al 1987). There was no effect seen on either ACTH or
corticosterone secretion when insulin was given at a dose of 2U/kg in any group,
despite a substantial decrease in blood glucose concentration. The higher dose of
insulin decreased blood glucose concentration for longer than the lower dose.
3.4.2. The involvement of CRH and AVP in the stimulation of ACTH
CRH and AVP are considered to be the principal stimulators of ACTH release. The
extent to which CRH and AVP are involved in the ACTH response to IIH is unclear.
It has previously been shown that hypothalamo-hypophysial portal blood
concentrations ofAVP are increased following IIH with no changes in CRH (Plotsky
et al, 1985). IIH has also been associated with increased levels of peripheral plasma
AVP in humans, which reflects magnocellular AVP neurone activation (Baylis et al,
1980). Robinson et al, (1992) have shown that in response to IIH there is an increase
in peripheral plasma AVP with no changes in PVN AVP mRNA expression. The
study used PVN punches to determine AVP mRNA content. It is suggested that
parvocellular neurones express less than 0.5% of the total AVP in the PVN
(Robinson et al, 1992). Thus only a very marked increase in the levels of
parvocellular AVP mRNA would have been detected with the punching technique. In
this study we found that IIH increased pPVN AVP mRNA expression in both virgin
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and pregnant rats. This corresponds with the increase in plasma ACTH seen in both
virgin and pregnant rats.
Increases in levels of pPVN CRH mRNA (Suda et al, 1988) and ARC POMC mRNA
(Tozawa et al, 1988) have been reported after IIH. The study by Suda et al (1988)
was done using anaesthetised rats. Another study by Robinson et al (1992) in freely
moving unanaesthetised rats showed that there was no change in the level of pPVN
CRH mRNA 90 minutes after IIH. In these studies similar increases in ACTH (and
corticosterone) plasma levels were achieved to the present study. Robinson et al
(1992) showed that the duration of hypoglycaemia was longer than in the Suda et al
(1988) study. In the present study we found no significant increase in pPVN CRH
mRNA 4 hours after IIH in either the virgin or pregnant rats, suggesting that the
stimulation ofACTH secretion by IIH does not involve CRH. It has previously been
suggested that CRH may play a permissive role in activation of the HPA axis by IIH
(Berkenbosch et al, 1989) or that IIH stimulates the release of CRH peptide
(Guillaume et al, 1989) without causing alterations in the level ofCRH mRNA. It
would seem therefore that IIH may increase ACTH secretion by preferentially
activating pPVN vasopressin-producing neurones. The mechanism whereby this is
achieved requires further study. Importantly the mechanism is intact during late
pregnancy.
AVP mRNA was measured in the parvocellular region of the PVN. It is very difficult
however to distinguish between the parvocellular and magnocellular AVP neurones
and some of the magnocellular neurones are mixed with the parvocellular neurones
in the PVN. Basal AVP mRNA expression is much lower in the parvocellular region
than the magnocellular region. It is thought anyway however that magnocellular
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AVP neurones may contribute to HPA regulation (Landgraf et al, 2002) although
magnocellular AVP neurones usually respond very slowly after stress (Ma et al,
1999).
3.4.3. Blood glucose concentration
Mammalian pregnancy near term is characterised by resistance to insulin's ability to
promote glucose metabolism (Buchanan et al, 1990) as well as by augmented P-cell
responses to glucose (Costrini et al, 1971). Experimental data from the rat have
shown that insulin resistance during late pregnancy is due to an impairment of
insulin's ability to stimulate glucose uptake in peripheral tissues and to suppress
hepatic glucose production (Leturque et al, 1986). Insulin resistance in late
pregnancy is in part compensated for by the appearance of pancreatic insulin
hypersecretion (Rossi et al, 1993). Nonetheless, basal blood glucose concentrations
were significantly lower in pregnant animals compared to virgins. This corresponds
with previous studies which have shown that basal glucose levels decline as
pregnancy progresses (Rossi et al, 1993). This could be due to the increasing
metabolic demands of the fetuses on the mother at this time. Blood volume in the
pregnant mother is also increased; this is perhaps another reason for the observed
reduced basal blood glucose concentration (Longo 1983). Blood glucose
concentrations were significantly reduced to the same level by IIH in both virgin and
pregnant rats for the same time period with levels returning to basal concentrations
by 60 minutes. Before beginning the present experiment, in pilot studies pregnant
rats were given different doses of insulin as they have been reported to show a 25-
30% reduction in the clearance of exogenous insulin (Rossi et al, 1993). However, as
different doses produced equal degrees of hypoglycaemia in pregnant and virgin
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animals it was decided to use the same concentration of insulin in both virgin and
pregnant rats in the present experiment. This also meant that the rats were exposed to
similar doses of insulin; this is important because the consequences of IIH may be
due to insulin, or hypoglycaemia, or an interaction between these.
3.4.4. The effect of IIH on the HPA-axis in pregnancy
It has previously been shown that during late pregnancy the responsiveness of the
HPA axis to physical and emotional stressors (Neumann et al, 1988; Brunton et al,
2005) and central neuropeptides signalling metabolic state is reduced (Brunton et al,
2003; 2006 see chapters 5 and 6). This reduced responsiveness is thought to be due
primarily to reduced responsiveness of the parvocellular PVN CRH/AVP neurones
or their inputs. In this study we have shown that IIH stimulates ACTH secretion and
pPVN AVP mRNA expression similarly in both virgin and pregnant rats, yet we
have shown that there is no stimulation of the pPVN CRH neurones, as assessed by
measuring CRH mRNA expression, in response to IIH in either the virgin or late
pregnant rats.
3.4.5 Conclusions
In summary, we have shown that IIH stimulates the hypothalamo-pituitary (HP) axis
similarly in both virgin and late pregnant rats. Insulin lowered blood glucose
concentration to a similar level in both virgin and pregnant rats. IIH did not increase
pPVN CRH mRNA expression in either the virgin or the pregnant group but
increased pPVN AVP mRNA expression in both virgin and pregnant rats. Thus we
can conclude that IIH is not stimulating ACTH secretion via the CRH parvocellular
PVN neurones, unless CRH has a permissive role, but more likely stimulates ACTH
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secretion through the AVP neurones in the pPVN. Alternatively, IIH stimulates
pPVN CRH/AVP neurones but selectively activates only AVP gene expression.
Insulin signals the metabolic status to the hypothalamus but also causes
hypoglycaemia. Several other neuropeptides signal metabolic status to the HPA axis;
these include ghrelin, orexin and NPY. All of these signal lack of energy (unlike
insulin). Insulin indicates abundant energy; in contrast, hypoglycaemia caused by
insulin obviously reduces energy availability. Insulin has been shown to inhibit
NPY/AgRP neurones (Porte et al, 2002), yet hypoglycaemia has been shown to
activate orexin neurones which in turn activate NPY neurones (Jaszberenyi et al,
2001). These signals conflict, and it is not known whether it is insulin or
hypoglycaemia that activates the HPA axis. This could be resolved by repeating the
present experiments and infusing glucose i.v. to maintain normal glucose
concentrations. The HPA axis has been shown to be unresponsive to orexin-A
(Brunton et al, 2003) and NPY (Brunton et al, 2006) in late pregnancy; this includes
also reduced stimulation of the pPVN CRH and AVP parvocellular neurones by NPY
in late pregnancy (Brunton et al, 2006). The neuropeptide ghrelin is produced in the
stomach and the ARC (Kojima et al, 1999). Ghrelin has also previously been shown
to stimulate food intake and the HPA axis (Wren et al, 2002). The responsiveness of
the HPA axis to ghrelin in late pregnancy is described in chapter 4. Chapter 4 also
addresses the question of whether insulin's actions on the HPA axis are exerted in
pregnancy through central ghrelin.
98
GHRELIN ACTIVATES THE HPA AXIS
Ghrelin and the HPA axis Chapter 4
4.1 Ghrelin
4.1.1 Ghrelin
Ghrelin is a 28-amino acid peptide hormone (Fig 4.1) that was discovered in 1999 as
an endogenous ligand for the growth hormone secretagogue receptor (GHS-R); it is
predominantly produced in the stomach and potently stimulates food intake and
growth hormone (GH) secretion (Kojima et al, 1999). It is produced and secreted by
the A like cells in the oxyntic glands of the stomach (Sakata et al, 2002). The testis
(Tanaka et al, 2001), placenta (Guabillo et al, 2001), kidney (Mori et al, 2000),
pituitary (Korbonits et al, 2001), small intestine (Date et al, 2000), pancreas (Volante
et al, 2002), lymphocytes (Hattori et al, 2001) and brain, specifically the arcuate
nucleus (ARC) (Lu et al, 2001), also express low levels of ghrelin.
4.1.2 The growth hormone secretagogue receptor (GHS-R)
The GHS-R is a heterotrimeric GTP-binding protein (G-protein) first identified in
1996. There are two types ofGHS-R: the functional type la and the non-functional
type lb. Both types are encoded by the same gene approximately 4.3kb in length but
the mRNA undergoes alternative splicing (Howard et al, 1996). Types la and lb
consist of seven or five trans-membrane domains, respectively. Receptor la contains
three intracellular and extracellular loops whereas receptor lb contains two (Fig 4.2).
Receptor type la is expressed mainly in the pituitary and at low levels in the thyroid
gland, pancreas, spleen, myocardium and adrenal gland (Gnanapavan et al, 2002).
Receptor lb is widespread in many tissues including the stomach, oesophagus,
intestine, liver, lung, muscle and testis (Gnanapavan et al, 2002). In the brain GHS-
R's a and b are expressed by some specific hypothalamic neurones in the ARC,
paraventricular nucleus (PVN), the ventromedial nucleus (VMH), dorsomedial
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hypothalamus (DMH) and lateral hypothalamic area (LHA) as well as by
somatotrophs of the anterior pituitary gland (Guan et al, 1997).
The widespread distribution of the GHS-R explains the wide spectrum of ghrelin's
actions which include stimulation of GH secretion, regulation of feeding and
activation of the HPA-axis (Kojima et al, 2001).
4.1.3 The structure of ghrelin
There is no structural homology between ghrelin and the synthetic growth hormone
secretagogues. Its amino acid sequence is highly conserved between species. The N-
terminal portion of ghrelin is the active core of the molecule. Ghrelin bioactivity is
ensured by post-translational acylation with octanoic acid at the 3rd serine residue
(Fig. 4.1). Acylation permits ghrelin to cross the blood brain barrier (Guan et al,
1997) and is essential for its binding to its receptor (Banks et al, 2002). Transport of
ghrelin across the blood brain barrier is a highly regulated and bi-directional process.
It has been shown that ghrelin can be readily transported across the blood-brain
barrier in the brain to blood direction but the quantity of its transport in the blood to
brain direction is negligible (Banks et al, 2002). It must therefore be through a
different mechanism that ghrelin exerts its central activities.
4.1.4. Ghrelin as a gut-brain peptide
It has recently been shown that ghrelin displays its central activity also via the vagus
nerve as well as to a minor extent by transfer across the blood brain barrier (Date et
al, 2002). Ghrelin receptors have been found in vagal afferent terminals in the
stomach (Date et al, 2002). These fibres are the major anatomical linkage between
the gastrointestinal (GI) tract and the nucleus of the solitary tract (NTS). Ghrelin
induces NPY neurone activation in the nucleus of the solitary tract (NTS) and in the
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ARC (Date et al, 2001). Thus it could influence appetite and energy expenditure via
these actions.
Recently it has been shown that vagotomy (ablation of the vagus nerve) resulted in
suppression of peripheral ghrelin-induced food intake and GH secretion (Date et al,
2002). Vagotomy did not interfere with GH or food intake when ghrelin was
administered by i.c.v. injection (Date et al, 2002). This could mean there are two
different independent ghrelin secreting systems: the central and the peripheral one.
Ghrelin secreted from peripheral tissues could affect food intake through vagal
afferents whereas ghrelin produced in the CNS acts through a direct effect on
neurones.
4.1.5. Ghrelin expression in the brain
Ghrelin mRNA is expressed in the rat brain, mainly produced in the ARC and the
NTS. Within the ARC ghrelin increases the expression ofmRNA for neuropeptide Y
(NPY), agouti related peptide (AgRP), somatostatin (SS) and growth hormone
releasing hormone (GHRH) (Dickson et al, 1997). Ghrelin is also synthesised
centrally in a group of neurones in the ARC (Cowley et al, 2003). In the brain
ghrelin is mainly expressed in axons (Cowley et al, 2003) and is associated with
dense core vesicles in pre-synaptic terminals. The axon terminals innervate several
hypothalamic nuclei including the ARC, DMH, LHA and PVN (Cowley et al, 2003)
and in all of these regions are neurones that express the GHS-R.
Ghrelin depolarises ARC NPY neurones and hyperpolarises POMC neurones
(Cowley et al, 2003). This effect is most likely mediated by the GABAergic
NPY/AgRP neurones (Cowley et al, 2003). These results can explain some of the
effects of ghrelin on energy homeostasis. The activation ofNPY/AgRP neurones
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enhances the release of neuropeptides from these neurones to increase food intake
and decrease energy expenditure (Fig.4.3).
4.1.6. Ghrelin's role in energy homeostasis
Ghrelin influences feeding via the orexin-NPY pathway (Dickson et al, 1997). NPY
is one of the most potent central appetite stimulants (Stanley et al, 1986). Six
receptor subtypes for NPY have been identified (Y1-Y6) and among these Y1 and
Y5 are involved in the control of food intake (Fekete et al, 2002). AgRP, co-
produced in the ARC NPY neurones, exerts a strong long-lasting stimulatory effect
on feeding by antagonising the hypothalamic melanocortin anorexigenic system
(Hahn et al, 1998). Ghrelin could also influence feeding by inhibition of leptin
activity (Shintani et al, 2001). The regulatory role of leptin in the control of body
weight is mediated at least partially through inhibition of the hypothalamic NPY/Y1
receptor pathway (Shintain et al, 2001). Ghrelin can reverse the leptin-induced down
regulation ofNPY mRNA expression in ARC neurones and thus inhibits leptin
action (Nakazato et al, 2001).
4.1.7. Ghrelin and GH release
GH secretion from the anterior pituitary is regulated by the interaction between
GHRH (which is stimulatory) and SS (which is inhibitory) (Roelfsema et al, 2001).
A third factor responsible for regulating GH release is ghrelin, as simulated by
artificial growth hormone secretagogues (Roelfsema et al, 2001). These stimulate
GH secretion via the GHS-R independently of the GHRH and SS receptors. I.c.v.
(Date et al, 2000) and i.v. (Seoane et al, 2000) administration of ghrelin increase GH
secretion with no influence on other pituitary hormones (Kojima et al, 1999). In
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some reports that suggest also that ghrelin both in rats and humans could influence
the secretion of some other pituitary hormones such as adrenocorticotropin (ACTH)
and prolactin (Wren et al, 2001).
4.1.8. The effect of ghrelin on the HPA axis
CRH and AVP act together to stimulate ACTH release in vivo (Gillies et al, 1979). It
has been shown that ghrelin can activate the HPA axis in rats when administered
centrally, by i.c.v. injection, but not systemically, and it stimulates release of both
CRH and AVP from hypothalamic explants (Wren et al, 2002). Administration of
growth hormone secretagogues systemically resulted in a variable or absent ACTH
response in rats (Thomas et al, 1997). In contrast both ghrelin and synthetic growth
hormone secretagogues have been shown to stimulate ACTH and prolactin secretion
following i.v. administration in humans (Arvat et al, 2001). The species disparity
may reflect a different hypothalamic action. It has been shown that ghrelin releases
NPY from rat hypothalamic explants in vitro (Wren et al, 2002); NPY neurones are a
likely target for the action of ghrelin as they express the GHS-R (Guan et al, 1997).
NPY neurones have been implicated in the orexigenic effect of ghrelin (Willesen et
al, 1999) and in activating the HPA axis (Small et al, 1997). HPA axis activation by
ghrelin would also lead to an increase in energy availability.
4.1.9 Aims of these experiments
Ghrelin appears to interact closely with the HPA axis and its regulatory pathways
due to its effects at the level ofCRH and AVP neurones in the pPVN (Wren et al,
2002). As discussed above ghrelin can activate the HPA axis in rats when
administered centrally but not systemically (Wren et al, 2002). In late pregnancy the
HPA axis is hyporesponsive to various physical and emotional stressors (Douglas et
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al, 1998) and to i.c.v orexin A (Brunton et al, 2002); this is thought to be a
consequence of reduced responsiveness ofPVN CRH/AVP neurones (Brunton et al,
2002). Since ghrelin has been shown to activate the HPA axis when administered by
i.c.v. injection we investigated if ghrelin activates the HPA axis in virgin and
pregnant female rats when administered centrally. Central ghrelin has been shown to
stimulate GH secretion; we measured blood glucose concentration as an indirect
indicator of activation ofmechanisms mobilising glucose including GH secretion.
Ghrelin has also been shown to stimulate food intake. I.c.v. administration of orexin-
A has revealed reduced responsiveness of the HPA axis in late pregnant rats but no
differences in the stimulatory effects of orexin-A on behaviours, which indicates that
loss ofHPA axis stimulation is not a result of a general loss of central responses to
orexin-A (Brunton et al, 2002).
Ghrelin has been shown to affect the release ofmany hormones including insulin;
ghrelin decreases insulin secretion (Broglio et al, 2001). In Chapter 3 I showed that
insulin activates the HPA axis similarly in virgin and pregnant rats. The main aims
of the present experiment were: firstly to discover if centrally administered ghrelin
would activate the HPA axis in female virgin rats and secondly to see if this response
was altered in pregnant rats. In the experiment rats were blood sampled and brains
processed for immunohistochemistry. Fos expression was evaluated in several areas
including the pPVN to investigate activity in the CRH/AVP neurones and in the
ARC, LHA, VMH, DMH to investigate circuitry regulating feeding responses to
centrally administered ghrelin.
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4.2 Methods
4.2.1 Animals
Female Sprague Dawley rats were used and housed individually after surgery. Rats
were maintained as described in section 2.1.
4.2.2 Surgery
Rats were implanted with an intracerebroventricular and a jugular vein cannula.
Surgery was performed under conditions described in section 2.3.
4.2.3 Experiment 1 - The effect of i.c.v. ghrelin on the HPA-axis
On the day of the experiment (day 21 of pregnancy) the cannulae were connected
between 07:30-08:30h. The jugular vein cannula was attached to PVC extension
tubing led out of the cage and connected to a 1ml syringe filled with heparinised
saline (0.9% saline, 50 units/ml). Rats were left undisturbed for 90 minutes and a
0.55ml basal blood sample was taken. Thirty minutes after the basal blood sample
rats were given either i.c.v. ghrelin (2nmols in 3pl) or vehicle (3pl artificial cerebro¬
spinal fluid, aCSF; pH 7.2, composition in mM: NaCl, 138; KC1, 3.36; NaFlCCb,
9.52; Na2HP04, 0.49; urea, 2.16; NaH2P04, 0.49; CaCl2, 1.26; MgCl2, 1.18), with
gentle restraint over a period of about 30 seconds. Further blood samples were taken
for glucose measurement (<1 OOju.1) at 10, 20, 30, 40, 50 and 60 minutes after i.c.v.
infusion.
Blood sampling
Glucose measurements were taken throughout the experiment using a Roche
Accuchek Active Meter. Blood samples at -30, 10, 30 and 60 minutes were placed
into eppendorfs containing 50pl of chilled 5% EDTA. After each blood sample,
blood was replaced with 0.9% sterile saline. Plasma was separated by centrifugation
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and stored at -20°C until radioimmunoassay for ACTH and corticosterone. Ghrelin
was given i.c.v. as it has previously been shown to activate the HPA axis when
administered centrally but not peripherally.
Behavioural observations
The following behaviours were noted continually: inactive, grooming, oral motor
activity, eating and drinking. Behavioural data were collected for 90 minutes; an
event was classified as occurring if an animal spent > 5 seconds exhibiting the
behaviour.
Terminal procedures
Rats were killed by conscious decapitation 90 minutes after ghrelin (this time point
has previously been shown as the optimum time for showing increased Fos
expression in the ARC after ghrelin) (Niimi et al, 2001). Rats were examined post¬
mortem to check fetuses and to check i.c.v. cannula placement. Brains were
processed for Fos immunohistochemistry on fixed sections and numbers of neurons
expressing Fos in each region of interest were counted.
4.2.4 Fos immunohistochemistry
Coronal brain sections (15pm) were cut on the cryostat onto gelatine coated slides.
With the aid ofmarker slides in consultation with the brain atlas (Konig et al, 1963),
sections with PVN (Bregma - 1.8mm), SON (Bregma - 1.8mm), ARC (Bregma -2.3
mm), LHA (Bregma -2.3mm), VMH (Bregma -2.3mm) and DMH (Bregma -2.3mm)
were selected. Fos immunohistochemistry was performed using the method
described in section 2.5.3 with post-fixed sections. Fos positive cells were counted in
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Plasma ACTH concentration was determined using a commercially available kit as
described in section 2.7.3. The sensitivity of the ACTH assay was 5pg/ml. The intra-
assay variation was <11%. All samples were measured in the same assay.
4.2.6. Corticosterone radioimmunoassay
Plasma corticosterone concentration was determined using a commercially available
kit as described in section 2.8. Plasma corticosterone was measured directly in
unextracted plasma (diluted 1:8 in assay buffer) using a double antibody
radioimmunoassay. The sensitivity of the corticosterone assay was 0.8ng/ml. The
intrassay variation was <6%. All samples were measured in the same assay.
4.2.7 Statistics
A two-way analysis of variance (ANOVA) was used to analyse behavioural and Fos
data. A two-way ANOVA with repeated measures was used for blood sampling
experiments. Each ANOVA that showed p<0.05 was followed by Student Newman
Keuls multiple comparison tests, to identify differences between groups. A p value of
less than 0.05 was considered statistically significant.
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4.3 Results
4.3.1. The effects of i.c.v. ghrelin in pregnancy
Behavioural data
Analysis of behavioural data using a two-way ANOVA showed a statistically
significant difference in eating behaviour among virgin and pregnant groups
(p<0.001). Ghrelin significantly increased eating behaviour in both the virgin and
late pregnant rats (p<0.001; two-way ANOVA) with a tendency for a greater effect
in the late pregnant rats (p=0.08) (Fig 4.4). There was a significant increase in
drinking in virgin rats (p=0.019; two-way ANOVA). There were no significant
differences for grooming between groups (Fig 4.4).
Blood glucose concentration
Analysis of blood glucose concentration data using a two-way RM ANOVA showed
a statistically significant difference in plasma glucose concentration among virgin
and pregnant groups (p<0.001). Basal blood glucose concentrations were
significantly lower in pregnant rats than in virgins (p<0.001; two-way RM ANOVA).
I.c.v. injection of ghrelin increased plasma glucose in the virgin group (p<0.001;
two-way RM ANOVA) within 10 min (7.4 ± 0.23 vs basal 5.88 ± 0.12 mmol/1) with
glucose concentrations returning to basal by 20 min (Fig 4.5). Ghrelin significantly
increased glucose concentration in pregnant rats (p=0.002; two-way RM ANOVA),
within 10 min (5.02 ± 0.37 vs basal 4.02 ± 0.28 mmol/1) with glucose concentrations
remaining elevated for 20 min (Fig 4.5). The overall effect of i.c.v. injection of
ghrelin can be seen by the percentage change in glucose concentration from basal
(Fig 4.6). Overall, the increase in blood glucose concentration was significantly
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Figure 4.4: The effect of i.c.v. ghrelin on behaviours in virgin and pregnant rats.
Values are the means ± SEM. Virgin/aCSF, n=8; virgin/ghrelin, n=10; pregnant/
aCSF, n=7; pregnant/ghrelin, n=8. A two-way ANOVA followed by Student
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Figure 4.5: The effect of i.c.v. ghrelin on blood glucose concentration in virgin and
pregnant rats. A basal blood sample was taken 30 min prior to i.c.v ghrelin (2nmols
or aCSF). Further blood samples were withdrawn 10, 20, 30, 40, 50 and 60 min
post-infusion. Values are group means ± SEM. Virgin/aCSF, n=4; virgin/ghrelin,
N=; pregnant/aCSF, n=5; pregnant/ghrelin, n=6. Two-way ANOVA for repeated
Measures followed by Student Newmanmultiple comparison tests: **p<0.001,
*p<0.05 significantly different from basal; #p<0.05 significantly different from
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Figure 4.6: The effect of i.c.v. ghrelin on blood glucose concentration in virgin and
pregnant rats. A basal blood sample was taken 30 min prior to i.c.v. ghrelin (2nmols
or aCSF). Further blood samples were withdrawn 10, 20, 30, 40, 50 and 60 min post-
infusion. Values are group means of plasma glucose concentrations expressed as %
of basal ± SEM. Virgin/aCSF, n=4; virgin/ghrelin, n=6; pregnant/aCSF, n=5;
pregnant/ ghrelin, n=6. Two-way ANOVA for repeated measures followed by
Student Newman Keuls multiple comparison tests: *p<0.05 significantly
different from virgin/ghrelin; #p<0.05 significantly different from pregnant/
ghrelin at the same time point, +p<0.05 significantly different from all other groups
at the same time point.
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Plasma ACTH concentration
Analysis of plasma ACTH concentration data using a two-way RM ANOVA showed
there was a statistically significant difference in plasma ACTH concentration among
virgin and pregnant groups (p<0.001). Basal plasma concentrations ofACTH were
not significantly different among groups. I.c.v injection of aCSF had no significant
effect on plasma ACTH concentration except in the virgin group at 10 min (p=0.004;
two-way RM ANOVA) which may have been due to stress of handling (Fig 4.7).
I.c.v injection of ghrelin increased plasma ACTH concentration in the virgin group
(p=0.013; two-way RM ANOVA) within 10 min (59.7 ± 5.3 vs basal 42.6 ± 6.8
pg/ml) (Fig 4.7) with concentrations remaining significantly elevated for 30 min (Fig
4.7). Ghrelin had no significant effect on plasma ACTH in the pregnant group (Fig
4.7). Thus, plasma ACTH concentration was significantly greater in the virgin group
than in the pregnant rats at 30, 60 and 90 min after i.c.v. ghrelin.
Plasma corticosterone concentration
Analysis of plasma corticosterone concentration showed there was no overall
statistically significant difference in plasma corticosterone concentrations among
virgin and pregnant groups (Fig 4.8). I.c.v. injection of ghrelin or aCSF did not
significantly increase plasma corticosterone concentration in any group (Fig 4.8).
Data are expressed as the percentage change from basal as basal values were
different among groups, although this was not statistically significant. Analysis of the
data at the 10 minute sample point using a two-way ANOVA showed there was a
statistically significant difference in plasma corticosterone concentrations among
virgin and pregnant groups (p=0.016) (Fig.4.9). I.c.v. injection of ghrelin
significantly increased plasma corticosterone only in the virgin group (p=0.003; two-
way ANOVA) (181.3 ± 29.1 vs control 77.7 ± 0.86) (Fig.4.9).
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Figure 4.7: The effect of i.c.v. ghrelin on ACTH concentration in virgin and pregnant
rats. A basal blood sample was collected 30 minutes before i.c.v. administration of
ghrelin (2nmols or aCSF). Values are the group means ± SEM. Virgin/aCSF, n=4;
virgin/ghrelin, n=6; pregnant/aCSF, n=5; pregnant/ghrelin, n=6. Two-way ANOVA
for repeated measures followed by Student Newman Keuls multiple comparison
tests: *p<0.05 significantly different from basal, #p<0.05 significantly different
from virgin/ghrelin group at the same time point, +p<0.05 significantly different from
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Figure 4.8: The effect of i.c.v. ghrelin on corticosterone concentration in virgin and
pregnant rats. A basal blood sample was collected 30 minutes before i.c.v. administration
of ghrelin (2nmols). Further blood samples were withdrawn 10, 30, 60 and 90 (trunk)
minutes post-infusion. Values are the group means ± SEM. Virgin/aCSF, n=4; virgin/
Ghrelin, n=6; pregnant/aCSF, n=5; pregnant/ghrelin, n=6. Two-way ANOVA for
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Figure 4.9: The effect of i.c.v. ghrelin on corticosterone concentration in virgin and
pregnant rats 10 minutes after i.c.v. ghrelin. Values are the group means ± SEM.
Virgin/aCSF, n=4; virgin/ghrelin, n=6; pregnant/aCSF, n=5; pregnant/ghrelin, n=6.
Two-way ANOVA followed by a Student Newman Keuls multiple comparison test.
*p<0.05 vs virgin aCSF. Data are shown as the % of basal values.
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Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p = 0.01) (Fig 4.10). The number of Fos positive cells per pPVN profile of
virgin rats given ghrelin was significantly greater (11-fold) than in the pregnant
ghrelin-treated group (Fig 4.10). I.c.v. injection of ghrelin significantly increased Fos
expression in the virgin group (p = 0.003) (11.9± 2.6 vs control 3.1 ± 1.2 Fos positive
cells per pPVN profile) (Fig 4.10 and Fig 4.11), but had no effect in the pregnant
group.
Arcuate nucleus Fos expression
Analysis of numbers of Fos-positive cells in the ARC using a two-way ANOVA
showed there was a statistically significant difference in Fos expression among virgin
and pregnant groups (p = 0.012). The number of Fos-positive cells in the ARC of
virgin rats given i.c.v. ghrelin was significantly greater (5-fold) than in the pregnant
ghrelin-treated group (Fig 4.12 and Fig 4.13). I.c.v. injection of ghrelin significantly
increased Fos expression in the virgin group (p<0.05) (Fos positive cells/section:
16.1 ± 4.7 vs control 3.0 ± 1.6), but not in the pregnant group (Fig 4.12 and Fig
4.13).
Lateral hypothalamic area Fos expression
Analysis of Fos expression in the LHA using a two-way ANOVA showed there was
a statistically significant difference in Fos expression among aCSF and ghrelin-
treated groups (p=0.021) (Fig 4.14). Ghrelin increased Fos expression in both virgin
and pregnant rats, however there was not a statistically significant difference in Fos
expression between virgin and pregnant groups for either ghrelin or aCSF treatment
(Fig 4.14).
Dorso-medial hypothalamus Fos expression
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Figure 4.10: The effect of i.c.v. ghrelin on Fos counts in the pPVN in virgin and
pregnant rats. Rats were killed by conscious decapitation 90 minutes post-injection
of ghrelin or aCSF.Values are the group means ± SEM of the mean counts of positive
cells per pPVN profile over three sections per rat. Virgin/aCSF, n=9; virgin/ghrelin,
n=l 1; pregnan/aCSF, n=7; pregnant/ghrelin, n=8. A two-way ANOVA followed
by a Student Newman Keuls multiple comparison test: *p=0.003 vs all other groups.
Figure 4.11: Representative photomicrographs of coronal sections through the
PVN of cryostat sections (15pm) in virgin and pregnant rats. Sections were
processed for Fos immunohistochemistry for (A) virgin aCSF; (B) virgin ghrelin;
(C) pregnant aCSF; (D) pregnant ghrelin. Small arrows indicate Fos-positive nuclei;
the solid line outlines the parvocellular PVN (pPVN), and the dashed line outlines the
magnocellular PVN (mgPVN).
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Figure 4.12: The effect of i.c.v. ghrelin on Fos positive cell counts in the ARC in
virgin and pregnant rats. Rats were killed by conscious decapitation 90 minutes
post-injection of ghrelin or aCSF. Values are the group means ± SEM of the mean
counts of Fos positive cells over three sections. Virgin/aCSF, n=9; virgin/ghrelin,
n=l 1; pregnant/aCSF, n=7; pregnant/ghrelin, n=8. A two-way ANOVA followed
by a Student Newman Keuls multiple comparison test: *p<0.05 vs all other groups.
Figure 4.13: Representative photomicrographs of coronal sections through the
ARC of cryostat sections (15pm) in virgin and pregnant rats. Sections were
processed for Fos immunohistochemistry for (A) virgin aCSF; (B) virgin ghrelin;
(C) pregnant aCSF; (D) pregnant ghrelin. Small arrows indicate Fos-positive nuclei;
the solid line outlines the arcuate nucleus. Scale bar = 100pm. 3V = 3rd ventricle.
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a statistically significant difference in Fos expression among virgin and pregnant
groups (p=0.001). I.c.v. injection of ghrelin significantly increased Fos expression in
the virgin group (p<0.05) (Fos positive cells/ profile: 8.1 ± 1.4 vs control 2.2 ± 0.8)
(Fig 4.15) and in the pregnant group (p <0.05) (2.5 ± 0.8 v control 0.3 ± 0.2) (Fig
4.15). The number of Fos positive cells in the DMH in the virgin/ghrelin group was
significantly greater (4-fold) than in the pregnant/ghrelin group (Fig 4.15).
Ventro-medial hypothalamus Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among aCSF and ghrelin treated
groups (p = 0.046) (Fig 4.16). However, post-hoc analysis showed there was not a






















Figure 4.14: The effect of i.c.v. ghrelin on Fos expression in the LHA in virgin and
pregnant rats. Rats were killed by conscious decapitation of ghrelin. Values are the
mean counts ofpositive cells over three sections and values are the group means ±
SEM. Virgin/Acsf, n=7; virgin/ghrelin, n=10; pregnant/aCSF, n=7; pregnant/ghrelin,
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Figure 4.15: The effect of i.c.v. ghrelin on Fos counts in the DMH in virgin and
pregnant rats. Rats were killed by conscious decapitation 90 minutes post-injection
of ghrelin or aCSF. Values are the mean counts of positive cells over three sections
and values are the group means ± SEM. Virgin/aCSF, n=9; virgin/ghrrelin, n=l 1;
Pregnant/aCSF, n=7; pregnant/ghrelin, n=8. A two-way ANOVA followed by a
Student Newman Keuls multiple comparison test: *p<0.05 vs all other groups.
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Figure 4.16: The effect of i.c.v. ghrelin on Fos counts in the VMH in virgin and
pregnant rats. Rats were killed by conscious decapitation 90 minutes post injection
of ghrelin or aCSF. Values are the mean counts of positive cells over three sections
and values are the group means ± SEM. Virgin/aCSF, n=9; virgin/ghrelin, n=l 1;
Pregnant/aCSF, n=7; pregnant/ghrelin, n=8. Two-way ANOVA: *P<0.05 vs
aCSF
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4.4 Discussion
4.4.1. The effect of i.c.v. ghrelin on food intake
The results show that centrally administered ghrelin stimulates eating behaviour in
both virgin and pregnant rats. This effect has been shown previously in male rats
(Wren et al, 2001). Ghrelin also stimulated drinking behaviour in virgin and pregnant
rats although not significantly in the pregnant group; this may relate to the tendency
of the pregnant rats to spend more time eating after ghrelin, and to the greater
drinking behaviour in the vehicle-treated pregnant rats. Other studies have shown no
significant changes in drinking or grooming in response to ghrelin administration
(Ishizaki et al, 2002). We found no significant effect of ghrelin on grooming.
4.4.2. The effect of i.c.v. ghrelin on blood glucose concentration
The results show that i.c.v. ghrelin significantly increases blood glucose
concentration to a similar maximal extent in both virgin and pregnant rats, although
the increase lasted for longer in the pregnant ghrelin-treated rats (Fig 4.6).
Hyperglycaemia and a decrease in insulin concentration have previously been shown
in ghrelin-treated rats (Broglio et al, 2001). Increase in GH secretion stimulated by
ghrelin may explain the hyperglycaemia seen in both virgin and pregnant rats. GH
suppresses the ability of insulin to stimulate uptake of glucose in peripheral tissues
and enhances glucose synthesis in the liver (Hayes et al, 2001). Consequently, GH
increases blood glucose (Ghanaatt et al, 2005), and has two other distinct metabolic
effects; a direct effect ofGH stimulates fat cells to breakdown triglyceride and
suppresses their ability to take up circulating lipids (Harant et al, 1994), and an
indirect effect mediated primarily by insulin like growth factor I (IGF-I), a hormone
secreted by the liver and other tissues in response to GH. GH is one of a battery of
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hormones, which includes glucocorticoids that serves to maintain blood glucose
within a normal range.
Basal blood glucose concentration was lower in pregnant rats compared to virgins;
this corresponds with previous studies (Rossi et al, 1993). This effect is probably due
to increased metabolic demands of the fetuses on the mother, as well as the fact that
blood volume is also increased in pregnancy.
The increased blood glucose levels in response to i.c.v. ghrelin returned to basal
levels by 20-30 minutes. GH was not measured neither was insulin in this experiment
however so we do not know the reason for the stimulatory effect of blood glucose.
Corticosterone seemed not responsible for the increase in blood glucose as it was not
increased by ghrelin in pregnant rats. However, the increase in blood glucose after
i.c.v. ghrelin in pregnant rats showed that sensitivity to this action is retained in late
pregnancy.
4.4.3 The effect of i.c.v. ghrelin on the HPA axis
The results show that ghrelin significantly increased plasma ACTH concentration in
virgin female rats, as shown previously in male rats (Wren et al, 2002). Virgin rats
given aCSF showed a significant transient increase in plasma ACTH concentration at
10 minutes which could be due to non-specific stress associated with the i.c.v.
injection. Virgin rats given i.c.v. ghrelin showed a significant sustained increase in
plasma ACTH concentration, for at least 90 minutes, which was more prolonged than
in rats given aCSF. No effect of i.c.v. ghrelin or aCSF on ACTH secretion was seen
in late pregnant rats. Virgin rats given i.c.v. ghrelin had significantly greater plasma
ACTH concentrations at 30, 60 and 90 minutes following ghrelin injection. Thus,
ACTH responses to i.c.v. ghrelin are suppressed in late pregnancy, which
corresponds with previous studies of orexin-A actions in pregnancy (Brunton et al,
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2003). An overall significant increase in plasma corticosterone concentration was not
demonstrated following ghrelin administration in either virgin or pregnant rats, but
there was a clear trend for plasma corticosterone concentration to increase in virgin
rats given ghrelin compared to virgin controls, which corresponds with previous
studies in male rats (Wren et al, 2002). In contrast there was no tendency for plasma
corticosterone concentration to increase in late pregnant rats after i.c.v. ghrelin.
One reason for reduced ACTH responsiveness in late pregnancy has been shown to
be reduced responsiveness of the pPVN CRH/AVP neurones in pregnancy. Here,
i.c.v. ghrelin significantly increased the number of Fos positive cells in virgin rats in
the pPVN compared with aCSF-treated rats. There was also a significantly greater
number ofFos-positive cells in the pPVN in virgin rats compared to late pregnant
rats, which did not respond compared to aCSF-treated pregnant rats. This suggests
there is reduced responsiveness of the CRH/AVP neurones in pregnancy in the
parvocellular PVN, as these neurones comprise a major population of the pPVN
neurones (e.g. 91%; Arima et al, 2000).
It is also known that ghrelin activates NPY neurones in the ARC that project to the
pPVN (Dickson et al, 1997) and NPY has been shown to activate the HPA axis
(Small et al, 1997, see chapter 6). Here, ghrelin significantly increased the number of
Fos-positive cells in virgin rats in the ARC. There was also a significantly greater
number of Fos positive cells in the ARC in virgin rats given i.c.v. ghrelin compared
to pregnant rats, which did not respond to i.c.v. ghrelin. As ARC NPY neurones
project to the pPVN to activate the HPA axis, the lack of a response ofARC NPY
neurones to i.c.v. ghrelin could be a reason why there is suppressed responsiveness
of the HPA axis to ghrelin in pregnancy. This is investigated further in chapter 6.
Ghrelin has also been shown to induce Fos expression in GHRH (Hewson et al,
2000), and somatostatin neurones (Lawrence et al, 2002). Fos expression in POMC
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neurones in the ARC has been shown to be unaffected by ghrelin (Kingzig et al,
2006). We do not know the phenotype of the neurones that were activated in virgin
rats in the ARC in response to i.c.v. ghrelin in the present experiment. Further studies
using double immunohistochemistry are needed to identify the neuropeptide
phenotype of neurones activated by i.c.v. ghrelin. Previous studies using double
labelling have shown that ARC NPY neurones are activated in response to i.c.v.
ghrelin (Huda et al, 2006), so it is likely that the ARC neurones activated in virgin
rats in the present study produce NPY/AgRP.
4.4.4. Activation of feeding circuitry by i.c.v. ghrelin
The LHA is a key feeding centre (Cripps et al, 2005), and the finding in the present
study that i.c.v. ghrelin increased the number of Fos positive cells in the LHA in both
virgin and late pregnant rats may account for the similar effects of i.c.v. ghrelin on
eating behaviour in virgin and pregnant rats. Ghrelin has also been shown to
stimulate food intake (Kojima et al, 1999), and this effect on food intake is mediated
through NPY neurones (Dickson et al, 1997). NPY neurones in the NTS are also
activated in response to i.c.v. ghrelin (Huda et al, 2006). NPY neurones project to
orexin containing neurones in the LHA (Broberger et al, 1998). It seems possible that
i.c.v. ghrelin induced Fos expression in the LHA via activation ofARC NPY
neurones in virgin rats, but in pregnant rats ghrelin may have acted directly or via
NTS NPY neurons (Lawrence et al, 2002). Activation of Fos expression in the LHA
by i.c.v. ghrelin in both virgin and pregnant rats corresponds with the finding that
eating behaviour was stimulated in both virgin and pregnant rats in response to i.c.v.
ghrelin. It would be interesting to evaluate actions of i.c.v. ghrelin on NTS neurones
in virgin and late pregnant rats.
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It has been shown that ghrelin induces Fos expression in the DMH (Lawrence et al,
2002). Dense projections ofARC NPY/AgRP neurones innervate the DMH (Graham
et al, 2003). I.e.v. ghrelin significantly increased the number of Fos positive cells in
the DMH in both virgin and pregnant rats compared to the control groups. The basal
expression of Fos expression in the DMH was lower in pregnant animals compared
to virgin animals and pregnant rats given i.c.v. ghrelin showed significantly less Fos
expression than virgin rats given i.c.v. ghrelin. The DMH contains a high proportion
ofNPY neurones (about 70%) (Chen et al, 2004). Both the DMH and VMH are
essential for basal and induced ACTH secretion (Fizol et al, 1977). Consequently,
the reduced Fos responses in the DMH after i.c.v. ghrelin in late pregnant rats might
contribute to the suppressed HPA axis response. Conversely, the intact VMH Fos
responses indicate that VMH activation is not sufficient to drive the HPA axis in late
pregnancy. Perhaps the reduced increase in Fos expression in the DMH after i.c.v.
ghrelin in late pregnant rats reflects failure of ARC NPY neurones to respond to i.c.v.
ghrelin.
It has also been shown that ghrelin induces Fos expression in the VMH after
administration of a growth hormone secretagogue (Lawrence et al, 2002) or ghrelin,
although the effect of ghrelin was not significant (Lawrence et al, 2002). It is known
that in the centre of the VMH there are glucose responsive neurones (Ono et al,
1982). The VMH responds to an increase in blood glucose levels (Borg et al, 2003)
and has also previously been identified as a "satiety centre" (King et al, 2006). We
have shown that i.c.v. ghrelin increased the number of Fos positive cells in the VMH
in both virgin and pregnant rats compared to control groups. This may have been due
entirely to a central action of ghrelin, perhaps a result of the hyperglycaemia
following ghrelin.
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ARC NPY neurones are also importantly implicated in the central regulation of
appetite (Small et al, 1997). The action of ghrelin in virgin rats in stimulating both
ARC nucleus neurones, as detected by Fos expression, and eating behaviour is
consistent with this. However, in late pregnant rats ghrelin strongly stimulated
eating behaviour without activating ARC neurones. These findings indicate that
ghrelin can stimulate eating in other ways than by stimulation of the ARC NPY
neurones. The mechanism could be by a direct action of ghrelin on the LHA (which
contains orexin neurones) and the DMH (which comprise 70% ofNPY neurones).
Indeed, regarding the VMH, ghrelin also increased Fos in both the virgin and
pregnant rats. Here ghrelin was shown to transiently increase blood glucose, the
VMH neurones are glucose sensing, their activation after ghrelin may reflect the
fluctutations in blood glucose.
4.4.5 Summary
In summary, the experiments have shown that i.c.v. ghrelin activates the HPA axis in
virgin but not in late pregnant rats, yet it increased eating behaviour and blood
glucose concentration in both virgin and pregnant rats. Fos expression was
stimulated by i.c.v. ghrelin in both virgin and pregnant rats in the LHA, VMH and
DMH which has already been shown in male rats (Lawrence et al, 2002). These
findings also correspond with the location of the GHS-R (Cowley et al, 2003). In
pregnancy HPA axis responses to i.c.v. ghrelin were suppressed. Fos expression was
not stimulated by central ghrelin in the pPVN or the ARC in pregnant rats. Reduced
expression in the pPVN neurones indicates that the reduced ACTH response was due
to lack of activation of the pPVN CRH and AVP neurones. Therefore the
responsiveness of the HPA axis to i.c.v. ghrelin is reduced in pregnancy but blood
glucose and feeding responses are still intact. Thus the loss of stimulatory actions of
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ghrelin in pregnancy on the HPA axis is not a result of a generalised loss of central
responses to i.c.v. ghrelin. The finding that there were reduced responses of the HP
axis to i.c.v. ghrelin which were not seen in response to i.v. insulin (Chapter 3)
suggests that insulin's actions on the HPA axis are not exerted via central ghrelin.
There have been several ideas as to the mechanisms ofHPA axis hyporesponsiveness
to stressors in late pregnancy. It has previously been shown that enhanced negative
feedback inhibition by glucocorticoids does not underlie the reduced responsiveness
of the HPA-axis to stress at the end ofpregnancy (Johnstone et al, 2000) and reduced
forward drive is more likely to account for the reduced activity (Johnstone et al,
2000). This may involve inhibition by a central opioid mechanism that emerges in
pregnancy (Douglas et al, 1998). Possible sources of endogenous opioid that could
regulate pPVN CRH/AVP neurones include noradrenergic NTS neurones which
coexpress pro-enkephalin-A (pENK-A) mRNA (Ceccatelli et al, 1989). pENK-A
mRNA expression is increased in the NTS in late pregnancy and evidently inhibits
CRH neurones following administration of interleukin-l(3 (Brunton et al, 2005).
NPY-containing neurones project from the NTS to the PVN. It was not known
whether this opioid mechanism would interfere with NPY signalling to the pPVN
CRH/AVP or ARC neurones (see Chapters 5 and 6). We aimed to investigate further
the mechanisms of reduced HPA axis responses in pregnancy, so in Chapter five we
have examined central effects of orexin-A in pregnancy and the role of endogenous
opioids to investigate this further, since orexin-A has been shown to activate the
HPA axis in part via NPY neurones (Jasberenzyi et al, 2001). A possible role for
endogenous opioids in the suppressed pPVN neurone and ACTH responses to ghrelin
remains to be investigated. The results lead us to consider that the central actions of
ghrelin on the HPA axis involve ARC neurone activation (since this was absent in
pregnant rats which did not show an HPA axis response), while the actions of ghrelin
117
Ghrelin and the HPA axis Chapter 4
on eating are not mediated by stimulatory actions in the ARC but may be mediated
by direct actions on the LHA and VMH, with a lesser role for the DMH. It should be
remarked that Fos expression allows detection of neurones that have been excited
(Hoffman et al, 1993) and different inhibitory actions of ghrelin on pools of neurones





Orexins A and B are neuropeptides originally isolated from the rat hypothalamus by
two different groups of investigators (De Lecea et al, 1998; Sakurai et al, 1998). Two
G-protein coupled receptors for orexins A and B were discovered and are named the
orexin receptor 1 (0X1-R) and the orexin receptor 2 (0X2-R) (De Lecea et al, 1998;
Sakurai et al, 1998).
The orexins have been implicated in playing a role in the regulation of energy
balance and feeding (Spinazzi et al, 2006) but they have also been importantly
involved in the regulation of the sleep-wake cycle (Lin et al, 1999). Orexin receptor
knock out mice with a non functional OX2-R, display a narcolepsy like condition
(Chemelli et al, 1999; Lin et al, 1999). It is thought that orexin may regulate sleep
by interacting through aminergic and cholinergic systems (Lin et al, 1999), and
inhibition of orexin neurones through GABAergic inputs from pre-optic and basal
forebrain areas is thought to be crucial for sleep initiation (Eggerman et al, 2003).
Narcoleptic humans have been shown to lack orexin-containing neurones in the
hypothalamus and orexin in cerebrospinal fluid (Nishino et al, 2000). As well as the
sleep-wake cycle and feeding the orexins can regulate blood pressure and heart rate
and can also activate the HPA axis (Taheri et al, 2001). The fact that orexin can
activate the HPA axis is very interesting as many peptides that are involved in the
central regulation of feeding (e.g. leptin and neuropeptide Y (NPY) also help control




The orexins are derived from the post-translational cleavage of an amino acid
precursor prepro (pp)-orexin. After detachment of the N-terminal 33 amino acid
residue pp-orexin is converted to pro-orexin, which is then cleaved to yield one
molecule each of orexin-A and orexin-B.
Orexin-A
Orexin-A is a 3.5kDa 33 amino acid peptide. It possesses a N-terminal residue, a C-
terminal and two disulphide bridges between adjacent cysteine residues (Fig 5.1).
Orexin-B
Orexin-B is a 2.9kDa 28 amino acid peptide. Orexin-A is more stable than orexin-B,
Orexin-A is found in higher concentrations in tissue and blood than orexin-B (Kastin
et al, 1999). Orexin-A can cross the blood brain barrier unlike orexin-B (Kastin et al,
1999).
5.1.3 Orexin receptors and their signalling mechanism
The orexin receptors are seven transmembrane domain G-protein coupled receptors
(Sakurai et al, 1998). OX1-R binds only orexin-A, whereas the OX2-R binds both
orexin-A and orexin-B. Activation of orexin receptors increases intracellular calcium
concentration (Smart et al, 1999). Activation of phospholipase C catalyses the
breakdown of phosphatidyl inositol to inositol triphosphate (IP3) and diacylglycerol
(DAG). DAG activates protein kinase C (PKC) and IP3 and increases calcium
release from intracellular calcium stores and also activates PKC (Zhin et al, 2003).
PKC and the increased intracellular calcium open voltage-gated calcium channels
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via the IP3 pathway orexin receptor binding also activates the adenylate cyclise
signalling pathway.
5.1.4 Expression of the orexins and their receptors in relation to the HPA axis
The orexins receptors were originally discovered in the rat brain. Pre-pro orexin
mRNA has been mainly found in the lateral hypothalamic area (LHA) (Lopez et al,
2000). Immunohistochemistry showed the orexin positive neurones project widely
throughout the brain, including to the arcuate nucleus (ARC), supraoptic nucleus
(SON) and paraventricular nucleus (PVN) (Chen et al, 1999). The LHA has been
importantly implicated in the regulation of food intake; fasting and IIH increased pp-
orexin mRNA expression (Cai et al, 2001).
OX1-R expression has been shown in the VMH and DMH whereas OX2-R
expression has been shown in the LHA, PVN, ARC, mammillary and
tuberomammillary nuclei (Trivedi et al, 1998). Food deprivation also increases the
expression ofOX1-R and OX2-R (Karteris et al, 2005).
OX1-R and 2 mRNAs have been detected in the pituitary gland (Date et al, 2000)
whereas no orexin mRNA or protein has been found (Arihara et al, 2000).
5.1.5 The effects of orexin on the HPA axis
The PVN contains orexin positive nerve terminals and also orexin receptors (Zhang
et al, 2005). Central administration of orexin-A increases c-fos mRNA expression in
the pPVN (Kuru et al, 2000) and CRH mRNA in the pPVN (Brunton et al, 2003).
Orexin-A also stimulates CRH release from hypothalamic explants (Russell et al,
2001). Administration of orexin-A depolarises PVN neurones in hypothalamic slices
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(Samson et al, 2002). Orexin-A stimulation ofCRH release is thought to be partly
mediated by NPY; orexin increases both CRH and NPY from hypothalamic explants
(Russell et al, 2001), and increased corticosterone release normally seen after central
administration of orexin-A was not seen after pre-treatment with a NPY antagonist
(Jaszberenyi et al, 2001).
Central administration of orexin-A increases release ofACTH (Brunton et al, 2003),
but it does not affect basal ACTH release from rat pituitary cells (Samson et al,
2001). Orexin-A does not affect either basal or CRH-stimulated cAMP production,
so it is suggested the effect of the orexins on the anterior pituitary are mediated by
OX1-R coupled to the PKC cascade (Samson et al, 2001).
5.1.6 The effect of orexin-A on the HPA axis in pregnancy
Central administration of orexin-A stimulates the HPA axis in virgin female rats
(Brunton et al, 2003). I.c.v. orexin-A increases plasma ACTH, corticosterone and
pPVN CRH mRNA expression in virgin but not pregnant rats (Brunton et al, 2003).
It is thought that the reduced responsiveness of the HPA axis could be due to
increased action of inhibitory inputs to the CRH neurones. Orexin-A may act
centrally directly on the pPVN CRH/AVP neurones (Brunton et al, 2003). The PVN
receives input directly from the LHA (Cuter et al, 1999). However, as discussed
orexin-A activates the HPA axis directly and indirectly through the NPY neurones
since administration of an NPY antagonist inhibits the corticosterone response to
orexin-A (Jaszberenyi et al, 2001). NPY has also been shown to activate the HPA
axis (Haas et al, 1989). Thus orexin-A may activate the HPA axis by acting either via
the ARC NPY neurones or directly on the PVN (Samson et al, 2002).
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It is not known what changes occur during pregnancy that lead to reduced HPA axis
responses to orexin-A in pregnancy; enhanced inhibitory inputs to the CRH neurones
are a possibility (Brunton et al, 2003); changes in orexin receptor expression during
pregnancy are not known. No differences in either eating, drinking or grooming
responses to i.c.v. orexin-A were found between virgin and pregnant rats, so the loss
of stimulation of the HPA axis in late pregnancy is not due to a general loss of
central responses to orexin-A (Brunton et al, 2003).
5.1.7 Aims of experiments
The reduced responsiveness of the hypothalamic CRH-expressing pPVN neurones to
centrally administered orexin-A in late pregnancy could be a result of reduced
excitatory drive by inputs on which either orexin or NPY have a stimulatory action.
There is no reduced capacity to secrete CRH or ACTH in late pregnancy (Ma et al,
2005). It has previously been shown that enhanced negative feedback inhibition by
glucocorticoids does not underlie the reduced responsiveness of the HPA axis to
stress at the end of pregnancy (Johnstone et al, 2000). Since NPY may mediate the
effect of orexin-A on the HPA axis, reduced HPA axis responses to orexin-A in late
pregnancy (Brunton et al, 2003) could be a result of the failure of the CRH neurones
to respond to NPY (see chapter 6). Endogenous opioid mechanisms have been shown
to inhibit SON oxytocin neurones in late pregnancy (Douglas et al, 1993). NTS
neurones projecting to the PVN may be the source of this opioid. Pro-enkephalin A
mRNA expression is upregulated in the NTS in late pregnancy (Brunton et al, 2005).
It was not known if in pregnancy opioids would interfere with orexin or NPY
signalling to the pPVN CRH/AVP neurones. The main aims of these experiments
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were: to investigate changes in excitation in hypothalamic circuitry regulating HPA
axis and eating responses to centrally administered orexin-A between virgin and
pregnant rats and to investigate if endogenous opioids interfere with orexin signalling





Female Sprague Dawley rats were used and housed individually after surgery. Rats
were maintained as described in section 2.1.
5.2.2 Surgery
Rats were implanted with an intracerebroventricular cannula in experiment 1 and an
intracerebroventricular and jugular vein cannula in experiment 2. Surgery was
performed under conditions described in section 2.3.
5.2.3 Experiment 1 - The effect of centrally administered Orexin-A in
pregnancy
On the day of the experiment (day 21 of pregnancy), rats were left undisturbed for 90
minutes after cannula connection. Rats were given either 5jag orexin-A (5pg in 2pl)
or vehicle (artificial cerebro-spinal fluid, aCSF; pH 7.2, composition in mM: NaCl,
138; KC1, 3.36; NaHC03,9.52; Na2HP04, 0.49; urea, 2.16; NaH2P04, 0.49; CaCl2,
1.26; MgCl2, 1.18) which was given i.c.v. with gentle restraint over a period of about
30 seconds. The following behaviours were noted continually: inactive, grooming,
oral motor activity, eating and drinking. Behavioural data were collected for 90
minutes; an event was classified as occurring if an animal spent > 5 seconds
exhibiting the behaviour. Rats were killed by transcardial perfusion of fixative (4%
PFA) under deep pentobarbitone anaesthesia 90 minutes after orexin-A (this time
point has previously been shown as the optimum time for showing increased Fos
expression in the central nervous system after orexin-A) (Niimi et al, 2001). Rats
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were examined post-mortem to check presence and number of fetuses (a lower limit
of 4 was not counted in the experiment) and to check i.c.v. cannula placement.
Brains were processed for Fos immunohistochemistry using free-floating sections
and Fos expression measured by counting numbers of neurones with Fos
immunoreactive nuclei in regions of interest.
5.2.4 Experiment 2 - The effect of naloxone on reduced HPA responses to
orexin-A in pregnancy, on blood glucose and eating behaviour.
On the day of the experiment (day 21 of pregnancy) the cannulae were connected
between 07:30-08:30h. The jugular vein cannula was attached to PVC extension
tubing led out of the cage and connected to a 1ml syringe filled with heparinised
saline (0.9% saline, 50 units/ml). Rats were left undisturbed for 90 minutes and a
basal blood sample (0.55ml) was taken. Immediately after the first basal blood
sample either naloxone (lOmg/ml) or saline both at 0.5ml/kg were given i.v. 15
minutes after the first basal blood sample, another basal blood sample was taken and
15 minutes later rats were given either 5pg orexin-A (5pg/2pl) or vehicle (artificial
cerebro-spinal fluid, aCSF; pH 7.2, (composition see 5.2.3) i.c.v. with gentle restraint
over a period of about 30 seconds. Further blood samples (0.55ml) were taken for
glucose and for ACTH assay at 15, 30, 60 and 120 minutes after i.c.v. infusion.
Glucose measurements were made throughout the experiment using a Roche
Accuchek Active Meter. Blood samples were placed into eppendorf tubes containing
50pl of chilled 5% EDTA. After each blood sample, blood was replaced with 0.9%
sterile saline. Plasma was separated by centrifugation and stored at -20°C until
radioimmunoassay. The following behaviours were noted continually: inactive,
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grooming, oral motor activity, eating and drinking. Behavioural data were collected
for 90 minutes; an event was classified as occurring if an animal spent > 5 seconds
exhibiting the behaviour. Rats were killed by conscious decapitation 4 hours after
orexin-A (this time point has previously been shown as the optimum for showing
increased CRH mRNA expression in the PVN following stress) (Harbuz et al, 1989).
Rats were examined post-mortem to check fetuses and to check i.c.v. cannula
placement. Blood samples were processed for ACTH assay and brains processed for
CRH and AVP in-situ hybridisation.
5.2.5 Fos immunohistochemistry
Coronal sections (52pm) of paraformaldehyde-fixed brains were cut through the
PVN, ARC, LHA, VMH and DMH on a freezing microtome onto gelatinised slides.
Fos immunohistochemistry was performed using the method described in section
2.5.2. for free floating sections. Fos-positive stained cells were counted in each
region with at least 3 sections evaluated per rat. Regions of interest were defined by
reference to a rat brain atlas (Konig et al, 1963). Cells were counted under x40
magnification on a Leica light microscope.
5.2.6 In Situ Hybridisation
Brains were cryostat sectioned at 15 pm and mounted onto Polysine slides (BDH)
(see section 2.4.2). To detect CRH mRNA expression a 42-mer oligonucleotide
probe (MWG-Biotech) was used complementary to bases 496-537, which encode




5'-CCT GTT GCT GTG AGC TTG CTG AGC TAA CTG CTC TGC CCT GCC- 3'
The probe was labeled with 35S as described in section 2.4.2. The melting
temperature for CRH was 78°C, therefore the heated SSC washes were performed at
58°C. Once dry the sections were dipped in photographic emulsion under safelight
conditions and stored at 4°C. The exposure time was 13 weeks for CRH mRNA. The
number of positive cells and the silver grain density were measured with the image
analysis system described in 2.4.2.
5.2.7 ACTH radioimmunoassay
Plasma ACTH concentration was determined using a commercially available kit as
described in section 2.7.3. The sensitivity of the ACTH assay was 6pg/ml. The intra-
assay variation was <11%.
5.2.8 Statistics
A two-way analysis of variance (ANOVA) was used with a repeated measures
ANOVA for blood sampling experiments. The ANOVA was followed, if it showed
significant differences, by Student Newman Keuls multiple comparison tests to





5.3.1 Experiment 1 - The effect of centrally administered orexin-A
Behavioural Data
Analysis of behavioural data using a two-way ANOVA showed a statistically
significant difference in eating behaviour following i.c.v. orexin administration
(P=0.001). Orexin-A significantly increased eating behaviour in virgin rats (p=0.005;
two-way ANOVA) (Fig 5.3). There were no significant differences in drinking
behaviour between groups (Fig 5.3). There was a statistically significant increase in
grooming behaviour following orexin administration (p<0.001) (Fig 5.3). Orexin-A
significantly increased grooming behaviour in virgin rats (p<0.001; two-way
ANOVA) (Fig 5.3). Occurrence of eating and grooming in late pregnant rats after
i.c.v. orexin were not significantly different from their occurrence in virgin rats;
although in pregnant rats eating and grooming were not significantly increased, there
was a trend for both eating and grooming to increase following administration of
orexin.
Parvocellular Paraventricular Nucleus (pPVN) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p=0.002). Quantification of Fos positive cells revealed that Fos expression in
the PVN of the virgin orexin-treated group was significantly greater (2-fold) than in
the pregnant orexin group (Fig 5.4). I.c.v. injection of Orexin significantly increased
Fos expression in the pPVN in the virgin group (p<0.001) (21.6 ± 1.4 vs control 10.5


































Figure 5.3: The effect of i.c.v. orexin-A on behvaiours in virgin and pregnant
rats. Behaviours were monitored ontinually for 90 minutes post i.c.v. injection
of orexin-A (5pg/rat). An event was classified as occuring if an animal spent
> seconds exhibiting the behaviour. Data represent group means ± SEM. Virgin/
aCSF n=7; virgin/orexin, n=8; pregnant/aCSF, n=7; pregnant/orexin, n=7.
**p<0.001 vs aCSF, *p<0.005 vs aCSF; two-way ANOVA followed by Student
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Figure 5.4: The effect of i.c.v. orexin-A on Fos expression in the pPVN in virgin and
pregnant rats. Rats were killed by transcardial perfusion fixation 90 minutes post-
Injection of orexin-A. Values are the mean count positive cells over three sections
per rat and values are the group means ± SEM. Virgin.aCSF, n=7; virgin/orexin, n=8;
pregnant/aCSF, n=7; pregnant/orexin, n=7. Two-way ANOVA followed by
Student Newman Keuls multiple comprison tests. **p<0.001 vs all other groups.
Figure 5.5: Representative photomicrographs of microtome sections
through the pPVN ofmicrotomal sections (52pm) in virgin and
pregnant rats. Sections were processed for Fos immunohistochemistry for
(A) virgin aCSF; (B) virgin orexin-A; (C) pregnant aCSF; (D) pregnant
orexin-A treated rats. Scale bar = 100pm. 3V = 3rd ventricle. pPVN =
parvocellular PVN.
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Arcuate nucleus (ARC) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among the virgin and pregnant
groups (p<0.001). Quantification of Fos positive cells revealed that Fos expression in
the ARC of virgin rats was significantly greater (3-fold) than in the pregnant orexin
group (Fig 5.6). I.c.v. injection of orexin significantly increased Fos expression in the
virgin group (p<0.001) (27.6 ± 2.9 vs control 9.6 ± 1.5 Fos positive cells/ARC
profile) (Fig 5.6 and Fig 5.7).
Lateral Hypothalamic Area (LHA) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among the virgin and pregnant
groups (p=0.017). Quantification of Fos positive cells revealed that Fos expression in
the LHA of pregnant rats was significantly greater (1.4-fold) than in the virgin orexin
group (Fig 5.8). I.c.v. injection of orexin significantly increased Fos expression in the
virgin group (p=0.006) (19.9 ± 3.0 vs control 11.1 ± 1.2 Fos positive cells/LHA
profile) (Fig 5.8) and in the pregnant group (p<0.001) (27.6 ± 2.3 vs 13.9 ± 1.6 Fos
positive cells/LHA profile) (Fig 5.8 and Fig 5.9).
Ventromedial Hypothalamus (VMH) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among the virgin and pregnant
groups (p=0.0033) (Fig 5.10). Quantification of the number of Fos positive cells
revealed that Fos expression in the VMH of pregnant rats given orexin-A was
significantly greater (1.5 times) than in the virgin orexin group (Fig 5.10). I.e.v.
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Figure 5.6: The effect of i.cv. orexin-A on Fos expression in the ARC in virgin
and pregnant rats. Rats weie killed by tianscardial fixation perfusion 90 minutes
Post-injection of orexin-A. Values are the mean counts of postiive cells over
three sections per rat and are shown as the group means ± SEM. Virgin/aCSF,
n=7; virgin/orexin, n=8; pregnant/aCSF, n=7; pregnant/orexin, n=7. Two-way
ANOVA followed by Student Newman Keuls multiple comparison tests.
**p<0.001 vs all other groups.
Figure 5.7: Representative photomicrographs of coronal sections
through the ARC of microtome sections (52pm) in virgin and pregnant
rats. Sections were processed for Fos immunohistochemistry groups: (A)
virgin aCSF; (B) virgin orexin-A; (C) pregnant aCSF; (D) pregnant orexin-
A. Small arrows indicate Fos-positive nuclei; the solid line outlines the
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Figure 5.8: The effect of i.c.v. orexin-A on Fos counts in the LHA in virgin and
pregnant rats. Rats were killed by transcardial fixation perfusion 90 minutes
post-injection of orexin. Values are the mean count positive cells over three sections
per rat and are shown as the group means ± SEM. Virgin/aCSF, n=7; virgin/orexin,


















Figure 5.9: Representative photomicrographs of coronal sections
through the LHA ofmicrotome sections (52|Jm) in virgin and pregnant
rats. Sections were processed for Fos immunohistochemistry groups: (A)
virgin aCSF; (B) virgin orexin-A; (C) pregnant aCSF; (D) pregnant orexin-
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Figure 5.10: The effect of i.c.v. orexin-A on Fos counts in the VMH in virgin and
pregnant rats. Rats were killed by transcardial perfusion 90 minutes post-injection
of orexin-A. Values are the mean count positive cells over three sections per rat and
are shown as group means ± SEM. Virgin/aCSF, n=7; virgin/orexin, n=8; pregnant/
aCSF, n=7; pregnant/orexin, n=7. Two-way ANOVA followed by Student Newman
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Figure 5.11: Representative photomicrographs of coronal sections
through the VMH ofmicrotome sections (52(Jm) in virgin and pregnant
rats. Sections were processed for Fos immunohistochemistry groups: (A)
virgin aCSF; (B) virgin orexin-A; (C) pregnant aCSF; (D) pregnant orexin-
A. Scale bar = 100pm. 3V = 3rd ventricle
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(p=0.003) (30.0 ± 3.2 vs control 20.3 ± 1.9 Fos positive cells/VMH profile) but not
in virgin rats (Fig 5.10 and Fig 5.11).
Dorsomedial Hypothalamus (DMH) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was not a
statistically significant difference in Fos expression among the virgin and pregnant
groups (Fig 5.12). I.c.v. injection of orexin did not significantly increase Fos
expression in either the virgin or the pregnant group (Fig 5.12).
6.3.2 Experiment 2 - The effect of naloxone on reduced HPA responses to
orexin-A in pregnancy, and on blood glucose and eating behaviour.
Behavioural data
Analysis of behavioural data using a two-way ANOVA showed there was no
statistically significant difference in eating behaviour among groups (Fig 5.13). Also
there were no significant differences in drinking or grooming between groups (Fig
5.13).
Blood glucose concentration
Analysis of blood glucose concentration using a two-way RM ANOVA showed a
statistically significant difference in plasma glucose concentration among virgin and
pregnant groups (p<0.001). Basal blood glucose concentrations were significantly
lower in pregnant rats overall than virgins (p<0.05; two-way RM ANOVA). Orexin
with i.v. saline significantly increased blood glucose in the virgin group (p<0.001;
two-way RM ANOVA) within 15 min (7.4 ± 0.2 vs 5.7 ± 0.4 mmol/1) with glucose
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Figure 5.12: The effect of i.c.v. orexin-A on Fos counts in the DMH in virgin and
pregnant rats. Rats were killed by transcardial fixation 90 minutes post-injection
of orexin. Values are the mean count positive cells over three sections per rats and
shown as group means ± SEM. Virgin/aCSF, n=7; virgin/orexin, n=8; pregnant/
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Figure 5.13: The effect of i.c.v. orexin-A and i.v. naloxone on behaviours in virgin and
pregnant rats. Behaviours were monitored continually for 120 minutes post-injection
of orexin-A (5pg/rat). An event was classified as occurring if an animal spent 5
seconds exhibiting the behaviour. Data represent group means ± SEM. Virgin
orexin/saline, n=6; virgin orexin/naloxone, n=7; pregnant orexin/saline, n=6;
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Figure 5.14:The effect of i.c.v. orexin-A and i.v. naloxone on blood glucose
concentration in virgin and pregnant rats. Three basal blood samples were taken
30, 15 and 1 min prior to i.c.v. orexin (5pg/rat). I.v. naloxone was given 30 minutes
prior to i.c.v. orexin. Further blood samples were withdrawn 15, 30, 60 and 120 min
post-infusion. Values are group means ± SEM. Virgin orexin/saline, n=6;
virgin orexin/naloxone, n=7; pregnant orexin/saline, n=6; pregnant orexin/
Naloxone, n=7. Two-way ANOVA for repeated measures followed by Student Newman
Keuls multiple comparison tests: **p<0.001, *p<0.05 significantly different from the
pt
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injection of orexin with i.v. naloxone significantly increased blood glucose in the
virgin group (p<0.001; two-way RM ANOVA) within 15 min (6.8 ± 0.4 vs basal 5.6
± 0.6 mmol/1) with glucose concentrations returning to the post-naloxone basal value
by 30 min (Fig 5.14). I.c.v. injection of orexin and i.v. naloxone had no significant
effect on blood glucose concentration in pregnant rats, nor did i.c.v. injection of
orexin and i.v. saline. Naloxone had no significant effect on the blood glucose
response to orexin-A in virgin rats, or the lack of a response in pregnant rats (Fig
5.14).
Plasma ACTH concentration
Analysis of plasma ACTH concentration data using a two-way RM ANOVA showed
there was a statistically significant difference in plasma ACTH concentrations among
the virgin and pregnant groups (p = 0.031). Data are shown as the percentages of the
basal values after i.v. naloxone as there was variation between basal values. Basal
values were virgin orexin + saline 70.1 ± 4.5 pg/rnl; virgin orexin + naloxone 40.3 ±
4.8 pg/ml; pregnant orexin + saline 77.7 ± 4.9 pg/ml; pregnant orexin + naloxone
77.0 ±3.7 pg/ml. These concentrations however were not significantly different
among groups. I.c.v injection of orexin-A and i.v. naloxone significantly increased
plasma ACTH concentration in the virgin group (p<0.001; two-way RM ANOVA)
within 15 min (231.3 ± 36.4 vs basal 100%) (Fig 5.15 and Fig. 5.16), with
concentrations remaining significantly elevated for 240 min (Fig 5.15). I.c.v.
injection of orexin and i.v. saline significantly increased plasma ACTH concentration
in the virgin group (p<0.001; two-way RM ANOVA) within 15 min; (188.4 ± 17.9
vs basal 100%) (Fig 5.15); with concentrations remaining significantly elevated for
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Figure 5.15: The effect of i.c.v. orexin-A and i.v. naloxnoe on plasma ACTH
concentration in virgin and pregnant rats. Three basal blood samples were taken
30, 15, and 1 min prior to i.c.v. injection of orexin-A (5pg/rat). Further blood samples
were taken 15, 30, 60, 120 and 240 (trunk blood) min post-injection. I.v. naloxone was
given 30 min prior to injection of orexin-A. Data represent group means ± SEM. Virgin
orexin/saline, n=6; virgin orexin/naloxone, n=7; pregnant orexin/saline, n=6;
pregnant orexin/naloxone, n=7. Two-way ANOVA for repeated measures followed
by a Student Newman Keuls multiple comparison test: **p<0.001, *p<0.05 vs basal,
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Figure 5.16: The effect of i.c.v. orexin-A and i.v. naloxone on plasma ACTH
concentration in virgin and pregnant rats. % delta values for the measurements at
15 minutes after orexin-A (5pg/rat) subtracted from the first basal blood sample
were calculated. Values are the group means ± SEM. Vrigin orexin/saline, n=6;
virgin orexin/naloxone, n=7; pregnant orexin/saline, n=6; pregnant orexin/naloxone,
n=7. A two-way ANOVA followed by a Student Newman Keuls multiple comparison
test. #p<0.05 vs all other groups.
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the pregnant group given i.v. naloxone (p=0.003; two-way RM ANOVA) within 15
min (159.2 ± 34.1 vs basal 100%) (Fig 5.16) with concentrations remaining elevated
for 15 minutes (Fig 5.15 and Fig 5.16). I.c.v. orexin given together with i.v. saline
did not alter plasma ACTH concentration in late pregnant rats at any time point.
Naloxone alone groups were not included in this experiment, however the effect of
naloxone alone was investigated on plasma ACTF1, CRH and AVP mRNA
expression and showed no differences (Brunton unpublished).
Parvocellular PVN (pPVN) CRHmRNA expression
Analysis ofCRH mRNA expression using a two-way ANOVA showed there was a
statistically significant difference in the number of pPVN neurones expressing CRH
mRNA among the virgin and pregnant groups (p=0.002). The number ofCRH
mRNA expressing neurones in the pPVN was significantly greater (2.5 fold) in the
virgin/orexin-A group than in the pregnant/orexin-A group, both treated with saline
(Fig 5.17). I.c.v. injection of orexin with i.v. naloxone significantly increased CRH
mRNA expression in the pregnant group (p<0.001) compared with i.c.v. injection of
orexin and i.v. saline, (Fig 5.17), and expression in the orexin/naloxone treated
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Figure 5.17: The effect of i.c.v. orexin-A on CRH mRNA expression in the
parvocellular PVN in virgin and pregnant rats. Rats were killed by conscious
decapitation 240 minutes post-injection of orexin-A. Values are the mean counts of
positive cells over at least three sections per rats and values are the group means ±
SEM. Virgin orexin/saline, n=6; virgin orexin/naloxone, n=7; pregnant orexin/saline,
n=6; pregnant orexin/naloxone, n=7. A two-way ANOVA followed by a Student
Newman Keuls multiple comparison test. **p<0.01 vs all other groups.
Orexin-A Chapter 5
5.4 Discussion
5.4.1. The effect of i.c.v. orexin-A and naloxone on behavioural parameters
The results show that centrally administered orexin-A stimulates eating behaviour in
both virgin and pregnant rats (Fig 5.3), confirming previous findings (Brunton et al,
2003). This has been shown also in male rats (Sakurai et al, 1998). Rats in
experiment two seemed to eat more than rats in experiment one, this is due to the
effect of different analysers in both experiments. Naloxone did not affect eating in
either virgin or pregnant rats given orexin-A. Nonetheless, there is strong evidence
that opioid peptides stimulate feeding and elicit satiety, and the stimulatory actions of
i.c.v. NPY on eating are inhibited by naloxone (see Chapter 6). Opioids have long
been known to play a role in the regulation of ingestive behaviour via the receptor
subtypes kappa, mu and delta (Baile et al, 1986). Central administration of opioid
agonists stimulate food intake; opioid peptides from all three families, endorphins,
enkephalins and dynorphins, have been shown to stimulate feeding in various species
(Baile et al, 1986). Administration of opioid antagonists does the reverse, decreasing
food intake (Yu et al, 1997). It seems however that orexin-A stimulates feeding
behaviour independently of opioid actions.
Orexin-A did not significantly stimulate drinking behaviour in either virgin or
pregnant rats. Other studies have shown no significant changes in drinking in
response to i.c.v. orexin administration (Brunton et al, 2003). Flowever, centrally
injected orexins have been found to increase drinking at doses similar to those that
elicit increased feeding (Kunii et al, 1999). The LHA is a primary drinking centre
(Greer et al, 1955), and orexin-A might exert any actions on drinking here, while
there is orexin innervation of the area postrema a region important in fluid
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homeostasis (Kunii et al, 1999). The lack of an increase in drinking in the present
study after orexin may reflect the weak effect on food intake.
The present results showed that orexin-A significantly increased grooming in virgin
rats with a tendency also for grooming to increase in pregnant rats. This has
previously been shown in male (Willie et al, 2001) and female rats (Brunton et al,
2003). The effects of centrally administered orexin-A on grooming could reflect
activational actions of orexin in the regulation of feeding and the sleep-wakefulness
cycle (Lin et al, 1999). The brain region receiving the densest innervation from
orexigenic neurones is the locus coeruleus, and orexin-A increases cell firing of
noradrenergic neurones (Hagan et al, 1999). Grooming has been linked to elevated
stress levels (Dunn et al, 1981), a suggestion consistent with the observations that
orexin-A increases plasma corticosterone levels (Jones et al, 2001). Naloxone did not
significantly alter drinking or grooming after orexin-A in either virgin or pregnant
rats.
5.4.2. Changes in Fos expression in hypothalamic circuitry regulating HPA axis
and eating behaviour after centrally administered orexin-A in late pregnancy
pPVN. I.c.v. orexin-A significantly increased the number of Fos positive cells in the
pPVN in virgin rats compared with aCSF treated virgin rats (Fig.5.5). There was also
a significantly greater number of Fos positive cells in the pPVN of virgin rats
compared to late pregnant rats given orexin-A. This suggests there is reduced
responsiveness of the CRH/AVP neurones in pregnancy in the pPVN as these




CRH neurones are also involved in reducing food intake. Responsiveness of the CRH
neurones other than in the pPVN in pregnancy is not known. Following i.e.v.
injection of orexin-A Fos expression was highly expressed in the PVN (Edwards et
al, 1999). Since many neurones are activated by injection of orexin-A, orexin was
injected into the PVN directly (Edwards et al, 1999) to determine whether this might
be the most sensitive area for the orexigenic effect of orexin-A. Orexin injected into
the PVN did not stimulate food intake to the same extent as i.c.v. orexin-A. Thus,
orexin-A may not have a direct effect on the PVN (Edwards et al, 1999). It is known
that the stimulatory action of orexin-A on pPVN CRH neurones is at least partly
mediated by NPY, and NPY neurones in the ARC have a major role in regulating
appetite (Jain et al, 2000). Orexin A increased CRH and NPY release from
hypothalamic explants and its stimulatory effect on CRH release was blocked by a
Y1 receptor antagonist (Russell et al, 2001).
ARC. In the present study centrally administered orexin-A significantly increased the
number of Fos positive cells in the ARC in virgin rats compared with aCSF treated
rats (Fig 5.7). There was also a significantly greater number of Fos positive cells in
the ARC after i.c.v. orexin-A in virgin rats compared to late pregnant rats. This
suggests that the lack of activation ofARC neurones in pregnancy does not interfere
with the actions of orexin-A in stimulating appetite in pregnancy since pregnant rats
showed undiminished eating behaviour responses to i.c.v. orexin. ARC NPY
neurones are importantly implicated in the role of orexin in feeding especially via the
Y1 receptor (Jain et al, 2000). Orexin neurones project to the ARC (Peyron et al,
1998) and specifically innervate NPY neurones (Horvath et al, 1999). Orexin-
stimulated feeding is only partially inhibited by pre-treatment with a selective NPY
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Y1 receptor antagonist, suggesting that activation of the NPY-mediated feeding
pathway is only partially responsible for orexin-stimulated feeding.
LHA. The present findings indicate that orexin-A can stimulate feeding other than
through this mechanism, e.g. by directly acting on the LHA, perhaps stimulating
MCH neurons. The LHA receives innervation from much of the neuraxis and can
also be influenced by actively transported peripheral factors e.g. leptin, insulin and
other hormones, as well as other diffusible factors including glucose, electrolytes,
amino acids and peptides (Bernardis & Bellinger, 1996). Therefore the regulation of
orexin neurones in the LHA is potentially complex. Orexin neurones in the LHA are
activated by hypoglycaemia; insulin increases Fos expression in orexin neurones in
the LHA (Moriguchi et al, 1999). When insulin and glucose are given together so
that euglycaemia was maintained no increase in Fos is found. Insulin is therefore
unlikely to act directly on these neurones. Insulin does not increase Fos in MCH
neurones (Bahjaoui-Bouhaddi et al, 1994) suggesting the mechanisms regulating the
orexin and MCH neurones are different.
Orexin receptor 2 (specific for both orexin-A and orexin-B) expression has been
found in the LHA (Trivedi et al, 1998). Compared with aCSF, orexin-A significantly
increased the number of Fos positive cells in the LHA in both virgin and pregnant
groups (Fig. 5.9). Pregnant rats given orexin-A also showed a significantly greater
number of Fos positive cells in the LHA than in virgin rats given orexin-A; the




Hypothalamic expression of orexin is significantly decreased during pregnancy
(Garcia et al, 2003). However it is thought that orexin may not be directly involved
in the regulation of the increased food intake observed during pregnancy (Lopez et
al, 2000). Pregnancy has been associated with changes in sleep patterns. In late
pregnancy there is enhanced sleep during the dark period and sleep loss during the
day time (Kimura et al, 1996) and LHA orexin neurones have been importantly
implicated during this time (Alam et al, 2002).
VMH. Orexin-A did not significantly increase the number of Fos positive cells in the
VMH of virgin rats compared with the aCSF-treated virgin group (Fig. 5.11). In
contrast, orexin-A significantly increased Fos expression in the VMH in late
pregnant rats, compared with aCSF-treated pregnant rats and with both aCSF and
orexin-A-treated virgin rats. The VMH has long been known to play a key role in the
control of satiety. The concept that the VMH is the satiety centre in the brain
whereas the LHA is the hunger centre was put forward by Elliot Stellar in 1954
(Stellar et al, 1954). VMH neurones are activated when food intake is stimulated in
hungry rats (Johnstone et al, 2006). This indicates that the inhibitory action of the
VMH is initiated with stimulation of feeding, although, unlike in the Johnstone et al,
study (2006) rats in the present study were not fasted. It is notable that in the late
pregnant rats Fos expression was more strongly stimulated in the VMH by orexin-A
than in virgin rats, while in virgin rats orexin-A did not increase Fos expression in
the VMH. This indicates activation by orexin-A of the VMH only in the pregnant
rats. Orexin receptor 1, which specifically binds orexin-A, has been found in the
VMH (Marcus et al, 2001). Nothing to date is known about orexin-receptor
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expression during late pregnancy, such changes may explain increased activation of
the LHA and VMH at this stage.
DMH. Orexin-A did not significantly increase Fos expression in the DMH in either
the virgin or pregnant rats compared to aCSF-treated groups. Orexin receptor 1
(which is specific for orexin-A) expression has been shown in the DMH. Food
deprivation has been shown to increase the expression of orexin receptor 1 as well as
to increase coupling to adenylate cyclase and PLC dependent cascades (Karteris et
al, 2005). Previous studies of responses to centrally administered orexin-A have not
shown increased Fos expression in the DMH indicating that the effects of orexin-A
on the HPA axis and feeding is not mediated through activation of neurons in the
DMH (Harris et al, 2005).
5.4.3. The effect of i.c.v. orexin-A on blood glucose concentration
The results show that i.c.v. orexin-A significantly increased blood glucose
concentration in virgin rats but did not significantly increase blood glucose
concentration in pregnant rats (Fig. 5.17). The LHA contains glucose-sensitive
neurones that are stimulated by decreased circulating glucose and inhibited by
signals such as the presence of food or an increase in glucose concentration (Cai et
al, 2001). During late pregnancy there is an impairment of insulin's ability to
stimulate glucose uptake in peripheral tissues and to suppress hepatic glucose
production (Leturque et al, 1986). This resistance is in part compensated for by
insulin hypersecretion in late pregnancy (Rossi et al, 1993), and basal blood glucose
levels decline as pregnancy progresses (Rossi et al, 1993). The increase in blood
glucose concentration seen in virgin rats after i.c.v. orexin-A may be a biomarker of
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the increase in circulating gluococorticoids that is not seen in late pregnancy, or a
result of increased sympathetic drive, or increased GH, glucagon or adrenaline
secretion.
The depressed basal plasma glucose level in late pregnant rats might reflect demand
from the fetuses or altered hepatic sensitivity to several hormones. The finding that
i.c.v. orexin-A significantly increased blood glucose in virgin rats but not pregnant
rats may be due to altered hepatic sensitivity to these factors, or to failure of orexin-
A to activate these systems. The HPA axis response to orexin-A is suppressed in
pregnant rats (Brunton et al, 2003), but altered effects on other neuroendocrine
systems are not known. The lower basal blood glucose concentrations in pregnant
animals compared to virgins were not affected by naloxone, which had no further
effect on blood glucose concentration in virgin rats. This suggests that the lack of
orexin-A's effectiveness in pregnant rats is not due to a lack of corticosterone as the
ACTH response was partially restored following administration of naloxone unlike
the blood glucose response.
5.4.4. The effect of i.c.v. orexin-A on the HPA axis and the role of endogenous
opioids
Centrally administered orexin-A significantly increased plasma ACTH concentration
in virgin but not pregnant rats. This result is consistent with previous studies
(Brunton et al, 2003). In the present study naloxone had no further effect on plasma




A common central opioid mechanism has been shown to inhibit neuroendocrine
stress responses during late pregnancy (Douglas et al, 1998). Naloxone is likely to be
exerting its effects on the HPA axis via the hypothalamus (Wang et al, 1996) and
thus may affect hypothalamic pituitary mechanisms through CRH release, p-opioids
appear to mediate the naloxone-induced reduction in stress responses (Cover &
Buckingham, 1989), whereas k- and S-opioids modulate HPA axis hormone secretion
under basal conditions (Iyengar et al, 1986). Hyporesponsiveness of the HPA axis to
immune challenge during late pregnancy is a result of endogenous opioid inhibition
of the pPVN CRH neurones (Brunton et al, 2005). This endogenous opioid inhibition
may be exerted by the enkephalins produced by NTS neurones and acting via p-
opioid receptors on noradrenergic terminals in the PVN. Proenkephalin mRNA
expression is increased during late pregnancy in the NTS (Brunton et al, 2005).
Orexin neurones project widely throughout the brain including projections to the
NTS (de Lecea et al, 1998). It has been shown following administration of IL-1 (3 that
in late pregnancy opioids inhibit CRH neurone responses by acting presynaptically
on noradrenergic inputs to the CRH neurones (Brunton et al, 2005); it was proposed
for the present study that opioids might similarly interfere with orexin signalling to
the pPVN CRH/AVP neurones.
Orexin-A significantly increased CRH and AVP mRNA expression in the pPVN in
virgin rats, but had no such effect in late pregnant rats, confirming previous findings
(Brunton et al, 2003). In the present study, naloxone restored pPVN AVP and CRH
mRNA responses to orexin-A in pregnant rats, indicating opioid inhibition of orexin
signalling to the CRH/AVP pPVN neurones in late pregnancy. Naloxone had no
effect in virgin rats, supporting previous studies that showed activation of an opioid
141
Orexin-A Chapter 5
mechanism inhibiting HPA axis responses in pregnancy (Brunton et al, 2005). The
action of naloxone in late pregnant rats might be a consequence of inhibition ofNPY
signalling to the HPA axis, or interference with orexin-A acting via the NTS, or via
direct signalling to the HPA axis in late pregnancy.
The HPA axis response to central administration ofNPY has also been shown to be
suppressed during late pregnancy (Brunton et al, 2006). The aim of the next
experiments was to investigate if the endogenous opioid inhibition seen in response
to orexin-A was interfering with NPY signalling to the PVN CRH/AVP neurones.
NPY has also been shown to stimulate oxytocin secretion which action is suppressed
during late pregnancy (Brunton et al, 2006). Endogenous opioids have been shown to
inhibit oxytocin neurones during late pregnancy also (Douglas et al, 1998).
5.4.5. Summary
Feeding and Fos responses to orexin A during late pregnancy
Orexin-A stimulated eating behaviour in both virgin and pregnant rats. Naloxone did
not affect eating response to orexin-A in either the virgin or the pregnant group,
indicating orexin-A stimulates eating behaviour independently of opioids. Orexin-A
did not significantly stimulate drinking in either the virgin or the pregnant group yet
it increased grooming in the virgin rats with a tendency for grooming to increase in
the pregnant rats. I.e.v. orexin-A increased the number of Fos-positive cells in the
pPVN of virgin rats compared to virgin controls and compared to pregnant rats given
orexin A, indicating reduced responsiveness of these neurones during late pregnancy.
NPY neurones in the ARC have been shown to play a major role in regulating
appetite. There was a significantly greater number of Fos positive cells in the ARC in
virgin rats given orexin compared to pregnant rats. Thus it seems the lack of
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activation ofARC NPY neurones by orexin-A during late pregnancy is not
interfering with the actions of orexin-A in stimulating eating behaviour. Orexin-
stimulated feeding in late pregnancy may be activated by direct orexin-A actions on
the LHA. The increased Fos expression in the VMFI in pregnant rats given orexin-A
suggests that the inhibitory action of the VMH is initiated with stimulation of feeding
although nothing to date is known about orexin receptor expression during late
pregnancy. Altered orexin receptor expression may explain increased activation of
the VMH and LHA during late pregnancy. Orexin-A did not increase Fos expression
in the DMH.
HPA axis responses to orexin-A during late pregnancy
Centrally administered orexin-A increased plasma ACTH concentration in virgin but
not late pregnant rats. Naloxone had no further effect on plasma ACTH secretion in
virgin rats but restored an ACTH response in pregnant rats. Orexin-A significantly
increased CRH and AVP mRNA expression in the PVN in virgin rats but had no
such effect in pregnant rats. Naloxone again restored pPVN AVP and CRH mRNA
responses to orexin-A in pregnant rats.
Reduced pPVN Fos responses indicate reduced responsiveness of the CRH/AVP
neurones in pregnancy. It seems that endogenous opioids are interfering with orexin-
induced signalling to the HPA axis during late pregnancy.
Opioid inhibition of the HPA axis responses at the level of the CRH/AVP neurones
may account for reduced orexin-A actions in pregnancy. Orexin-A acts on the HPA
axis in part via the ARC NPY neurones, so the aim of the next experiments was to
investigate if the endogenous opioid inhibition seen on responses to orexin-A was
interfering with NPY signalling to the PVN CRH/AVP neurones.
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6.1 Neuropeptide Y (NPY)
NPY is a 36 amino acid polypeptide that belongs to the pancreatic family of
polypeptides. High levels ofNPY are detected in the central and peripheral nervous
system of humans and other animals (Heilig et al, 1995).
The distribution of central NPY-pathways is summarised in Figure 6.1.
NPY can function as a neurotransmitter or a neuromodulator. Its action is mediated
by specific receptors, Yl, Y2, Y3, Y4, Y5 and Y6 (Balasubramaniam et al, 1997).
There are several major effects ofNPY on the central nervous system which include
stimulating food intake, an anti-anxiety effect, controlling circadian rhythms and
regulating hormone synthesis (White et al, 1993).
6.1.1. Distribution of NPY
In the central nervous system NPY is prominently synthesised in the arcuate nucleus
(ARC). It is also synthesised in the brain stem in the nucleus of the solitary tract
(NTS) (Heilig et al, 1995). In the brain stem NPY is colocalised with adrenaline and
noradrenaline (Heilig et al, 1995). NPY neurones project to many areas in the brain,
particularly to the paraventricular nucleus (PVN) as well as to the supraoptic nucleus
(SON), the ARC, the dorsal medial hypothalamus (DMH) and the ventro-medial
hypothalamus (VMH) (Li et al, 1994). NPY neurones also project to the medial
preoptic area, the lateral hypothalamic area (LHA) and the NTS (de Quidt et al,
1986).
NPY is considered to be the most abundant and widely distributed neuropeptide
present in the mammalian central and peripheral nervous system. In the periphery it
is generally found in the sympathetic nervous system; co-stored and co-released with
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noradrenaline (Heilig et al, 1990). NPY has also been found in several other organs
including the GI tract, salivary glands, thyroid gland, pancreas, urogenital system,
the airways and the heart (Jackerott et al, 1997).
The distribution ofNPY in the central nervous system is complex. In general it is
distributed in similar neurones (with somatostatin and GABA) in the cerebral cortex
and forebrain, whilst it is also found in a variety of other neurones in the brain
containing either noradrenaline, adrenaline or serotonin in other areas of the brain
(Heilig et al, 1990). NPY is found in high concentrations in the hypothalamus, and
periventricular areas contain the highest density ofNPY while the lowest quantities
are found in the mammillary bodies (Kalra et al, 1991).
6.1.2. The NPY receptors
All the NPY receptors cloned to date possess seven transmembrane domains
characteristic of the G-protein coupled super-family of receptors.
Y1 receptor
There is high expression of the Y1 receptor in the colon, kidney and placenta
(Wharton et al, 1993). Y1 receptors have also been found in high quantities in
ganglia, the myenteric and submucous plexuses, submucosal blood vessels and the
fetal adult myocardium (Wharton et al, 1993). Y1 receptors are coupled to both
cyclic AMP (cAMP) (Fuhlendorff et al, 1990) and also calcium channels (Daniels et
al, 1992). It is thought that the action of feeding on NPY is mediated through the Y1
receptor (McLaughlin et al, 1991).
Y2 receptor
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The Y2 receptor possesses a 30% homology with the Y1 receptor (Rose et al, 1995).
Y2 receptors are expressed in chromaffin cells (Gerald et al, 1995) and have been
found in nerve endings, hippocampus, renal proximal tubular cells, the hypothalamus
and dorsal root ganglia (Aicher et al, 1991). They are also coupled to intracellular
calcium stores as well as cAMP (Bleakman et al, 1991).
Y3 receptor
It has been suggested that several types of Y3 receptor exist (Balasubramaniam et al,
1990). Y3 receptors have been identified in chromaffin cells (Wahlestedt et al,
1992), cardiac ventricular cells (Balasubramaniam et al, 1990) and also in the
brainstem (Grundemar et al, 1994). The Y3 receptors have all been shown to be
coupled to adenylate cyclase (Harfstrand et al, 1987).
Y4 receptor
The human (Bard et al, 1995), rat (Lundell et al, 1996) and mouse (Gregor et al,
1996) pancreatic polypeptide (PP) receptor was cloned and defined as the Y4
receptor. The human form only shares 75% homology with the rat form. Y4
receptors are located mainly in the human colon, but are found in the testis, lungs and
heart in the rat and mouse. Y4 receptors are also linked to cAMP and to calcium
stores (Bard et al, 1995).
Y5 receptor
It is suggested that the Y5 receptor may well also be involved in NPY-induced
feeding (Gerald et al, 1996). Y5 receptors have been found in the dentate gyrus,
hippocampus and in parts of the hypothalamus.
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Y6 receptor
The Y6 receptor has been identified as another form of the Y5 receptor (Hu et al,
1996). This is found to be highly localised in the hypothalamus.
6.1.3. The function of NPY in the central nervous system
A large number of studies have focussed on the potential roles played by NPY within
the hypothalamus and pituitary with respect to the control of food intake and energy
homeostasis (White et al, 1993). NPY is one of the most powerful orexigenic agents
known. When administered icv in rats it produces a powerful and prolonged increase
in food intake (Clark et al, 1984). When administered chronically it produces
hyperphagia, decreased thermogenesis and obesity (Stanley et al, 1986). The Yl, Y2
and Y5 receptors are found in the hypothalamus. Yl and Y5 receptors have been
implicated as important receptors that mediate the feeding effects ofNPY (Marsh et
al, 1998).
NPY has also been shown to be involved as an anti-anxiety agent. Many studies have
found reduced concentrations ofNPY in cerebrospinal fluid (CSF) or plasma from
depressed patients (Mathe et al, 1996). In many models of depression rats have been
found to have reduced levels ofNPY in the hippocampus and exaggerated mobility
(Holmes et al, 1998). Central administration ofNPY reduces immobility to a similar
level as imipramine (Husum et al, 2000). Taken together these studies suggest an
antidepressant-like profile ofNPY and support the hypothesis that NPY plays a role
in the pathophysiology of depression.
NPY also plays a role in modulating mammalian circadian rhythms (Soscia et al,
2004). NPY resets the circadian clock during the subjective day, mediating non-
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photic inputs (Hannibal et al, 2002). Previous studies using receptor-selective
agonists have indicated that this action ofNPY is mediated by the Y2 receptor in
hamsters (Golombek et al, 1996).
Finally NPY also plays a role in regulating hormone synthesis. NPY influences the
synthesis of luteinising hormone (Wankowska et al, 2002) thyrotrophin releasing
hormone (TRH) and melanocyte concentrating hormone (MCH) (Korner et al, 2003).
NPY also regulates the growth hormone (Peng et al, 1993) and glucococorticoid axes
(Hanson et al, 1995). It is widely believed then that hypothalamic and pituitary NPY-
expressing cells represent an important and critical site of integration of peripheral
hormonal signals with regulation of energy homeostasis (White et al, 1993).
6.1.4 The role of NPY in regulating the HPA axis
The PVN is the main site where nerve terminals ofNPY-containing neurones are
found. The PVN, especially the parvocellular area, is the main site of synthesis of
corticotrophin releasing hormone (CRH) in the hypothalamus (Liposits et al, 1988).
Electron microscopy has shown that there are synapses between neurones containing
NPY and the cell bodies of CRH neurones (Liposits et al, 1988). The synapses are
asymmetrical in shape indicating a stimulatory transmission of activity (Cohen et al,
1982). In vivo (Haas et al, 1987) and in vitro (Tsagarakis et al, 1993) studies have
shown that NPY stimulates CRH release. After i.e.v. administration ofNPY the level
ofPOMC mRNA in the anterior pituitary also increases (Suda et al, 1993) as does
the release of adrenocorticotropic (ACTH) hormone (Haas et al, 1989). NPY inhibits
GABA neurones around the PVN (Fu et al, 2004). So NPY action in the pPVN
causes overall activation of the HPA axis. In vivo the HPA axis can be stimulated by
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NPY given via a variety of routes, either intra-venously, through the lateral ventricle
(Suda et al, 1993) into the third ventricle (Brooks el al, 1994) or directly into the
PVN (Haas et al, 1989). The greatest CRH release occurred when NPY was injected
directly into the PVN suggesting its importance in the activation of the HPA axis by
NPY. The permeability of the blood-brain barrier to NPY is low so intravenous
administration does prove to be less effective.
It seems that NPY directly affects CRH release (Suda et al, 1993), but an indirect
effect through adrenergic receptors cannot be excluded (Haas et al, 1989). The NPY
receptor that mediates an increase in HPA axis activity is as yet still unknown.
It is also likely that the pituitary gland is involved in regulating the HPA axis
response to NPY because large amounts ofNPY are released from the hypothalamus
into the pituitary portal circulation (McDonald et al, 1987). It is thought that NPY
acts on the pituitary to stimulate GH release (Peng et al, 1990) and possibly ACTH
release (Ruiz-Gayo et al, 2000).
NPY is also likely to be involved in direct regulation of activity of the adrenal
glands. NPY-containing nerve terminals have been found in the zona glomerulosa
(Mazzocchi et al, 1987) though it seems that the role ofNPY in the physiological
regulation of the HPA axis is of less importance at the level of the adrenal glands
than in the hypothalamus.
6.1.5 The effect ofNPY on the HPA axis in pregnancy
It has previously been shown that during late pregnancy the excitatory effects of
orexin-A on HPA activity are suppressed as a result of reduced activation of CRH
neurones in the pPVN. NPY stimulates CRH release from the median eminence
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(Haas et al, 1987), increases CRH mRNA expression in the pPVN and increases
plasma concentrations of ACTH (Haas et al, 1989) and corticosterone (Harfstrand et
al, 1987). Orexin-A stimulates NPY release from hypothalamic explants (Lang et al,
1983), so its actions on the HPA axis may be mediated by NPY neurones.
During late pregnancy secretion of oxytocin, a stress hormone, in response to
emotional and physical stressors is reduced (Neumann et al, 1998). Although
neuroendocrine stress responses to centrally administered NPY are absent in late
pregnant rats, behavioural responses are intact (Brunton et al, 2006); absent HPA
axis responses to NPY are in pregnancy due to decreased activation of the CRH/AVP
pPVN neurones. A lack of oxytocin secretory responses to NPY in late pregnancy is
a result of a failure to activate SON and mPVN oxytocin neurones (Brunton et al,
2006).
6.1.6 Aims of these experiments
Reduced HPA axis responses to centrally administered orexin-A in pregnancy are
evidently a result of a reduced response of the CRH neurones to NPY at this time.
Endogenous opioids act to inhibit supraoptic oxytocin neurones in late pregnancy
(Douglas et al, 1995); it is not known whether in late pregnancy opioids interfere
with NPY signalling to pPVN CRH and/or AVP neurones, or to supraoptic oxytocin
neurones. NTS neurones may be the source of the endogenous opioid, since
proenkephalin mRNA expression is up regulated in the NTS during late pregnancy.
Opioids inhibit CRH neurone responses following cytokine challenge during late
pregnancy by acting presynaptically on noradrenergic inputs to the CRH neurones
(Brunton et al, 2005). In chapter 5 we showed endogenous opioids interfere with
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orexin signalling to the HPA axis in pregnancy. Here we investigated activation of
hypothalamic neurones regulating HPA responses to NPY, and whether opioids were
interfering with NPY signalling to pPVN CRH/AVP or SON oxytocin neurones. The
two main aims of this experiment were to investigate hypothalamic circuitry
regulating HPA and eating responses to NPY during pregnancy and to investigate the
role of endogenous opioids to see if, like their actions on orexin-A, opioids are
interfering with NPY signalling to the HPA axis during late pregnancy.
6.2 Methods
6.2.1. Animals
Female Sprague Dawley rats were used and housed individually after surgery. Rats
were maintained as described in section 2.1.
6.2.2. Surgery
Rats were implanted with an intracerebroventricular cannula for experiment one and
an intracerebroventricular and jugular vein cannula in experiments two and three.
Surgery was performed under conditions described in section 2.3.
6.2.3 Experiment 1 - The effect of centrally administered NPY in pregnancy
On the day of the experiment (day 21 of pregnancy), rats were left undisturbed for 90
minutes. At between 07:30-08:30 rats were given either NPY (lnmol in 2pl) or
vehicle (artificial cerebro-spinal fluid, aCSF; pH 7.2, composition in mM: NaCl, 138;
KC1, 3.36; NaHC03,9.52; Na2HP04, 0.49; urea, 2.16; NaH2P04, 0.49; CaCl2, 1.26;
MgCl2, 1.18) which was given i.c.v. with gentle restraint over a period of about 30
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seconds. The following behaviours were noted continually: inactive, grooming, oral
motor activity, eating and drinking. Behavioural data were collected for 90 minutes;
an event was classified as occurring if an animal spent > 5 seconds exhibiting the
behaviour. Rats were killed by transcardial perfusion-fixation under deep anaesthesia
90 minutes after NPY (this time point has previously been shown as the optimum
time for showing increased Fos expression in the central nervous system after NPY)
(Niimi et al, 2001). Rats were examined post-mortem to check fetuses and i.c.v.
cannula placement. Brains were processed for Fos immunohistochemistry on free
floating sections and Fos expression measured.
6.2.4 Experiment 2 - The effect of endogenous opioids on reduced HPA
responses to NPY in pregnancy
On the day of the experiment (day 21 of pregnancy) the cannulae were connected
between 07:30-08:30h. The jugular vein cannula was attached to PVC extension
tubing led out of the cage and connected to a 1ml syringe filled with heparinised
saline (0.9% saline, 50 units/ml). Rats were left undisturbed for 90 minutes and a
basal blood sample (0.55ml) was taken. Immediately after the first basal blood
sample either naloxone (lOmg/ml) or saline both at 0.5ml/kg were given i.v.; 15
minutes after the first basal blood sample another basal blood sample was taken, and
a further 15 minutes later rats were given either NPY (lnmol in 2pl) or vehicle
(artificial cerebro-spinal fluid, aCSF; pH 7.2, composition in mM: NaCl, 138; KC1,
3.36; NaHC03,9.52;Na2HP04, 0.49; urea, 2.16; NaH2P04, 0.49; CaCl2, 1.26;
MgCl2, 1.18) i.c.v. with gentle restraint over a period of about 30 seconds. Further
blood samples (0.55ml) were taken for glucose measurement and for ACTH assay at
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15, 30, 60 and 120 minutes after i.c.v. infusion. Blood samples were placed into
eppendorfs containing 50pl of chilled 5% EDTA. After each blood sample, blood
was replaced with 0.9% sterile saline. Glucose measurements were taken throughout
the experiment using a Roche Accuchek Active Meter. Plasma was separated by
centrifugation and stored at -20°C until radioimmunoassay. Rats were killed by
conscious decapitation 4 hours after NPY (this time point has previously been shown
as the optimum time for showing increased CRH mRNA expression in the PVN
following stress) (Harbuz et al, 1989). Rats were examined post-mortem to check
fetuses and i.c.v. cannula placement. Blood samples were processed for ACTH assay
and brain sections processed for CRH and AVP in situ hybridisation.
6.2.5 Experiment 3 - Fos expression in response to NPY after administration of
naloxone
On the day of the experiment (day 21 of pregnancy) the jugular vein cannula was
attached to PVC extension tubing led out of the cage and connected to a 1ml syringe
filled with heparinised saline (0.9% saline, 50 units/ml). Rats were left undisturbed
for 90 minutes and then given either naloxone (lOmg/ml) or saline, both at 0.5ml/kg
i.v.; 30 minutes later rats were given either NPY (lnmol in 2pl) or vehicle (artificial
cerebro-spinal fluid, aCSF; pH 7.2, composition in mM: NaCl, 138; KC1, 3.36;
NaHC03j 9.52; Na2HP04, 0.49; urea, 2.16; NaH2P04, 0.49; CaCl2, 1.26; MgCl2,
1.18) i.c.v. with gentle restraint over a period of about 30 seconds. The following
behaviours were noted continually: inactive, grooming, oral motor activity, eating
and drinking. Behavioural data were collected for 90 minutes; an event was
classified as occurring if an animal spent > 5 seconds exhibiting the behaviour. Pre-
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weighed food was given to the rats and re-weighed after the experiment. Rats were
killed by transcardial perfusion-fixation under deep anaesthesia 90 minutes after
NPY (this time point has previously been shown as the optimum time for showing
increased Fos expression in various brain areas following administration of a stressor
(Niimi et al, 2001). Rats were examined post-mortem to check fetuses and to check
i.c.v. cannula placement. Brains were processed for Fos immunohistochemistry on
free floating sections and Fos expression measured.
6.2.6. Fos immunohistochemistry
Brain sections (52pm) were cut through the PVN, SON, ARC, LF1A, VMH and
DMH on a freezing microtome onto gelatinised slides. Fos immunohistochemistry
was performed using the method described in section 2.5.2. with free floating
sections. Sections for double labeling were further washed in PB-T for 2 x 5 min and
incubated in 0.3% hydrogen peroxide for 15 minutes, washed again in PB-T before
being incubated in an anti-rabbit oxytocin antibody (dilution 1:1000 in PB-T
containing 1% NSS; Calbiochem, Nottingham, UK) for 24 hours. Sections were then
washed and incubated with the ABC kit described in section 2.5.2. Sections were
visualised by incubating sections in 0.1M PB containing 0.025% DAB and 0.03%
hydrogen peroxide. The reaction was stopped in 0.1M PB. Fos-positive stained cells
were counted in each region with at least 3 sections counted per rat.
6.2.7 In Situ Hybridisation
Brains were cryostat sectioned at 15 pm and mounted onto Polysine slides (BDH; see
section 2.4.2). To detect CRH mRNA expression a 42-mer oligonucleotide probe
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(MWG-Biotech) was used complementary to bases 496-537, which encode amino
acids 22-35 of the rat CRH peptide (Jingami et al, 1985). The probe sequence used
was:
5'-CCT GTT GCT GTG AGC TTG CTG AGC TAA CTG CTC TGC CCT GCC- 3'
To detect AVP mRNA expression a 36-mer oligonucleotide probe (MWG-Biotech)
was used, complementary to bases 486-521 of rat AVP mRNA (Majzoub et al,
1983). The probe sequence used was:
5'-GAC CCG GGG CTT GGC AGA ATC CAC GGA CTC TTG TGT-3'
-3 c
Both probes were labeled with S as described in section 2.4.2. The melting
temperature for the CRH mRNA probe was 78°C and for the AVP mRNA probe was
76°C, therefore the heated SSC washes were performed at 58°C and 56°C
respectively. Once dry the sections were dipped in photographic emulsion under
safelight conditions and stored at 4°C. The exposure time was 13 weeks for CRH
mRNA and 7 days for AVP mRNA. The number of positive cells and the grain
density were measured by the image analysis system described in 2.4.2.
6.2.8 ACTH radioimmunoassay
Plasma ACTH concentration was determined using a commercially available kit as
described in section 2.7.3. The sensitivity of the ACTH assay was 1 lpg/ml. The
intra-assay variation was <7%.
6.2.9 Statistics
A two-way analysis of variance (ANOVA) was used with a repeated measures
ANOVA for blood sampling experiments. A significant ANOVA (p<0.05) was
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followed by Student Newman Keuls multiple comparison tests, to identify
differences. A p value of less than 0.05 was considered statistically significant.
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6.3 Results
6.3.1 Experiment 1 - The effect of centrally administered NPY in pregnancy
Behavioural data
Analysis of behavioural data using a two-way ANOVA showed a statistically
significant difference in eating behaviour following i.c.v. NPY administration
(p<0.001). NPY significantly increased eating behaviour in virgin and pregnant rats
(p<0.001; two-way ANOVA) (Fig.6.2). There were no significant differences in
drinking between groups (Fig.6.2). There was a statistically significant difference in
grooming behaviour following NPY administration (p=0.017) (Fig.6.2). NPY
significantly increased grooming behaviour in virgin rats (p=0.019; two-way
ANOVA) (Fig.6.2).
Parvocellularparaventricular nucleus (pPVN) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p=0.010). Quantification of Fos positive cells revealed that Fos expression in
the pPVN of virgin rats was significantly greater (2.5 times) than in the pregnant
NPY group (Fig.6.4). I.c.v. injection ofNPY significantly increased Fos expression
in the virgin group (p<0.001) (28.1 ± 4.3 vs control 11.9 ± 1.3 Fos positive
cells/PVN), but had no effect in late pregnant rats (Fig.6.3 and Fig.6.5).
Magnocellular paraventricular nucleus (mPVN) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p=0.011). Quantification of Fos positive cells revealed that Fos expression in
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Figure 6.2: The effect of i.c.v. NPY on behaviours in virgin and pregnant rats.
Values are group means ± SEM. Virgin/aCSF, n=6; virgin/NPY, n=6; pregnant/
aCSF, n=6; pregnant/NPY, n=5. Two-way ANOVA followed by a Student Newman
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Figure 6.3: The effect of i.c.v. NPY on Fos positive cell counts in the pPVN in
virgin and pregnant rats. Rats were killed by transcardial perfusion-fixation 90
minutes post-injection ofNPY. Values are the mean counts of positive cells over
three sections and values are the group means ± SEM. Virgin/aCSF, n=6;
virgin/NPY, n=6; pregnant/aCSF, n=6; pregnant/NPY, n=5. Two-way ANOVA
followed by a Student Newman Keuls multiple comparison test:
**p<0.001 vs all other groups.
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group (Fig.6.4). I.c.v. injection ofNPY significantly increased Fos expression in the
virgin group (p=0.004) (15.6 ± 3.6 vs control 5.6 ± 0.8 Fos positive cells/PVN), with
no significant effect in the pregnant group (Fig 6.4 and Fig. 6.5).
Analysis of Fos and oxytocin expression using a two-way ANOVA showed there
was a statistically significant difference in the percentage of oxytocin neurons
expressing Fos in virgin rats compared to pregnant rats (p< 0.02). Quantification of
percentage ofOT cells expressing Fos revealed that the percentage of oxytocin cells
activated in the mPVN of virgin rats was significantly greater (12-fold) than in the
pregnant NPY group (Fig 6.6). There were approximately 50 OT neurons counted
per mPVN section. I.c.v. injection ofNPY significantly increased the percentage of
oxytocin neurones activated (p < 0.001) (12.6 ± 2.7 vs control 0.8 ± 0.5 Fos positive
cells/PVN) in virgin rats, with no effect in pregnant rats (Fig 6.6). A representative
photomicrograph of a Fos-positive oxytocin cell is seen in figure 6.7.
Supraoptic Nucleus (SON) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p= 0.013). (Fig.6.8). Quantification of Fos positive cells revealed that Fos
expression in the SON of virgin rats given NPY was significantly greater (2-fold)
than in the pregnant NPY group (Fig.6.8). I.c.v. injection ofNPY significantly
increased Fos expression in the virgin group (p<0.001) (19.2 ± 4.4 vs control 3.9 ±
0.8 Fos positive cells/SON), with no effect in the pregnant group (Fig 6.8 and Fig
6.9). Analysis of Fos and oxytocin expression using a two-way ANOVA showed
there was a statistically significant difference in the percentage of oxytocin neurones
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Figure 6.4: The effect of i.c.v. NPY on Fos positive cell counts in the mPVN in
virgin and pregnant rats. Rats were killed by transcardial perfusion fixation 90
minutes post-injection ofNPY. Values are the mean counts of positive cells over
three sections and values are the group means ± SEM. Virgin/aCSF, n= 6;
Virgin/NPY, n=6; pregnant/aCSF, n=6; pregnant/NPY, n=5. Two-way ANOVA
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Figure 6.5: Representative photomicrographs of coronal sections through
the PVN in virgin and pregnant rats. Sections were processed for Fos
Immunohistochemistry: (A) virgin aCSF; (B) virgin NPY; (C) pregnant
aCSF; (D) pregnant NPY. Scale bar = 100pm. 3V = 3rd ventricle
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Figure 6.6: The effect of i.c.v. NPY on oxytocin neurone activation in the mPVN in
virgin and pregnant rats. Rats were killed by transcardial perfusion fixation 90
Minutes post-injection o NPY. The number of oxytocin cells were counted and the
number of oxytocin cells expressing Fos was divided by the total number and
expressed as a percentage. Values are the group means ± SEM. Virgin/aCSF, n=6;
Virgin/NPY, n=6; pregnant/aCSF, n=6; pregnant/NPY, n=5. Two-way ANOVA
Followed by a Student Newman Keuls multiple comparison test: **p<0.001 vs
all other groups.
Figure 6.7 Representative photomicrograph of a double-labelled oxytocin and
Fos positive cell from a mPVN section. Scale bar = 25pm.
Virgin aCSF Virgin NPY Pregnant aCSFPregnant NPY
Figure 6.8: The effect of i.c.v. NPY on Fos positive cell counts in the SON in
virgin and pregnant rats. Rats were killed by transcardial perfusion fixation 90
Minutes post-injection ofNPY. Values are the mean count positive cells over
three sections and values are the group means ± SEM. Virgin/aCSF, n=6;
Virgin/NPY, n=6; pregnant/aCSF, n=6; pregnant/NPY, n=5. Two-way
ANOVA followed by a Student Newman Keuls multiple comparison test: **
p<0.001 vs all other groups.
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Figure 6.9: Representative photomicrographs of coronal sections through the
SON in virgin and pregnant rats. Sections were processed for Fos immunohistochemistry:
(A) virgin aCSF; (B) virgin NPY; (C) pregnant aCSF; (D) pregnant NPY. Scale
Bar = 100pm. OT = optic tract.
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percentage OT cells revealed that the percentage of oxytocin cells activated in the
mPVN of virgin rats was significantly greater (12 fold) than in the pregnant NPY
group (Fig 6.10). I.e.v. injection ofNPY significantly increased the percentage of
oxytocin neurones activated in virgin rats (p < 0.001) (59.6 ± 5.3 vs control 9.5 ± 5.1
Fos positive cells/SON), with no effect in the pregnant rats (Fig 6.10).
Arcuate nucleus (ARC) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p=0.023). Quantification of Fos positive cells revealed that Fos expression in
the ARC of virgin rats after NPY was significantly greater (2-fold) than in the
pregnant NPY group (Fig.6.11). I.c.v. injection ofNPY significantly increased Fos
expression in the virgin group (p<0.001) (20.9 ± 2.7 vs control 10.3 ± 0.7 Fos
positive cells/ARC), with no effect in the pregnant group (Fig.6.11 and Fig.6.12).
Lateral Hypothalamic Area (LHA) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was not a
statistically significant difference in Fos expression among virgin and pregnant
groups (Fig.6.13). I.c.v. injection ofNPY did not significantly increase Fos
expression in either the virgin or the pregnant group. (Fig.6.13)
Ventro-medial Hypothalamus (VMH) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was not a
statistically significant difference in Fos expression among virgin and pregnant
groups (Fig.6.14). I.c.v. injection ofNPY did not significantly increase Fos
expression in either the virgin or the pregnant group (Fig.6.14).
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Figure 6.10: The effect of i.c.v. NPY on oxyotcin neurone activation in the SON in
virgin and pregnant rats. Rats were killed by transcardial perfusion fixation 90
minutes post-injection ofNPY. The number of oxytocin cells were counted and the
number of oxytocin cells expressing Fos was divided by the total number and
expressed as a percentage. Values are the group means ± SEM. Virgin/aCSF, n=
6; virgin/NPY, n=6; pregnant/aCSF, n=6; pregnant/NPY, n=5. Two-way ANOVA
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Figure 6.11: The effect of i.c.v. NPY on Fos positive cell counts in the ARC in
virgin and pregnant rats. Rats were killed by transcardial perfusion fixation 90
minutes post-injection ofNPY. Values are the mean counts of positive cells over
three sections and values are the group means ± SEM. Virgin/aCSF, n=6; virgin/
NPY, n=6; pregnant/aCSF, n=6; pregnant/NPY, n=5. Two-way ANOVA followed
by a Student Newman Keuls multiple comparison test: **p<0.001 vs all other groups.
Figure 6.12: Representative photomicrographs of coronal sections through the
ARC in virgin and pregnant rats. Sections were processed for Fos immunohistochemistry:
(A) virgin aCSF; (B) virgin NPY; (C) pregnant aCSF; (D) pregnant NPY. Scale
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Figure 6.13: The effect of i.c.v. NPY on Fos positive counts in the LHA in
virgin and pregnant rats. Rats were killed by transcardial perfusion fixation
90 minutes post-injection ofNPY. Values are the mean counts of positive cells
over three sections and values are the group means ± SEM. Virgin/aCSF,
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Figure 6.14: The effect of i.c.v. NPY on Fos positive cell counts in the VMH in
virgin and pregnant rats. Rats were killed by transcardial perfusion 90 minutes
post-injection ofNPY. Values are the mean counts of positive cells over three
sections and values are the group means ± SEM. Virgin/aCSF, n=6; virgin/NPY,
n=6; pregnant/aCSF, n=6; pregnant/NPY, n=5. Two-way ANOVA.
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Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p=0.033) (Fig.6.15). I.e.v. injection ofNPY did not significantly increase
Fos expression in either the virgin or the pregnant group (Fig.6.15). Quantification of
Fos positive cells revealed that Fos expression in the DMH of pregnant rats was
significantly greater (1.5-fold) than in the virgin aCSF group (Fig.6.15).
6.3.2 Experiment 2 - The effect of naloxone on reduced HPA responses to NPY
in pregnancy
Blood glucose concentration
Analysis of plasma glucose concentration using a two-way RM ANOVA showed a
statistically significant difference in plasma glucose concentration among virgin and
pregnant groups (p<0.001). Basal blood glucose concentrations were significantly
lower in pregnant rats than virgins (p<0.001; two-way RM ANOVA). NPY with i.v.
saline significantly increased plasma glucose in the virgin group (p< 0.001; two-way
RM ANOVA) within 15 min (7.8 ± 0.25 vs basal 6.7 ±0.13 mmol/1) with glucose
concentrations returning to basal by 30 min (Fig.6.16). I.c.v. injection ofNPY with
i.v. naloxone significantly increased plasma glucose in the virgin group (p<0.001;
two-way RM ANOVA) within 15 min (8.0 ±0.1 vs basal 5.8 ±0.12 mmol/1) with
glucose concentrations returning to basal by 30 min (Fig.6.16). I.c.v. injection of
NPY and i.v. saline had no significant effect on blood glucose concentration in
pregnant rats, nor did i.c.v. injection ofNPY and i.v. naloxone. There were no
significant differences in blood glucose concentration following i.v. naloxone or
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Figure 6.15: The effect of i.c.v. NPY on Fos positive cell counts in the DMH in
virgin and pregnant rats. Rats were killed by transcardial perfusion 90 minutes
post-injection ofNPY. Values are the mean counts of positive cells over three
Sections and values are the group means ± SEM. Virgin/aCSF, n=6; virgin/NPY,
n= 6; pregnant/aCSF, n=6; pregnant/NPY, n=5. Two-way ANOVA followed by
a Student Newman Keuls multiple comparison test: *p<0.05 vs virgin aCSF.
i.c.v. NPY
i.v. naloxone /aCSF
-40 -20 0 20 40 60 80 100 120 140
Time (minutes)
Figure 6.16: The effect of i.c.v NPY and i.v. naloxone on blood glucose concentration
in virgin and pregnant rats. Three basal blood samples were taken 30, 15 and 1 min
prior to i.c.v. NPY (5pg/rat). I.v. naloxone was given 30min prior to i.c.v. NPY.
Further blood samples were withdrawn 15,30, 60 and 120 min post infusion. Values
are group means ± SEM. Virgin NPY/saline, n=6; virgin NPY/naloxone, n=6;
pregnant NPY/saline, n=6; pregnant NPY/naloxone, n=6. Two-way ANOVA for
repeated measures followed by Student Newman Keuls multiple comparison tests:
**p<0.001 significantly different from basal.
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Plasma ACTH concentration
Analysis of plasma ACTH concentration data using a two-way RM ANOVA showed
there was a statistically significant difference in plasma ACTH concentrations among
virgin and pregnant groups (P<0.001). Basal plasma concentrations ofACTH were
not different among groups. I.c.v. injection ofNPY and i.v. saline significantly
increased plasma ACTH concentration in the virgin group (p<0.001; two-way RM
ANOVA) within 15 min (214.8 ± 50.7 vs basal 54.8 ± 9.4 pg/ml) (Fig .6.17) with
concentrations remaining significantly elevated for 30 min (Fig.6.17). I.c.v injection
ofNPY and i.v. naloxone significantly increased plasma ACTH concentration in the
virgin group (p<0.001; two-way RM ANOVA) within 15 min (175.5 ± 35 vs basal
61.8 ± 14.3 pg/ml) (Fig.6.17) with concentrations remaining significantly elevated
for 60 min (Fig.6.17). I.c.v NPY and i.v. saline had no significant effect on plasma
ACTH in the pregnant group (Fig. 6.17). There was a tendency for plasma ACTH
concentration to increase from basal in the pregnant group treated with i.v. naloxone
(p=0.059; two-way RM ANOVA) within 15 min (128.7 ± 25 vs basal 42.7 ± 3.6
pg/ml), and ACTH concentration at this time was greater than in the pregnant group
given NPY and i.v. saline, and not different from ACTH concentration in the virgin
rats at this time after NPY (Fig.6.17). Analysis of changes in plasma ACTH
concentration from basal at 15 min using a two-way ANOVA showed there was a
statistically significant difference in plasma ACTH concentration among virgin and
pregnant groups (p = 0.023), and that the ACTH concentration in the pregnant rats
given naloxone and NPY was not different from that in virgin rats, but was greater
than in the pregnant rats given NPY and saline (Fig.6.18). Basal ACTH


























Figure 6.17: The effect of i.c.v. NPY and i.v. naloxone on plasma ACTH concentration
in virgin and pregnant rats. Three basal blood samples were taken 30, 15 and 1 min
prior to i.c.v. NPY. Further blood samples were withdrawn 15, 30, 60 and 120 min
post-infusion. Trunk blood was collected at 240 min. Values are group means ± SEM.
Virgin NPY/saline, n=6; virgin NPY/naloxone, n=6; pregnant NPY/saline, n=6;
pregnant NPY/naloxone, n=6. Two-way ANOVA for repeated measures followed
by Student Newman Keuls multiple comparison tests: **p<0.001, significantly
different from basal. + p<0.05 significantly different from all other groups at the same
time point.
Virgin NPY + saline
virgin NPY + naloxone
Pregnant NPY + saline
Pregnant NPY+ naloxone
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Figure 6.18: The effect of i.c.v NPY and i.v. naloxone on plasma ACTH concentration
in virgin and pregnant rats. Delta values for the measurements at 30 minutes after
NPY subtracted from the first basal blood sample were calculated. Values are the
measurements at 30 minutes after NPY subtracted from the first basal blood sample
Were calculated. Values are the group means ± SEM. Virgin NPY/saline, n=6;
virgin NPY/naloxone, n=6; pregnant NPY/saline, n=6; pregnant NPY/naloxone,
n=6. Two-way ANOVA followed by a Student Newman Keuls multiple comparison
Test: *p<0.05 vs all other groups.
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CRH mRNA expression in the parvocellular PVN
Analysis ofCRH mRNA ISH data using a two-way ANOVA showed there was a
statistically significant difference in CRH mRNA expression in the pPVN among
virgin and pregnant groups (p = 0.046). Quantification of the number ofCRH
positive cells revealed that CRH mRNA expression in the dorsomedial parvocellular
subdivision of the PVN was significantly greater (1.5-fold) in virgin rats given NPY
and saline than in the pregnant group given NPY and saline (Fig. 6.19). I.c.v
injection ofNPY and naloxone significantly increased CRH mRNA expression in the
pregnant group (p = 0.041) compared with i.c.v. injection ofNPY and saline (Fig
6.19).
A VP mRNA in the parvocellular PVN
Analysis ofAVP mRNA ISH data using a two-way ANOVA showed there was a
2*i
statistically significant difference in AVP mRNA grain area (mm ) in the pPVN
among virgin and pregnant groups (p=0.003). Quantification of grain area revealed
that AVP mRNA expression in the parvocellular area of the PVN was significantly
greater in virgin rats given i.c.v NPY and i.v. saline (10-fold) than in the pregnant
NPY-treated group given saline (Fig 6.20 and Fig 6.21). I.c.v. injection ofNPY with
i.v. naloxone significantly increased AVP mRNA expression in the pregnant group
(p=0.004) compared with i.c.v. injection ofNPY with i.v. saline, with no significant
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Figure 6.19: The effect of i.c.v. NPY and i.v. naloxone on CRH mRNA expression
in the pPVN in virgin and pregnant rats. I.v. naloxone was given 30 min
prior to i.c.v. NPY (5jug/rat). Rats were killed 240 min after NPY. Values are
group means ± SEM. Virgin NPY/saline, n=6; virgin NPY/naloxone, n=6;
pregnant NPY/saline, n=6; pregnant NPY/naloxone, n=6. Two-way ANOVA
followed by a Student Newman Keuls multiple comparison test: *p<0.05 vs






o.oo —i— —i— —i— —i—
Virgin NPY Virgin NPY Pregnant NPY Pregnant NPY
+ saline + naloxone + saline + naloxone
Figure 6.20: The effect of i.c.v. NPY and i.v. naloxone on AVP mRNA (mm2/mm2)
in the pPVN in virgin and pregnant rats. I.v. naloxone was given 30 min prior to
i.c.v. NPY (5pg/rat). Rats were killed 240 min after NPY. Values are group means
± SEM. Virgin NPY/saline, n=6; virgin NPY/naloxone, n=6; pregnant NPY/saline,
n = 6; pregnant NPY/naloxone, n=6. Two-way ANOVA followed by a Student
Newman Keuls multiple comparison test: *p<0.05 vs all other groups.
Figure 6.21: Representative photomicrographs of coronal sections through
the PVN hybridised with a 35S labelled probe complementary to AVP mRNA:
(A) virgin NPY/saline; (B) virgin NPY/naloxone; (C) pregnant NPY/saline;
(D) pregnant NPY/naloxone. Scale bar = 100pm. 3V = 3rd ventricle.
pPVN = parvocellular PVN
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6.3.3 Experiment 3 - Fos expression in response to i.c.v. NPY after
administration of naloxone
Behavioural Data
Analysis of behavioural data using a two-way ANOVA showed a statistically
significant difference among groups in eating behaviour following NPY
administration (p=0.003). Behavioural observations showed that NPY significantly
increased eating behaviour in both virgin and pregnant rats given saline (p=0.017;
two-way ANOVA) (Fig.6.22) or naloxone (p=0.043; two-way ANOVA) (Fig.6.22).
There were no significant differences between rats given NPY and naloxone vs rats
given NPY and saline in either the virgin or the pregnant group although naloxone
showed a tendency to decrease eating in all groups; eating behaviour after NPY was
lower in the pregnant/ naloxone treated group, than in the virgin/ naloxone
(Fig.6.22). There were no statistically significant differences in drinking between
groups, except that drinking behaviour was significantly less in the pregnant group
given NPY+ naloxone than in the pregnant group given NPY+ saline (Fig 6.22).
There were no significant differences in grooming between groups, except that
grooming was significantly less in the pregnant group given NPY+ naloxone than in
the pregnant group given NPY+ saline (Fig 6.22).
Analysis of food weight data using a two-way ANOVA showed a statistically
significant difference in food weights following NPY administration (p<0.001). NPY
significantly reduced food weight in virgin and pregnant rats (p=0.003; two-way
ANOVA) given saline (Fig 6.23). In virgin and pregnant rats given NPY and
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Figure 6.22: The effect of i.c.v. NPY and i.v. naloxone on behaviours in virgin and
pregnant rats. Values are the group means ± SEM. Virgin aCSF/saline, n=2 (values
shown as circles); virgin aCSF/naloxone, n=4; virgin NPY/saline, n=7; virgin NPY/
naloxone, n=6; pregnant aCSF/saline, n=5; pregnant aCSF/naloxone, n=5;
pregnant NPY/saline, n=5; pregnant NPY/naloxone, n=6/ Two-way ANOVA
followed by Stduent Newman Keuls multiple comparison tests excluding virgin aCSF
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Figure 6.23: The effect of i.c.v. NPY and i.v. naloxone on food intake in virgin
and pregnant rats. Values are the group means ± SEM. Virgin aCSF/saline, n=2
(values shown as circles); virgin aCSF/naloxone, n=4; virgin NPY/saline, n=7;
virgin NPY/naloxone, n=6; pregnant aCSF/saline, n=5; pregnant aCSF/naloxone,
n=5; pregnant NPY/saline, n=5; pregnant NPY/naloxone, n=6. Two-way ANOVA
Followed by Student Newman Keuls multiple comparison tests excluding virgin
aCSF/saline: significant effect of pregnancy, p<0.001 of naloxone p=0.003;
*p=0.022 vs virgin NPY/naloxone; +p<0.033 vs virgin NPY/saline; #p<0.001
vs virgin NPY/naloxone.
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Analysis of the time taken to start eating using a two-way ANOVA showed a
statistically significant difference following NPY administration between virgin and
pregnant rats (p=0.018). Pregnant rats given NPY and naloxone took significantly
longer to begin eating than virgin rats given NPY and naloxone (p=0.027) (Fig 6.24).
Pregnant rats given NPY and naloxone also took significantly longer to begin eating
than pregnant rats given NPY and saline (p=0.025) (Fig 6.24).
Parvocellularparaventricular nucleus (PVN) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p = 0.006). Quantification of Fos positive cells revealed that Fos expression
in the pPVN of virgin rats given NPY and saline was significantly greater than in the
pregnant NPY + saline group (P<0.001). Fos expression in the PVN of virgin rats
given NPY and saline was 3.5-fold greater than in the pregnant NPY group given
saline (Fig.6.25). Fc.v. injection ofNPY and i.v. saline significantly increased Fos
expression in the virgin group (p=0.002) (26.5 ± 5.6 vs control 7.6 ± 0.6 Fos positive
cells/PVN), but not in the pregnant rats (Fig.6.25 and Fig. 6.26).
Quantification of Fos positive cells revealed that Fos expression in the PVN of virgin
rats given NPY and naloxone was not significantly greater than in the pregnant NPY
and naloxone group (Fig.6.25). I.c.v. injection ofNPY and i.v. naloxone significantly
increased Fos expression in the virgin group (p=0.031) (20.0 ± 4.5 vs control 8.2 ±
0.6 Fos positive cells/PVN) (Fig.6.25 and Fig.6.26). Fc.v. injection ofNPY and i.v.
naloxone significantly increased Fos expression in the pregnant group (p=0.025)
(13.8 ± 1.4 vs respective control (aCSF + naloxone 5.1 ± 0.12 Fos positive
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Figure 6.24: The effect of i.c.v NPY and i.v. naloxone on the time taken to
begin eating in virgin and pregnant rats. Virgin NPY/saline, n=7; virgin NPY
/naloxone, n=6; pregnant NPY/saline, n=5; pregnant NPY/naloxone, n=6.
Two-way ANOVA followed by Student Newman Keuls multiple comparison
Tests: *p<0.05 vs virgin; +p<0.05 vs pregnant NPY/saline. Values are the
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Figure 6.25: The effect of i.c.v NPY and i.v. naloxone on Fos positive cell counts
in the pPVN in virgin and pregnant rats. Rats were killed by transcardial perfusion
90 minutes post-injection ofNPY. Values are the mean count positive cells over
three sections and values are the group means ± SEM. Virgin aCSF/saline, n=4;
virgin aCSF/naloxone, n=4; virgin NPY/saline, n=7; virgin NPY/naloxone, n=6;
pregnant aCSF/saline, n=5; pregnant aCSF/naloxone, n=5; pregnant NPY/saline,
n=5; pregnant NPY/naloxone, n=6. Two-way ANOVA followed by a Student
Newman Keuls multiple comparison test. *p<0.05 vs aCSF; ##p<0.001 vs virgin
NPY/saline.
Figure 6.26: Representative photomicrographs of coronal sections through
the PVN in virgin and pregnant rats. Sections were processed for Fos
Immunohistochemistry: (A) virgin aCSF/saline; (B) virgin aCSF/naloxone;
(C) virgin NPY/saline; (D) virgin NPY/naloxone; (E) pregnant aCSF/saline;
(F) pregnant aCSF/naloxone; (G) pregnant NPY/saline; (H) pregnant NPY/
naloxone. Scale bar = 100pm. 3V= 3rd ventricle.
mPVN
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Magnocellular paraventricular nucleus Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (P = 0.003). Quantification of Fos positive cells revealed that Fos expression
in the mPVN of virgin rats given NPY and saline was significantly greater (2-fold)
than in the pregnant NPY + saline group (P<0.001). I.c.v. injection ofNPY and i.v.
saline significantly increased Fos expression in the virgin group (p<0.001) (17.8 ±
4.7 vs control 4.7 ± 0.4 Fos positive cells/mPVN) (Fig.6.27 and Fig.6.26).
Quantification of Fos positive cells revealed that Fos expression in the mPVN of
virgin rats given NPY and naloxone was significantly greater (2-fold) than in the
pregnant NPY + naloxone group (P=0.003). I.c.v. injection ofNPY and i.v. naloxone
significantly increased Fos expression in the virgin group (p=0.012) (16.2 ± 2.7 vs
control 16.2 ± 1.2 Fos positive cells/PVN) (Fig.6.27and Fig. 6.26). In pregnant rats,
Fos expression in the mPVN was greater in the group given NPY and naloxone than
in the group given aCSF and naloxone (Fig 6.26).
Supraoptic Nucleus (SON) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p=0.007). Quantification of Fos positive cells revealed that Fos expression in
the SON of virgin rats given NPY and saline was significantly greater (2-fold) than
in the pregnant NPY and saline group (p=0.05). I.c.v. injection ofNPY and i.v.
saline significantly increased Fos expression in the virgin group (p=0.009) (18.6 ±
4.6 vs control 5.8 ± 0.8 Fos positive cells/SON) (Fig.6.28). Quantification of Fos
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Figure 6.27: The effect of i.c.v. NPY and i.v. naloxone on Fos positive cell
counts in the mPVN in virgin and pregnant rats. Rats were killed by transcardial
Perfusion fixation 90 minutes post injection ofNPY. Values are the mean count
positive cells over three sections and values are the group means ± SEM.
virgin aCSF/saline, n=4; virgin aCSF/naloxone, n=4; virgin NPY/saline, n=7;
virgin NPY/naloxone, n=6; pregnant aCSF/saline, n=5; pregnant aCSF/naloxone,
n = 5; pregnant NPY/saline, n=5; pregnant NPY/naloxone, n=6. Two-way
ANOVA followed by a Student Newman Keuls multiple comparison test:
**p<0.001 vs aCSF saline and naloxone; ##p<0.001 vs virgin aCSF/saline,
#p<0.05 vs virgin aCSF/naloxone. Two-way ANOVA followed by a Student
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Figure 6.28: The effect of i.c.v. NPY and i.v. naloxone on Fos positice cell
counts in the SON in virgin and pregnant rats. Rats were killed by transcardial
Perfusion fixation 90 minutes post-injection ofNPY. Values are the mean counts
of positive cells over three sections and values are the group means ± SEM.
Virgin aCSF/saline, n=4; virgin aCSF/naloxone, n=4; virgin NPY/saline, n=7;
Virgin NPY/naloxone, n=6; pregnant aCSF/saline, n=5; pregnant aCSF/naloxone,
n=5; pregnant NPY/saline, n=5; pregnant NPY/naloxone, n=6. Two-way
ANOVA followed by a Student Newman Keuls multiple comparison test:
*p<0.05 vs virgin aCSF groups, #p<0.05 vs virgin NPY/saine; +p<0.05
vs pregnant aCSF/naloxone.
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given NPY and naloxone and pregnant rats given NPY and naloxone (Fig.6.28). Fos
expression was greater in pregnant rats given NPY and naloxone than in pregnant
rats given aCSF and naloxone (Fig 6.28).
Arcuate nucleus (ARC) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p<0.001). Quantification of Fos positive cells revealed that Fos expression in
the ARC of virgin rats given NPY and saline was significantly greater (1.5-fold) than
in the pregnant NPY and saline group (p<0.001). I.c.v. injection ofNPY and i.v.
saline significantly increased Fos expression in the virgin group (p<0.001) (11.3 ±
0.9 vs control 5.3 ±1.3 Fos positive cells/ARC) (Fig.6.29).
Quantification of Fos positive cells revealed that Fos expression in the ARC of virgin
rats given NPY and naloxone was significantly greater (1.5-fold) than in the pregnant
NPY and naloxone group (p<0.001). I.c.v. NPY and i.v. naloxone significantly
increased Fos expression in the virgin group (p<0.001) (11.6 ± 0.8 vs control 6.9 ±
0.6 Fos positive cells/ARC) (Fig.6.29). However, naloxone had no effect on
responses to NPY in either virgin or pregnant rats.
Lateral hypothalamic area (LHA) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was not a
statistically significant difference in Fos expression among virgin and pregnant
groups (Fig. 6.32) I.c.v. injection ofNPY did not significantly increase Fos
expression in either the virgin or pregnant group under any treatment (Fig.6.30).
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Figure 6.29: The effect of i.c.v. NPY and i.v. naloxone on Fos positive cell counts
in the ARC in virgin and pregnant rats. Rats were killed by transcardial perfusion
Fixation 90 minutes post-injection ofNPY. Values are the mean count positive cells
over three sections and values are the group means ± SEM. Virgin aCSF/saline,
n=4; virgin aCSF/naloxone, n=4; virgin NPY/saline, n=7; virgin NPY/naloxone,
n=6; pregnant aCSF/saline, n=5; pregnant aCSF/naloxone, n=5; pregnant NPY/
saline,n=5; pregnant NPY/naloxone, n=6. Two-way ANOVA followed by a Student
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Figure 6.30: The effect of i.c.v. NPY and i.v. naloxone on Fos positive cell counts
in the LHA in virgin and pregnant rats. Rat were killed by transcardial perfusion
90 minutes post-injection ofNPY. Values are the mean count positive cells over
three sections and values are the group means ± SEM. Virgin aCSF/saline, n=4;
virgin aCSF/naloxone, n=4; virgin NPY/saline, n=7; virgin NPY/naloxone, n=6;
pregnant aCSF/saline, n=5; pregnant aCSF/naloxone, n=5; pregnant NPY/saline,
n= 5; pregnant NPY/naloxone, n=6. Two-way ANOVA showed no significant
differences.
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Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p=0.008). Quantification of Fos positive cells revealed that Fos expression in
the VMH of virgin rats given aCSF and naloxone was significantly greater (1.5-fold)
than in the pregnant aCSF and naloxone group (p=0.024). I.c.v. injection ofNPY did
not significantly increase Fos expression in either the virgin or the pregnant group
under any treatment, and naloxone had no effect (Fig.6.31).
Dorsal Medial Hypothalamus (DMH) Fos expression
Analysis of Fos expression using a two-way ANOVA showed there was a
statistically significant difference in Fos expression among virgin and pregnant
groups (p<0.001).
Quantification of Fos positive cells revealed that Fos expression in the DMFI of
virgin rats given aCSF and naloxone was significantly greater (1.5-fold) than in the
pregnant aCSF and naloxone group (p=0.005). I.c.v. injection ofNPY did not
significantly increase Fos expression in either the virgin or the pregnant group under
any treatment (Fig.6.32).
6.4 Discussion
6.4.1. The effect of i.c.v. NPY on food intake
We have shown that NPY significantly increases eating behaviour and food intake in
both virgin and pregnant female rats (Fig. 6.2 and Fig. 6.23). This corresponds with
previous studies shown in male (Levine et al, 1984) and female rats (Brunton et al,
2006). Naloxone reduced NPY-induced feeding behaviour in both virgin and
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Figure 6.31: The effect of i.c.v. NPY and i.v. naloxone on Fos positive cell
counts in the VMH in virgin and pregnant rats. Rats were killed by transcardial
perfusion fixation 90 minutes post injection ofNPY. Values are the mean counts
of positive cells over three sections and values are the group means ± SEM.
virgin aCSF/saline, n=4; virgin aCSF/naloxone, n=4; virgin NPY/saline, n=7;
virgin NPY/naloxone, n=6; pregnant aCSF/saline, n=5; pregnant aCSF/naloxone,
n= 5; pregnant NPY/saline, n=6; pregnant NPY/naloxone, n=6. Two-way
ANOVA followed by a Student Newman Keuls multiple comparison test.
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Figure 6.32: The effect of i.c.v. NPY and i.v. naloxone on Fos positive cell
counts in the DMH in virgin and pregnant rats. Rats were killed by transcardial
Perfusion 90 minutes post injection ofNPY. Values are the mean counts of
Positive cells over three sections and values are the group means ± SEM. Virgin
aCSF/saline, n=4; virgin aCSF/naloxone, n=4; virgin NPY/saline, n=7; virgin
NPY/naloxone, n=6; pregnant aCSF/saline, n=5; pregnant aCSF/naloxone,
=5; pregnant NPY/saline, n=6; pregnant NPY/naloxone, n=6. Two-way
ANOVA followed by a Student Newman Keuls multiple comparison test.
*p<0.005 vs virgin aCSF.
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NPY and naloxone ate significantly less than virgin rats given NPY and naloxone,
and took much longer to initiate feeding behaviour (Fig 6.23 and Fig. 6.24). These
findings are consistent with other evidence that endogenous opioid peptides stimulate
feeding (Baile et al, 1986). Administration of naltrexone (another opioid receptor
antagonist) into the NTS decreased feeding induced by NPY injected into the PVN,
indicating that feeding produced by NPY in the PVN relies on functional opioid
receptor pathways within the NTS (Kotz et al, 1998). It is thought that feeding
signals arising from stimulation ofNPY receptors in the PVN result in opioid release
from the NTS, in particular the medial region (Kotz et al, 2000), and blockade of
these opioid receptors prevents binding and action of the released opioids. In the
present study naloxone reduced the NPY-induced increase in food intake as
measured by a reduction in food weight (Fig 6.23). In virgin rats naloxone reduced
the NPY-induced food intake by 60% yet in pregnant rats naloxone reduced the
NPY-induced food intake by 90% (Fig.6.23). During pregnancy it has been shown
that endogenous opioid mechanisms in the brain are up-regulated (Brunton et al,
2005; Douglas et al, 1998). The greater reduction in food intake after naloxone
before NPY in late pregnant rats than in virgins is consistent with an important role
in regulation of appetite of up-regulated opioid mechanisms in the brain in
pregnancy. Pregnant rats given NPY and naloxone also took significantly longer to
begin eating than the virgin rats given NPY and naloxone (Fig 6.24). Hence,
endogenous opioids facilitated NPY-induced feeding in both virgin and late pregnant
rats, but are evidently more important in late pregnant rats. NPY did not significantly
increase drinking in any group. This is consistent with previous studies in male rats
(Stanley et al, 1985) although one study suggested that NPY will increase drinking in
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male rats (Clark et al, 1985). Grooming was increased by i.e.v. NPY only in virgin
rats, and not consistently (Fig. 6.2 and Fig. 6.22). Pregnant rats given NPY and
naloxone spent least time grooming and drinking, consistent with their reduced
eating behaviour (Fig. 6.22)
6.4.2. Changes in pregnancy in responses to centrally administered NPY of
hypothalamic circuitry regulating HPA axis and eating behaviour
pPVN
The results show that i.e.v. NPY significantly increased the number of Fos positive
cells in the pPVN of virgin rats compared with aCSF treated rats (Fig.6.3). After
i.c.v. NPY there was also a significantly greater number of Fos positive cells in the
pPVN in virgin rats compared to late pregnant rats (Fig.6.3). This indicates reduced
responsiveness in late pregnancy of the CRH/AVP neurones to NPY as these
neurones are found in large quantities in the pPVN (see FIPA axis section below). In
male rats i.c.v. NPY induces Fos expression in the pPVN (Li et al, 1994). NPY
injection markedly increased Fos-like immunoreactivity in the medial subdivision of
the PVN, and after food ingestion additional populations of neurones in the lateral
subdivision of the pPVN were activated (Li et al, 1994).
mPVN and SON
I.c.v. NPY also significantly increased the number of Fos positive cells in the mPVN
(Fig. 6.4) and SON (Fig. 6.8) in virgin rats compared to rats given aCSF, and
significantly increased the number of Fos positive cells in the mPVN (Fig.6.4) and
SON (Fig 6.8) in virgin rats compared to late pregnant rats. NPY has been shown to
increase plasma oxytocin concentration in female rats, but is ineffective during late
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pregnancy (Brunton et al, 2006). The results show that NPY significantly increased
the percentage of oxytocin neurones expressing Fos in the SON (Fig. 6.10) and the
mPVN (Fig. 6.7) in virgin rats given NPY compared to virgin controls and compared
to pregnant rats given NPY. There was a greater percentage of oxytocin neurones
activated in response to NPY in the SON compared to the mPVN in virgin rats.
These results suggest that oxytocin neurones in the SON are more involved in the
response to NPY than oxytocin neurones in the mPVN. Studies in male rats have
shown that the number of Fos positive cells in the PVN in response to NPY increased
in association with feeding (Yokosuka et al, 1998). This suggests a subpopulation of
neurones in the mPVN containing NPY receptors may be involved in regulating
feeding upon activation of the NPY input. Administration of a Y1 receptor antagonist
suppressed the feeding response ofNPY neurones (Yokusuka et al, 1999). The
finding that oxytocin neurones are activated by i.c.v. NPY is consistent with previous
findings (Brunton et al, 2006). In previous studies in male rats there is an increase in
Fos-like immunoreactivity in the SON in rats that were allowed to eat, this may be
due to osmotic stimulation; rats have been shown to drink after NPY administration
(Clark et al, 1985), though this was not evident in the present study (Fig. 6.2 and Fig.
6.22). It has also been proposed that activation of the SON in response to NPY
involves activation of oxytocin, vasopressin and CCK producing cells (CCK cells
have also shown to be present in the SON) (Li et al, 1994). It has however also been
proposed that a subset of oxytocin, vasopressin and CCK neurones respond to NPY
only in conjunction with food consumption (Li & Rowland, 1994). In the present
study, the rats were allowed access to food, and even so oxytocin neurones did not
respond to NPY in late pregnant rats (Fig. 6.4, Fig. 6.10), despite stimulation of
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eating behaviour and food intake (Fig. 6.2). Notably, Fos expression in oxytocin
neurones is stimulated by a-MSH, which inhibits eating (Sabatier, 2006), as does
central oxytocin administration (Brunton et al, 2006).
ARC
The present results show that NPY also significantly increased Fos expression in
virgin rats in the ARC compared to virgin controls and compared to pregnant rats
given NPY (Fig. 6.11). It has been shown that NPY induces Fos expression in the
ARC in the area where Y1 receptor mRNA has been localised (Li et al, 1994). Diet
restriction and starvation rapidly induce accumulation ofNPY in the PVN by
increasing NPY mRNA levels in the ARC (White & Kershaw, 1990). NPY mRNA
levels in the ARC have been reported to be significantly increased during pregnancy
(Garcia et al, 2000), and not to change (Wilding et al, 1997). Increased NPY gene
expression during pregnancy may be part of the adaptive mechanisms present in the
physiological state of pregnancy. Nothing is known about NPY receptor expression
in the ARC during late pregnancy. It would be interesting to characterise the
phenotype of the ARC neurones responding to NPY.
The lack of Fos activation in the ARC in late pregnant rats by i.c.v. NPY suggests
that lack of excitation of a pool ofARC neurones might explain the lack of an HPA
axis response, and indicates that ARC neurone excitation is not essential for eating
responses to i.c.v. NPY.
LHA
The results show that NPY did not significantly increase the number of Fos positive
cells in the LHA (the hunger centre) in either virgin or pregnant rats compared to
control animals (Fig.6.13). It has previously been shown that Fos expression in the
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LHA in response to NPY is very weak (Li et al, 1994). Y1 and Y5 receptors that are
mainly involved in the food intake stimulatory activity ofNPY are present in the
LHA (Wolak et al, 2003) and NPY containing terminals innervate orexigenic
neurones in the LHA. I.e.v. administration ofNPY also increases Fos activity in the
lateral hypothalamic orexigenic neurones of fasted rats (Campbell et al, 2003).
Similarly rats that were given food showed no extra activation in the LHA where Fos
expression had been shown to be weak following i.e.v. NPY (Li et al, 1994). Rats in
the present study were not fasted before the experiment.
It is important to note that Fos expression indicates excitation of neurones (Windle et
al, 2004), and any direct inhibitory actions ofNPY are not revealed.
VMH
The present results also show that NPY did not significantly increase the number of
Fos positive cells in the VMH (the satiety centre), although there was a slight
tendency for the number of Fos positive cells to increase in the VMH in both virgin
and pregnant rats after NPY (Fig.6.14). Again previous studies in male rats showed
Fos expression to be weak following administration ofNPY (Li et al, 1994) and
these results did not change following food intake (Li et al, 1994). Injection ofNPY
into the VMH increases food intake (Morley et al 1987). NPY was found to inhibit
one fifth ofVMH neurones, and this inhibition was potentiated by overfeeding
(Heidel et al, 1999).
DMH
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The results showed that NPY did not significantly increase the number of Fos
positive cells in the DMH (Fig.6.15). Pregnant rats given aCSF showed a
significantly greater number of Fos positive cells compared to all other groups,
which might be interpreted as showing an inhibitory action ofNPY in late
pregnancy. In previous studies with male rats a moderate Fos response was seen in
response to NPY in the DMH and this was increased to strong with food intake (Li et
al, 1994). Microinjection ofNPY into the DMH results in stimulation of feeding
(Corp et al, 1990). It is possible that this region may also contain NPY target cells
involved in feeding behaviour.
Six receptor subtypes have been found to mediate the actions ofNPY (Gerald et al,
1996). These are widely distributed throughout the brain. The PVN, SON and the
ARC express the Y1 and Y5 receptor (Wolak et al, 2003). To date there is no
evidence regarding NPY receptor expression in which could also explain changes in
neuroendocrine responses seen in late pregnancy. It should also be reiterated that Fos
expression allows detection of neurones that have been excited (Hoffman et al, 1993)
and differences in inhibitory actions on pools of neurones would not be detected.
Overall, the above findings indicate, since feeding responses to NPY are intact in late
pregnancy, that activation of the pPVN, magnocellular oxytocin neurones and ARC
neurones is not essential for stimulation of feeding by NPY in late pregnancy.
However, stimulation of these neurones may be important in the activation of the
HPA axis by NPY (see below).
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6.4.3. The effect of endogenous opioids on NPY-induced Fos expression in
hypothalamic circuits
Previous results have shown that the reduced responsiveness of the CRH/AVP pPVN
neurones to centrally administered NPY in late pregnancy (Brunton et al, 2006)
could be due to enhanced inhibition by a central opioid mechanism that emerges in
pregnancy. Possible sources of endogenous opioid that could regulate PVN
CRH/AVP neurones include noradrenergic NTS neurones which coexpress pro-
enkephalin-A (pENK-A) mRNA (Cecatelli et al, 1989). pENK-A mRNA expression
is increased in the NTS in late pregnancy and may be the source of opioid inhibiting
noradrenaline release onto CRH neurones following administration of interleukin-ip
(Brunton et al, 2005). NPY-containing neurones project from the NTS to the PVN.
It was not known previously whether the opioid mechanism would interfere with
NPY signalling to pPVN CRH/AVP, mPVN, SON or ARC neurones which is shown
here (see above) to be reduced during pregnancy.
pPVN
The present results show that NPY increased the number of Fos-positive cells in the
pPVN in virgin rats compared to pregnant rats, consistent with previous experiments
(Brunton et al, 2006). Naloxone given before NPY had no further effect on the
number of Fos positive cells in virgin rats, but significantly increased the number of
Fos positive cells in pregnant rats given NPY and naloxone compared to pregnant
rats given NPY and saline (Fig.6.25). There was no significant difference between
virgin rats given NPY and naloxone and pregnant rats given NPY and naloxone
(Fig.6.25). This provides further evidence for the presence of an opioid inhibition on
the CRH/AVP neurones in pregnancy, and that this extends to the actions ofNPY.
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mPVN
NPY significantly increased the number of Fos positive cells in the mPVN in virgin
rats with no further changes following administration of naloxone. The number of
Fos-positive cells was significantly lower in pregnant rats given NPY compared to
virgin rats, but there was no further change in Fos expression following naloxone
(Fig.6.27). However, pregnant rats given NPY and naloxone had a significantly
greater number of Fos-positive cells compared to pregnant controls given naloxone
alone, whereas pregnant rats given NPY and saline showed no significant difference
from aCSF treated rats (Fig 6.27).This suggests that there is a weak degree of opioid
inhibition on the mPVN neurone response to NPY during late pregnancy.
SON
NPY significantly increased the number of Fos-positive cells in the SON in virgin
rats compared to virgin controls and compared to pregnant rats. Naloxone did not
affect the SON neurone Fos response to NPY in virgin rats. The number of Fos
positive cells in virgin rats given NPY and naloxone was not significantly different
from the number of Fos positive cells in pregnant rats given NPY and naloxone.
There was a significantly greater number of Fos positive cells in pregnant rats given
NPY and naloxone compared to pregnant rats given aCSF and naloxone (Fig. 6.28);
but again this suggests only a weak opioid inhibition on the SON neurone responses
to NPY during late pregnancy, in contrast with previous studies, using other stimuli
where there is strong opioid inhibition (Douglas et al, 1995; Russell and Brunton,
2005). It has been shown in response to a cytokine stressor that the failure of
oxytocin neurones to respond in pregnant rats is a result of an opioid inhibition;
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naloxone not only restored the oxytocin secretory response in pregnant rats but
unmasked an exaggerated response (Russell & Brunton, 2005). Importantly,
electrophysiological recording has shown that naloxone acts centrally to reverse the
opioid inhibition on oxytocin neurone responses to interleukin-1P in late pregnancy
(Brunton et al. 2005). It is important to note that further studies, involving
measurement of oxytocin secretion and electrophysiological recording are required to
resolve the issue of opioid involvement in suppressed oxytocin neurone responses to
i.c.v. NPY in late pregnancy.
ARC, LHA, VMH, DMH
I.c.v. NPY significantly increased the number of Fos positive cells in the ARC in
virgin rats compared to virgin controls with no significant difference seen following
administration of naloxone. There were significantly more Fos positive cells in the
ARC in virgin rats following NPY compared to pregnant rats; there was however a
tendency for the number of Fos positive cells to increase after NPY in pregnant rats
compared to pregnant aCSF-treated controls (Fig. 6.29). Naloxone had no effects and
did not alter Fos expression in response to NPY in the LfIA (Fig. 6.30), VMPI
(Fig.6.31) or DMH (Fig.6.32). Hence neither the restoration ofHPA axis responses
(Figs. 6.17, 18, 19, 25) nor the suppression of eating behavioural responses (Figs
6.22, 23, 24) to i.c.v. NPY in late pregnancy by naloxone is attributable to excitation
of neurones in these areas.
6.4.4. The effect of i.c.v NPY and i.v. naloxone on blood glucose concentration
The results show that NPY significantly increased blood glucose concentration in
virgin rats, with no change following administration of naloxone (Fig.6.16).
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Within the brain, subgroups of neurones respond differently to altered blood glucose
concentrations. Identification ofNPY in hypothalamic neurones that sense glucose
suggests a role for NPY in glucose sensing (Gozali et al, 2002). The reflex control of
blood glucose is mediated by the NTS. The medulla receives sensory inputs from the
stomach and portal vein which signals to the pancreas to release insulin. Insulin
inhibits NPY release (Shwartz et al, 1996). Blood glucose can be an indicator of the
overall metabolic response to NPY. Blood glucose concentration gives an indication
of the balance between insulin, glucagon, growth hormone, corticosterone and
sympathetic activity in the rat.
Basal blood glucose levels were significantly lower in pregnant rats (Fig.6.16).
Previous studies have shown that basal blood glucose levels decline as pregnancy
progresses (Rossi et al, 1993). NPY given i.e.v. did not significantly increase blood
glucose in pregnant rats; naloxone did not alter this lack of effect ofNPY in pregnant
rats (Fig.6.16). Reduced responses in blood glucose during pregnancy could be due
to reduced corticosterone secretion during pregnancy which has previously been
shown (Brunton et al, 2006) or reduced noradrenergic responses during pregnancy
which has been shown in response to other stressors (Douglas, 2005). As
corticosterone responses are not evident until 30 minutes after administration ofNPY
(Brunton et al, 2006) the latter explanation is perhaps more probable as the increase
in blood glucose is seen at 15 minutes. Furthermore, naloxone did not permit a
hyperglycaemic response to i.c.v. NPY in late pregnant rats, indicating lack of
corticosterone involvement since naloxone restored an ACTH response to NPY (see
below). It would be interesting to measure the secretory profiles of the hormones
mentioned above after i.c.v. NPY in late pregnant and virgin rats.
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6.4.5. The effect of i.c.v. NPY and i.v. naloxone on the HPA axis
The results show that NPY significantly increased plasma ACTH secretion in virgin
but not pregnant rats (Fig.6.17), consistent with previous studies (Brunton et al,
2006). Naloxone showed no further effect on plasma ACTH concentration in virgin
rats, although the response appeared to be slightly more sustained which is consistent
with other studies with different stressors looking at the effect of endogenous opioids
(Brunton et al, 2005). Naloxone restored an ACTH response in pregnant rats
(Fig.6.17, 18) indicating that opioids are interfering with NPY signalling to the HPA
axis during late pregnancy. The results also show that NPY significantly increased
CRH (Fig.6.19) and AVP mRNA expression (Fig.6.20) in the pPVN in virgin rats,
but not in late pregnant rats; this has also been previously been shown for stressors
(Brunton et al, 2006). Naloxone showed no further effect on pPVN CRH mRNA
expression in virgin rats, yet restored a response to NPY in the pregnant rats
(Fig.6.19). Similarly, naloxone showed no further effect on AVP mRNA expression
in virgin rats after NPY although there was a tendency for AVP mRNA to be
increased in virgin rats given NPY and naloxone compared to virgin rats given NPY
and saline. Naloxone restored the pPVN AVP mRNA response to NPY in pregnant
rats (Fig.6.20), further indicating that opioids are interfering with NPY signalling to
the paraventricular CRH/AVP neurones in late pregnancy. Alternative mechanisms
of suppressed oxytocin neurone responses to NPY in late pregnancy need to be
considered. In late pregnancy the GABA input to the PVN and SON oxytocin
neurones is more effective. Increased levels of allopregnanolone in the brain in
pregnancy enhance the actions ofGABA through actions at the GABAa receptor
(Brussaard et al, 2000) and there are increased GABAergic synaptic contacts with
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oxytocin neurones (Montagnese et al, 1987). Allopregnanolone restrains interleukin-
1P stimulated ACTH secretion (Brunton et al, 2005) in late pregnancy, possibly
through its actions on GABAa receptors. This mechanism may also stand for reduced
oxytocin neurone (and HPA axis) responses in late pregnancy which would be
interesting to investigate.
The many changes that occur in late pregnancy in the responses to central
administration ofNPY are summarised in table 6.2.
6.4.6. Summary
We have shown that in late pregnancy the increase in Fos expression is significantly
reduced in the dorsomedial parvocellular division of the PVN, indicating reduced
responses of the CRH/AVP expressing neurones, and confirming central suppression
ofHPA axis responsiveness in late pregnancy. Furthermore, naloxone partially
reversed the attenuation of the HPA-axis responses to NPY in late pregnancy as
shown by restoring pPVN CRH, AVP mRNA and ACTH, responses. We can
conclude that endogenous opioids are evidently involved in suppressing HPA axis
responses to NPY in late pregnancy.
Similarly there was a reduced Fos response in the SON and magnocellular PVN;
specifically oxytocin neurones were not activated by NPY in pregnancy.
We have also shown there was no stimulation by NPY of Fos in the ARC in
pregnancy, indicating another possible mechanism of reduced responsiveness of the
HPA-axis in pregnancy. However, the finding that naloxone did not restore ARC
responses indicates that ARC stimulation is not essential for NPY actions on the
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responsiveness of the HPA-axis and the neurohypophysial oxytocin system in
response to various stressors in late pregnancy.
Naloxone partially restored a Fos response to NPY in the pPVN and SON, with a
slight effect in the mPVN, These results indicate that opioids may indeed be
interfering in late pregnancy with NPY signalling to the pPVN, but effects on NPY
signalling to the mPVN and supraoptic neurones in pregnancy may not be important.
Although Fos expression is not stimulated by i.e.v. NPY in certain hypothalamic
areas eating responses to NPY remained intact in late pregnancy, except that
naloxone attenuated the eating responses to NPY. It is possible then that NPY
projections from the brainstem to the PVN are important in the orexigenic response
to NPY. NPY did not induce Fos expression in the LHA, DMH or VMH in either
virgin or pregnant rats. Fos expression remained significantly lower in pregnant rats
in the ARC following naloxone and NPY, which indicates the lack ofHPA axis
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7.1 General Discussion
Remarkable changes occur during pregnancy. These include increased appetite and
reduced HPA axis responses during exposure to a stress (Brunton et al, 2006). The
responsiveness of the HPA axis and the magnocellular oxytocin neurones to stressors
is altered. This includes suppressed responses to both emotional and physical
stressors in rats (Neumann et al, 1998) and mice (Douglas et al, 2003), in particular
to immune challenge with IL-ip in rats (Brunton et al, 2005). The HPA axis is also
hyporesponsive to the appetite regulating peptide orexin-A during late pregnancy
(Brunton et al, 2003). This reduced responsiveness is known to be due to reduced
responsiveness of the pPVN CRH and AVP neurones (Brunton et al, 2003). This
may be a consequence of reduced neural drive or enhanced inhibitory inputs to these
CRH neurones at the end of pregnancy. Evidently, enhanced negative feedback
inhibition by corticosterone does not explain the hyporesponsiveness of the HPA axis
to stress during late pregnancy (Johnstone et al, 2000). The attenuation ofHPA axis
responses to psychogenic stressors (Douglas et al, 1998) and IL-ip (Brunton et al,
2005) involves inhibition by a central endogenous opioid mechanism in pregnancy.
There are several possible sources of endogenous opioid that restrain CRH neurones
during late pregnancy including the ARC (Sawchenko et al, 1982), perifornical
region and the NTS neurones (Ceccatelli et al, 1989). Suppression ofHPA axis stress
responses during late pregnancy protects the foetuses from excess glucocorticoids
which can cause adverse programming. Suppression ofHPA axis responses to
centrally administered orexin-A during late pregnancy helps maintain a positive
energy balance because glucocorticoids mobilise energy stores. Glucocorticoids
stimulate both feeding and insulin secretion (Dallman et al, 1995). The relationship
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between the HPA axis and factors relating to adipose tissue storage is very
interesting. The aim of this thesis was to investigate changes in central mechanisms
underlying reduced HPA responses to central neuropeptides signalling metabolic
state during late pregnancy.
HPA axis responses to insulin-induced hypoglycaemia were maintained during late
pregnancy which is in contrast to other stressors at this time. It is very interesting that
this HPA axis activation is maintained when there is a severe energy lack, as opposed
to a presumably more modest energy shortage signalled by orexin-A, to which the
HPA axis is less responsive during late pregnancy. An interesting area for further
investigation would be identification of the pathways involved in activating the
various brain regions in response to insulin-induced hypoglycaemia. Insulin-induced
hypoglycaemia may have stimulated ACTH secretion through AVP instead of CRH,
which corresponds with similar studies where hypothalamo-hypophyseal portal
blood concentrations ofAVP were increased following insulin-induced
hypoglycaemia with no changes in CRH (Plotsky et al, 1985). It seems that insulin-
induced hypoglycaemia increases ACTH secretion by preferentially activating the
pPVN AVP neurones - and very importantly the mechanism remains intact during
pregnancy unlike responses to other metabolic signals such as orexin or NPY
(Brunton et al, 2003 and 2006). Both of these signals activate the HPA axis in non¬
pregnant rats through stimulation of the pPVN CRH and AVP neurones. Ghrelin has
been shown to activate the HPA axis in a similar way through NPY, so reduced
action ofNPY on the HPA axis in late pregnancy may underlie the reduced
responses to orexin and ghrelin.
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The mechanisms ofACTH regulation by ghrelin have been proposed to include
hypothalamic release ofCRH, AVP and NPY. The ARC NPY neurones are a likely
target as they express the GHS-R. Ghrelin did not activate the HPA axis during late
pregnancy, but the mechanisms ofwhy ghrelin does not stimulate ACTH secretion
during late pregnancy are not known although several possibilities exist. It has
previously been shown that in response to orexin A reduced activation of the HPA
axis is due to reduced stimulation of the pPVN CRH/AVP neurones, and a similar
explanation was confirmed for reduced HPA responses to i.c.v. ghrelin. I.c.v. ghrelin
increased c-fos expression in the pPVN in virgin rats, which corresponds with
previous studies (Hu et al, 2005) yet was not activated in pregnant rats. Reduced
responsiveness of the CRH and AVP neurones was also shown following i.c.v.
injection of orexin or NPY where the HPA axis response was also reduced during
late pregnancy, which also corresponds with previous studies (Brunton et al, 2003;
2006). A central opioid mechanism that emerges during late pregnancy has been
shown to be responsible for reduced HPA responses to psychogenic stressors and
immune challenge. The primary role of the PVN CRH neurones in response to
challenge with IL-ip involves direct nor-adrenergic projections from the NTS in the
brain stem; naloxone (an opioid receptor antagonist) triggers a pPVN CRH mRNA
response to IL-ip indicating a role for endogenous opioids in restraining CRH
neurones during late pregnancy (Brunton et al, 2005). It was not known if opioids
would be involved in restraining CRH neurones in response to metabolic signals
such as ghrelin, orexin and NPY. It was shown that the HPA axis was inhibited by
endogenous opioids in late pregnant rats following administration of orexin and
NPY, since after i.v. naloxone ACTH responses were restored following i.c.v.
182
Chapter 7 General Discussion
injection of either i.c.v. NPY or orexin; this was also shown with in-situ
hybridisation where naloxone increased both CRH and AVP mRNA following i.c.v.
NPY. Further evidence for the presence of an opioid inhibition on the CRH/AVP
neurones was shown when a Fos response was restored after i.c.v. NPY and i.v.
naloxone. The same Fos study suggested there was a weak degree of opioid
inhibition on the mPVN. Endogenous opioids are evidently involved then in
suppressing HPA axis responses to metabolic signals in pregnancy.
7.2 What causes the changes in pregnancy?
These studies indicate that activation of inhibitory opioid mechanisms in the brain
during pregnancy underlie the suppressed action of these orexigenic peptides on the
FIPA axis, and other studies indicate a similar mechanism restrains oxytocin
neurones (Douglas ; Russell and Brunton 2006). It has been hypothesised that
pregnancy is signalled to the brain to induce the mechanisms that suppress appetite
peptide action on stress circuits by neurosteroids produced from progesterone
(Russell and Brunton 2006). Neurosteroids accumulate in the brain independently of
the levels in peripheral tissues (Hu et al, 1987) and systemic administration of
progesterone or its metabolite allopregnanolone (AP) induces various anxiolytic
effects by enhancing the function of GABAa receptors (Majewska, 1992). Both of
these findings indicate that changes in plasma and brain concentrations of
progesterone or allopregnanolone may control neuronal excitability, through
enhancing the function ofGABAa receptors, by increasing the opening time of the
chloride channel in the GABAa receptor (Bitran et al, 1995). There are more GABA
synapses on oxytocin neurones during late pregnancy (Montagnese et al, 1987)
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indicating enhanced action through GABAa receptors at this time. AP content in the
brain is increased during late pregnancy because of increased secretion of
progesterone (Luisi et al, 2000); the brain itself can metabolise progesterone to AP
via 5a-reductase (Russell & Brunton, 2005). In late pregnant rats given the 5a-
reductase inhibitor finasteride, to reduce AP levels to virgin levels, oxytocin
responses after IL-ip were restored; additional treatment with naloxone did not
further alter this response (Russell & Brunton, 2006). It has been proposed that
increased AP could act by inducing opioid mechanisms during late pregnancy.
7.3 What is it all for?
Non stress levels of glucocorticoids play a key physiological role in promoting and
maintaining a positive energy balance (Syed & Weaver, 2005). Glucocorticoids
stimulate feeding and insulin secretion (Dallman et al, 1985). Pregnancy is a
hypermetabolic state with a great increase in maternal body fat and weight, there is
no increase in energy efficiency and energy balance becomes positive primarily
because of an increase in food intake and this prevents depletion of maternal energy
stores (Richard & Trayhurn, 1985). In the rat food intake increases by about 50% and
food consumption usually occurs in the dark phase only (Booth & Nicholls, 1974).
As described in this thesis several hypothalamic peptides have been identified as
possible regulators of food intake and metabolism e.g. NPY, orexin and ghrelin. Diet
restriction and starvation increase NPY in the PVN by increased NPY mRNA
expression in the ARC. NPY mRNA levels in the ARC have previously been shown
to be increased during late pregnancy (Garcia et al, 2003). This is surprising due to
high leptin levels during late pregnancy, however it has been shown there is leptin
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resistance in late pregnant rats (Garcia et al, 2000). In food-restricted late pregnant
rats there is also an increase in circulating ghrelin levels (Guallio et al, 2002). None
of the rats used in this thesis were food restricted, and ghrelin was administered
centrally since this has previously been shown to increase NPY mRNA in the
hypothalamus (Seone et al, 2003). Whether ghrelin still increases NPY mRNA in the
ARC in late pregnant rats is not yet known. Surprisingly, hypothalamic expression of
orexin has been shown to be reduced during late pregnancy (Garcia et al, 2002).
Food restriction does not increase orexin mRNA levels as has previously been shown
in virgin rats (Lopez et al, 2000). It is possible that there is inhibition of prepro-
orexin expression in the hypothalamus that counteracts the stimulatory effect of low
leptin levels in fasted pregnant rats (Garcia et al, 2002). This also indicates that
orexin may not be involved in the regulation of increased food intake during
pregnancy. Orexin is also related to arousal and sleep, and pregnancy is also
associated with changes in sleep patterns (Santiago et al, 2001). It seems there are
complex neural pathways involved in the mechanisms established during late
pregnancy. Increased NPY gene expression may be part of the adaptive mechanisms;
it is interesting that insulin-induced hypoglycaemia still stimulates ACTH responses
during late pregnancy. Overall during late pregnancy reduced HPA axis and
specifically corticosterone responses after i.c.v. ghrelin, orexin and NPY may reflect
a switch to anabolic metabolism which would help meet the demands of the foetus
without causing a negative energy balance in the pregnant mother. These responses
are suppressed by endogenous opioids. Endogenous opioids also facilitate NPY-
induced feeding in both virgin and late pregnant rats but are evidently more
important in late pregnant rats, when central opioid mechanisms are up-regulated.
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Activation of endogenous opioid mechanisms in pregnancy have opposite effects on
neuroendocrine stress responses and appetite regulation.
7.4 Future plans
Since it is not known if it is insulin or hypoglycaemia that activates the HPA axis
after acute bolus insulin injection, it would be interesting to see if insulin injection,
whilst maintaining blood glucose by infusing glucose i.v., would still activate the
HPA axis in virgin and pregnant rats.
Since increased AP in the brain during late pregnancy could also play a role in
inducing the opioid mechanisms in pregnancy that suppress the orexigenic peptide
actions on stress circuits, administration of finasteride to reduce AP production from
progesterone levels would be an interesting experiment. The effects of centrally
administered orexigenic peptides after finasteride, measured as plasma ACTH
concentration, AVP and CRH mRNA and Fos expression changes in virgin and
pregnant rats would be interesting to investigate.
Y1 and Y5 receptors have been identified in the PVN (Wolak et al, 2003). Y2
receptors are thought to play a key role in activating the HPA axis (Small et al,
1997). To date there are no reports about NPY receptor expression during late
pregnancy. In situ hybridisation in virgin and pregnant rats to measure expression of
Y receptor mRNAs would answer whether reduced expression might contribute to
reduced NPY action on the HPA axis.
Neuroendocrine stress responses to centrally administered NPY are suppressed in
late pregnant rats but ingestive behavioural responses remain intact. Double labelling
immunohistochemical studies would identify the phenotype of neurones stimulated
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by ghrelin, orexin and NPY and prove a useful way for further dissecting the
pathways that are essential in the feeding response to NPY.
NPY-containing catecholaminergic neurones in the medulla project to the PVN
(Sawchenko et al, 1985). Orexin (Willie et al, 2001) and ghrelin (Wynne et al, 2002)
neurones also have projections to the NTS. Fos immunohistochemistry on brain stem
sections from rats given ghrelin, orexin or NPY would indicate if the brain stem
circuitry is activated in response to these orexigenic peptides.
A pilot study of Fos immunohistochemistry has begun in insulin-treated virgin rats to
see the pattern of activation in the hypothalamus in these animals. Preliminary results
showed activation in various areas involved in regulation of eating and in activating
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